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The health impacts of prenatal Pb exposure can be framed with the 
Developmental Origins of Health and Disease (DOHaD) theory, which postulates that 
exposure to environmental factors (i.e., diet, chemicals, stress, etc.) during sensitive 
periods of development (i.e., pre-conception, gestation, neonatal, etc.) alters an 
organism’s molecular biology, physiology, and metabolism, potentially leading to myriad 
effects on cognition, growth, and maturation. Around the world, exposure to lead (Pb) 
continues to be a persistent problem. A particularly vulnerable population includes 
pregnant women, where Pb from both current and past exposures can affect their 
developing fetuses. Disruptions in normal epigenetic processes during gestation impact 
gene regulation and subsequent outcomes. Accumulating evidence for DOHaD includes 
potential mechanisms such as epigenetic reprogramming via DNA methylation (5mC) 
and, less studied, DNA hydroxymethylation (5hmC), linking developmental exposures to 
later-life outcomes. This dissertation aims to examine whether Pb exposure influences 
DNA 5mC and 5hmC and susceptibility to early cognitive delays. 
 A human longitudinal cohort, Early Life Exposure in Mexico to Environmental 
Toxicants (ELEMENT), was used to investigate whether developmental Pb exposure 
would alter epigenetics at birth and in adolescence, and if these alterations are 
associated with decreases in neurodevelopmental scores in early infancy. The first aim 
of this dissertation characterized the association between prenatal Pb exposure 
measured in maternal blood and bone and CpG site-specific DNA methylation at 
 xiii 
>750,000 loci at birth in infant umbilical cord blood cells. Linear regression models were 
used to identify differentially methylated CpG sites by prenatal Pb exposure, using the 
false discovery rate method to correct for multiple testing. In the second aim, we 
evaluated both gene-specific DNA 5mC and 5hmC in adolescent whole blood from the 
same cohort to determine whether the association of prenatal Pb exposure and 
epigenetics persisted into adolescence and determine if 5hmC is associated with the 
exposure. Finally, in the third aim we assessed whether DNA methylation at birth 
mediates the association between prenatal Pb exposure and adverse 
neurodevelopmental outcomes at 12- and 24-months of age. 
 In Aim 1, we found that trimester-specific developmental Pb exposures were 
associated with gene-specific DNA methylation changes at birth, and most changes 
were identified in genes related to neurodevelopment. Next, we showed that some of 
these Pb-induced DNA methylation changes were stable into adolescence, particularly 
those associated with first trimester exposure. This potentially suggests that 
perturbations occurring during the first trimester are reprogramming the epigenome and 
these changes remain into adolescence. Within Aim 2, we observed widespread, 
variable 5hmC levels in adolescent whole blood. We also revealed that prenatal Pb 
exposure has independent associations with both 5mC and 5hmC. These associations 
were also sex-specific at some loci, indicating a sexually dimorphic effect on the 
epigenome. Finally, the Aim 3 mediation analysis showed DNA methylation mediated 
the association between second trimester Pb exposure and cognition scores at 24-
months of age at multiple neurodevelopmental measures.  
 xiv 
 Overall, this dissertation illustrates that prenatal exposures to Pb can modulate 
epigenetics, and this may be one mechanism linking exposure to persistent effects on 
development and offspring health. Additional studies in larger cohorts or animal studies 
are needed in order to confirm these findings. These results emphasize the importance 
of distinguishing between 5mC and 5hmC during epigenetic studies, thus presenting a 
new conceivable mechanism describing the underlying biology behind the association 
between exposure and outcome, 5hmC. 
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Chapter 1 Introduction 
Childhood Lead (Pb) Exposure and Public Health Epidemiology 
The metal lead (Pb) is an element that has been used for thousands of years due 
to the ease of extraction from ores, relative abundance on earth, and low cost 1. Pb is a 
ubiquitous environmental pollutant with potential sources from industries, mining and 
smelting, leaded gasoline, lead-based paint, watering piping, and consumer products 
(such as toys) that use Pb. The most common sources of human exposure include 
paint, dust, water, or soil through ingestion, inhalation, and skin absorption 2-4. Pb’s 
inorganic forms have favorable absorption, distribution, and excretion related to 
respiratory and digestive poisoning, whereas organic Pb is easily absorbed through the 
skin 5. Blood lead levels (BLLs) within the US population has fallen dramatically, 93.6% 
on average from 1976-1980 to 2015-2016, since the phasing out of leaded gasoline and 
bans of Pb-based paint, and canned foods and other consumer products with Pb solder 
6, 7. These results suggest that public health reforms targeting Pb exposure were largely 
successful. However, concern has now grown regarding chronic low-level exposure 
within the environment, such as in dust from older homes with Pb-based paint and 
aging infrastructures where Pb leaches from old pipes into the water source 8-10. It is 
estimated that roughly 800 million children worldwide have blood Pb concentrations 
greater than 5 µg/dL with the US having nearly 1.23 million children above this limit and 
approximately 159,000 over 10 µg/dL 11. The incidence of Pb poisoning is associated 
with numerous factors, including socioeconomic status, rurality, race, age, and the 
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dates one’s residence was built. In low- and middle-income countries, Pb exposure 
occurs through various contamination sources such as use of Pb-glazed ceramics and 
Pb-acid battery production and recycling 12.  
The number of children exposed annually to Pb in the U.S. and globally is 
astonishing, nearly 800 million globally 11 and accounting for 0.6% of the global burden 
of disease with most of the exposures affecting children 1. Worldwide Pb exposure is 
responsible for 24.4 million disability-adjusted life years from intellectual disability 13. 
Cognitive delays can compromise school performance and increase aggressiveness, 
making Pb poisoning a public health concern. It is a natural toxicant that can adversely 
affect nearly every organ, particularly the brain resulting in neurodevelopment 
impairments. Most research has been examining toxicity at high levels of exposure, but 
more recent research has focused on understanding the impact of Pb exposure at or 
around the blood Pb reference of <10 µg/dL or <5 µg/dL, especially within pregnant 
women and children. Pb exposure is more toxic on developing brains in children than on 
mature brains, even at low BLLs, highlighting the importance of reducing exposures 
among pregnant women and young children 14, 15. There is no known physiological role 
of Pb in the body and there is no known level of Pb that is considered safe.  
While environmental health scientists have long known of the adverse 
neurological effects of high levels of Pb exposure, epidemiological studies continue to 
demonstrate that Pb exposure affects cognition and behavior with major impacts on 
proper functions, including academic development even at very low levels of exposure. 
A meta-analysis of 1,333 children (233 with BLLs ≤10 μg/dL and 103 ≤7.5 μg/dL) found 
an inverse relationship between ln-transformed BLLs and cognition using the 
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intelligence quotient compromise, estimated at a 3.9 point decrease when levels rise 
from 2.4 to 10 μg/dL 14. Interestingly, the BLLs <7.5 μg/dL showed greater loss of 
intelligence quotient points per unit increase in Pb compared to the BLLs at or above 
7.5 μg/dL providing data on low dose neurocognitive effects. Another study analyzed 
data from 534 children and found that BLLs <10 μg/dL had significant decreases in 
intelligence and academic achievement, specifically 5.0 points lower intelligence 
quotient scores when comparing those with exposures 5-10 μg/dL to children with lower 
BLLs of 1-2 μg/dL 16. Negative associations between Pb and multiple cognitive 
measures were even observed with exposures as low as 3 μg/dL. In addition to 
intelligence quotient, numerous studies have suggested that Pb exposure contributes to 
the incidence of behavioral disorders 14, 17-19. Specifically, a study comprising 294 
children found that BLLs at 12 months of age were significantly associated with weaker 
psychomotor development at 24 months of age, which measures attention and 
processing speed 18. Another study found that children with BLLs as low as 3 μg/dL 
exhibited deficits in basic reaction time, fine motor skills, and attention 19. Each study 
concludes that there is no apparent safe lower threshold for postnatal Pb exposure, and 
while we understand the gross effects of Pb on cognition, further research is needed to 
more comprehensively understand the biological mechanisms that underlie Pb-related 
adverse impacts on cognitive development. 
Fetal Pb Exposure and Developmental Origins of Health and Disease  
In addition to childhood Pb exposure, fetal Pb exposure is of great public health 
concern. Fetal Pb exposure is associated with developmental and cognitive deficits, 
many of which are long-lasting. This is line with the Developmental Origins of Health 
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and Disease hypothesis which states that exposures to nutritional and environmental 
factors during prenatal and early postnatal periods impact health outcomes into 
adulthood 20-23. This theory stems from the idea that the fetal environment primes the 
organism for the environment in which they will soon live, where perturbations during 
these early critical periods can result in reprogramming of cells and tissues that 
influence susceptibility to disease. There is strong evidence for DOHaD with respect to 
Pb exposure. Research into the Developmental Origins of Health and Disease has 
shown that perinatal exposure to Pb increases susceptibility to cognitive deficits later in 
life. Permanent cognitive and behavioral changes have been documented with early-life 
Pb exposure 18, 24, 25.  
Epidemiological studies of Pb exposed pregnant women have reported BLLs 
below 5µg/dL can be associated with disturbances in early mental growth and later 
intellectual function including negative temperament and dramatic IQ point decreases. 
Specifically, gestational exposure measures in mothers below 5 μg/dL 26 and in cord 
blood below 2 μg/dL 27 have been associated with decreased neonatal and infant 
behavioral neurological scores utilizing the neonatal behavioral neurological 
assessments and Bayley Scales of Infant Development II Mental Development Index, 
respectively. Another study provided evidence for lower Mental Development Index 
scores as early as 6 months of age due to late pregnancy maternal Pb exposures below 
5 μg/dL 28. Lastly, the Early Life Exposure in Mexico to Environmental Toxicants 
(ELEMENT) maternal-offspring pregnancy and birth cohort utilizes a series of 
longitudinal birth cohorts to investigate the influence of Pb exposure – in utero and in 
childhood – on sensitive periods of development. They found that first trimester 
 5 
maternal BLLs are associated with decreases upwards of 6.94 points in 24-month-old 
offspring per log microgram per liter Pb using the BSID-II Mental Development Index 24.  
Mothers were recruited during prenatal visits and samples were collected at each 
trimester and offspring continue to be followed to collect vast amounts of data on 
biological, psychological, and physical measures. The current dissertation will take 
advantage of the available biological samples and neurodevelopmental measures from 
ELEMENT to expand on this research study.  Despite major advances to reduce 
environmental exposures, epidemiological studies continue to demonstrate that Pb 
exposure affects cognition and behavior with major impacts on proper neurological 
functions 14, 17, 29, 30. 
Pb Exposure Affects Early-Life Neurotoxicity 
The development fetus is particularly sensitive to environmental contaminants, 
including Pb 31. The fetus can be exposed by stored Pb in bone from the mother’s 
previous exposures nearly decades prior as well as concurrent Pb exposure circulating 
in the blood. The half-life of Pb, which is documented to be about 40 days in blood, 
results in its lingering presence in the bloodstream after initial exposure 32. Once in the 
bloodstream, it distributes throughout the body and accumulates in bone. Pb forms 
highly stable complexes with phosphate that can replace calcium in the calcium-
phosphate crystalline matrix of bone 33. Residence time in bone ranges from several 
years to decades 34, accounting for more than 90% and 50% of total body burden of Pb 
in adults and infants, respectively 35. Physiological states, such as pregnancy, 
menopause, advanced age, and diseases states, such as osteoporosis, are associated 
with increased bone resorption to blood 36, 37. 
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Pb is known to be released into blood from bone during pregnancy and becomes 
a source of exposure in utero 36. Further, early life exposure can occur via placental 
transfer and in infancy through breast milk. Bone stores the highest content of Pb, and 
as bone resorption increases during pregnancy, this consequently releases Pb into the 
bloodstream, from where it could prospectively reach the developing fetus potentially 
causing abnormalities in fetal development 37, 38. The placenta does not provide an 
effective barrier against Pb 39, 40. Therefore, it could cross the placenta barrier, disrupt 
the blood-brain barrier, and disturb brain development and architecture by interfering 
with hardwiring and ongoing neurotransmission during development in utero. 
Neurotransmitters are chemicals used by neurons to send signals to other cells, Pb can 
disrupt communication between cells by affecting neurotransmitter storage and release 
and altering receptor density 25, 41.  
In addition to disrupting neurotransmission, there are several other known 
mechanisms of Pb neurotoxicity. Pb competes with Ca++ and disrupts its homeostasis, 
substitutes for zinc, alters lipid metabolism, can accumulate in astrocytes, and causes 
mitochondrial damage through various avenues such as opening pores, damaging 
membranes, stimulating release of Ca++, which results in apoptosis 41, 42. When Pb 
alters the release of neurotransmitters from presynaptic nerve endings, spontaneous 
release is evoked and release is inhibited resulting in disruption of neuronal activity, 
thus, altering the developmental processes of synapse formation 43. These processes 
result in damage to the central nervous system, potentially causing loss of memory and 
vision, and lowered cognitive and behavioral abilities leading to brain damage and/or 
neurodegeneration later in life. Studies have shown that developmental Pb exposure in 
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rats decreases hippocampal long-term potentiation, which is necessary for learning and 
memory 44-46. This study provided evidence that memory and spatial learning are 
vulnerable to impairment by Pb because Pb damages the developing hippocampus. 
Thus far, there is epidemiological evidence for the link between prenatal Pb exposure 
and evidence for several biological mechanisms by which Pb exerts its’ effects. 
Recently, evidence for an addition mechanism by which Pb may impart long-term 
effects on children is emerging: epigenetic regulation.   
Epigenetics and the Distinct Differences between DNA Methylation (5mC) and 
Hydroxymethylation (5hmC) 
One way in which developmental exposures impact infant and adult disease 
status is through alterations in gene regulation via epigenetic modifications, such as 
DNA methylation, histone modifications, and non-coding RNA interactions 47-50. 
Epigenetics is the study of mitotically heritable and potentially reversible changes in 
gene expression that are independent of DNA sequence. DNA 5mC is the addition of a 
methyl group covalently bound to the 5’-carbon of Cytosine (Figure 1.1); in mammals 
this typically occurs on a Cytosine adjacent to a Guanine, referred to as a CpG site 51, 52. 
These CpG sites are normally found near promoter regions, exon junctions, and 
enhancers, which influence gene expression 53. Increased levels of 5mC are associated 
with decreased transcription factor binding at promoter/enhancer sites and suppression 
of transcription 54. DNA methyltransferases add the methyl groups and if DNA 
methyltransferases fail to add new methyl marks during cellular replication, DNA can 
become demethylated, which is termed passive demethylation or loss of methylation 
(Figure 1.1) 55, 56. Alternatively, active DNA demethylation can also occur when the 
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methyl group is oxidized by TET enzymes into hydroxyl group (5hmC) followed by 
formyl (5fC) and carboxy (5caC) groups that are removed by base excision repair 
pathways and targeted demethylation (Figure 1.1) 57-59. Active demethylation involves 
the activity of thymine DNA glycosylase-mediated base excision repair, which only 
recognizes 5fC and 5caC and removes them, thus restoring unmethylated cytosines 
(Figure 1.1).  These intermediates have a short half-life while 5hmC is believed to be a 
more stable modification of cytosine 58, 60-62.  
The role of 5hmC as an important epigenetic mark of active DNA demethylation 
remains a great debate 63. Genome-wide 5hmC is associated with increased gene 
expression in human and mouse embryonic stem cells, suggesting a role in 
transcriptional control 64, 65. 5hmC mediates the binding affinity of proteins that recruit 
5hmC-binding proteins by acting as an intermediate for oxidative demethylation or a 
stable modification that eliminates the need for the removal of the methyl groups 66-68. 
Global 5hmC is highest in the brain and is also present in the liver, testes, placenta, 
colon, and blood, though in progressively lower levels 67, 69-73. In several human and 
animal studies, early-life neurologic disorders and later-life neurodegenerative disorders 
have been associated with 5hmC perturbations in the brain 74-77. Unfortunately, most 
current methods, including the gold standard sodium bisulfite sequencing, collectively 
measure 5mC and 5hmC without distinguishing between the two. Detecting changes in 
levels of 5hmC by exposures such as Pb may provide additional insights into 
mechanisms related to neurodevelopment toxicity.  
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Epigenome and the Environment 
The epigenome responds to environmental exposures. Environmentally sensitive 
regions of gene regulation can influence long-term epigenetic reprogramming 48, 50. 
There is evidence in vitro, humans, and animal studies that Pb can alter epigenetic 
regulation (Tables 1.1 & 1.2). One study exposed rat pheochromocytoma cells (PC12) 
to three concentrations of Pb (50, 250 and 500 nM) and assessed DNA methylation 
patterns in amyloid precursor protein (APP), which has been associated with the 
pathogenesis of Alzheimer’s disease, and DMNT1 78. They showed that exposure at all 
three doses were associated with hypomethylation in the APP promoter, and 500 nM 
group had global methylation and DNMT1 expression changes as soon as 2 days post-
exposure. Another study investigated the effects of various Pb concentrations (0.4μM, 
0.8μM, 1.2μM, 1.5μM, and 1.9μM) on neuronal differentiation in human embryonic stem 
cells (hESCs). Interestingly, Pb exposure did not prevent hESCs from generating neural 
progenitor cells 79. Pb induced rapid changes in global undifferentiated and 
differentiated hESCs DNA methylation in a dose-dependent manner. These studies 
provide evidence for potential neurotoxic effects through mechanisms altering both 
global and promoter methylation patterns. 
Human epidemiological studies have also identified DNA methylation associated 
with Pb exposure (Table 1.1). A U.S. prospective human pregnancy cohort, Project 
Viva, with an average prenatal Pb exposure of 1.22 ± 0.63 µg/dL in erythrocytes of 
pregnant mothers, conducted an epigenome-wide analysis on umbilical cord blood 
samples (n=268) to evaluate the association between maternal Pb exposure and DNA 
methylation 80. They identified sex-specific differentially, mainly hypomethylated, CpG 
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sites associated with increased Pb; in sex-stratified analyses, more inverse 
relationships were found between Pb and DNA methylation while the reverse was found 
among males. Another U.S. study utilizing samples from the Healthy Families Project in 
southeast Michigan measured at-birth Pb and DNA methylation in dried blood spots 
(n=96; mean Pb: 0.78 µg/dL), and identified similar associations of mostly 
hypomethylation with increasing Pb exposure in gene pathways association with 
development and neurological functions 81. Another Michigan study measured Pb and 
DNA methylation profiles in dried blood spots of males (n=25) and females (n=18) 3 
months to 5 years of age who reside in Detroit, where nearly half the children had BLLs 
at or above the Centers for Disease Control and Prevention BLL of concern (5 µg/dL) 31. 
Their pilot study identified conserved (irrespective of sex) loci of Pb-associated 
methylation, as well as female- and male-specific DNA methylation alterations related to 
Pb exposure. The Early Autism Risk Longitudinal Investigation (EARLI) U.S.-based 
cohort study investigated prenatal Pb (mean: 0.4 μg/dL) with DNA methylation in 
maternal first or second trimester whole blood (n=97), and identified global 
hypermethylation associated with increasing Pb but also site-specific hypermethylation 
of genes related to nervous system development, and calcium ion binding 82. Lastly, 
another study within the ELEMENT cohort (n=247) identified differential IGF2 
hypermethylation in umbilical cord blood with maternal patella bone Pb measures 
(mean Pb: 14.4 μg/g) and HSD11B2 hypermethylation among girls while conducting 
their candidate gene analysis 83. These studies found modest evidence for the 
association between prenatal Pb and DNA methylation, sex- and CpG-site specific, but 
one limitation encompasses each of these studies: assessment of neurodevelopment. 
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None of these studies evaluated the potential link between DNA methylation and 
neurodevelopment, nor did they assess the probability of DNA methylation playing a 
mediating role in the associations between prenatal Pb and adverse 
neurodevelopmental outcomes. 
In animal research studies (Table 1.2), differential methylation by Pb exposure 
was also identified. For example, a few studies utilized a murine model were post-
pubertal virgin a/a females, genetically invariant mice 93% identical to C57BL/6J strain, 
were prenatally exposed to Pb in water at three levels of human physiologically relevant 
doses two weeks prior to mating with Avy/a, and exposure in the females lasted through 
lactation. Exposure groups were 2.1 ppm, 16 ppm, and 32 ppm with BLL ranges (mean) 
of 2.0-5.88 µg/dL (4.1), 13-40 µg/dL (25.1), and 16-60 µg/dL (32.1), respectively. DNA 
total methylation was assessed via pyrosequencing at four Intracisternal A particle (IAP) 
elements in the brain of 10 month mice 84. IAPs are a class of murine retrotransposons 
that are environmentally responsive 47. Prenatal Pb exposure reduced DNA methylation 
around 2-3% at three of the intracisternal A particles in the brain with dose-dependent 
and sex-specific effects compared to control mice. Another candidate gene analysis 
assessing Avy and IAP (CabpIAP) with PND21 tail tissue identified hypermethylation at the 
2.1ppm Pb levels, but there was hypomethylation at the higher levels, where the sex-
effects were driven by males 85. A genome-wide analysis of 10 month aged cortex 
nuclei of the mice from the same exposure model identified only hypomethylated CpG 
sites within each exposure group 86. Two studies looking at the association between 
high prenatal Pb exposure (32ppm) in blood and liver DNA methylation at PND21 87 and 
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5 months of age 88 identified thousands of tissue- and sex-specific differentially 
methylated sites and regions with very little overlap between the tissues. 
One possible mechanism of Pb-induced changes in DNA methylation levels is 
through induction of active DNA demethylation. Metal exposures, such as Pb, cause 
indirect reactive oxygen species formation with thiol depletion resulting in oxidative 
stress 89, 90. Mechanistically, oxidative DNA damage is known to inhibit the ability of 
DNA methyltransferases to interact with DNA, causing hypomethylation at CpG sites 91, 
92. Subsequently, Pb-induced oxidative stress results in the accumulation of α-
ketoglutarate 93, a co-factor for TET enzymes which are involved in the oxidation of 5mC 
to 5hmC 94, 95. Thus, Pb may increase activity of TET enzymes and increase 5hmC 
across the genome 94. Thus, long-term exposure to Pb-induced oxidative stress could 
result in oxidative damage of methylated cytosines and decrease the level of 5mC while 
subsequently increasing 5hmC (Figure 1.1). Despite the great progress over the years, 
there are still gaps in animal and human studies regarding where perinatal Pb 
exposure-mediated epigenomic changes in 5mC and 5hmC occur and whether these 
are related to adverse neurodevelopmental outcomes. 
ELEMENT Cohort Overview 
The aims within this dissertation utilize samples from a well-established 
longitudinal birth cohort, ELEMENT 96. The ELEMENT Project is a mother-child 
pregnancy cohort that began in the mid-1990s in Mexico City, Mexico. It consists of 
three cohorts where data was collected from 1994-1995, 1997-2000, and 2001-2003, 
respectively. ELEMENT was originally set up to explore two main topics: 1) determine 
whether fetal growth and neurodevelopment are at risk from enhanced mobilization of 
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Pb during pregnancy from maternal bone, and 2) determine whether bone lead 
mobilization during pregnancy and lactation can be suppressed by maternal calcium 
supplementation and whether the calcium can mitigate adverse effects on offspring 
health and development. Since then, ELEMENT has become a major research resource 
on early-life exposures and developmental outcomes, and we continue to study the 
long-term consequences of toxicant exposures during perinatal period on adolescent 
children and young adults, some of whom have been followed for over 20 years. We 
hope to eventually study intergenerational effects of in utero exposures. This 
dissertation utilizes data and biological samples from Cohorts 2 and 3 that contain all 
the data needed in order to answer each aim’s hypothesis. 
Dissertation Overview 
This project utilizes a human birth cohort to study the underlying mechanisms of 
the association between prenatal Pb exposures with adverse neurodevelopmental 
outcomes. The overarching hypotheses for this dissertation are as follows: 1. 
Developmental exposure to Pb will result in alterations of DNA methylation (5mC) 
and hydroxymethylation (5hmC) at birth and these changes will persist into 
adolescence; 2. Epigenetics mediates the association between prenatal Pb 
exposure and adverse neurodevelopmental outcomes as early as infancy. To test 
these hypotheses, Aim 1 uses maternal trimester-specific human whole blood samples 
and matched infant UCB to identify genome-wide DNA methylation changes associated 
with prenatal Pb exposure. We expected to see a majority of the changes in methylation 
to be associated with the first trimester exposure. Further, we expected to see more 
hypomethylation by Pb genome-wide. Aim 2 expands from the first aim to assess 
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persistence of associations and also associations between Pb and 5hmC. Matched 
offspring human blood samples were collected in adolescence to determine if those 
significant changes in DNA 5mC and 5hmC by prenatal Pb exposure, measured with 
target gene pyrosequencing, will persist at this later timepoint in neurocognitive-related 
candidate genes. We expected the ability to detect 5hmC in human whole blood but at 
low levels (~1-5%). We anticipated the epigenetic reprogramming to persist into 
adolescence, particularly the changes related to first trimester exposure. Further, we 
predicted that as 5hmC increased, 5mC would decrease, and prenatal Pb exposure 
would have associated effects with each. Aim 3 uses mediation modelling to assess 
whether DNA methylation changes at birth in human umbilical cord blood may mediate 
the association of trimester-specific Pb exposure and adverse early-life 
neurodevelopmental indicators. We projected that DNA methylation would indeed 
mediate the association between prenatal Pb exposure and neurodevelopmental 
outcomes, and these mediating effects would be noticed as early as 12-months of age. 
This dissertation generated data necessary for better understanding of prenatal health 
risks surrounding developmental Pb exposure. This dissertation aims to fill knowledge 
gaps and contribute to the idea that epigenetics plays a key role in the adverse health 
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Tables and Figures 
Table 1.1: Epidemiological studies showing prenatal and childhood Pb exposure and associations with DNA methylation. 
Reference Region DNAm timing, 
tissue, and 
analysis 
Biomarkers used and Pb 





Sen et. al.97 USA 3 mos to 7 yrs 
Dried blood spot 
450K array 
Dried blood spot: 7.78 
(6.91) μg/dL 
Childhood Pb influences DNA methylation patterns in a 
gender-dependent manner.  
Goodrich et. al.83 Mexico Neonates 
UCB 
Pyrosequencing 
Maternal tibia: 9.82 (9.45) 
μg/g; Maternal patella: 
14.4 (14.8) μg/g; UCB: 
6.49 (3.52) μg/dL; 
Prenatal and 
at birth 
DNA hypermethylation in genes such as IGF2 
in neonates related to ≥10 μg/g in maternal 
patella bone. 
Rygiel et. al.98 Mexico Neonates 
UCB 
EPIC array 
T1: 6.56 (5.35) µg/dL; T2: 
5.93 (5.00) µg/dL; T3: 
6.09 (4.51) µg/dL; 
Maternal patella: 11.8 
(9.25) µg/g; Maternal tibia: 
11.8 (6.73) µg/g 
Prenatal DNA hypomethylation with increasing Pb at 
multiple CpG sites. DNA hypermethylation 
with increasing Pb at the regional level 
Montrose et. al.81 USA Neonates 
Dried blood spot 
EPIC array 
Dried blood spot: 0.78 
(0.85) µg/dL 
At birth  Majority (82%) of statistically significant CpG 
sites exhibiting hypomethylation with 
increasing Pb exposure. 
Aung et. al.82 USA T2 or T3  
Whole blood 
450K 
Maternal T2/T3: 0.4 (1.6) 
μg/dL 
Prenatal Hypermethylation at 11 DNA methylation sites 
associated with Pb. 50.9-55.8% 
hypermethylation globally with covariate or 
surrogate models. 
Wu et. al.80 USA Neonates 
UCB 
450K 
Maternal RBC: 1.22 (0.63) 
μg/dL 
Prenatal  Low-level Pb exposure associated with DNA 
hypomethylation. Sex-stratified analysis 
identified more hypermethylation in males but 
hypomethylation in females. 
Note: DNAm, DNA methylation; mos, months; yrs, years; 450K, Human Methylation 450K Bead chip; UCB, umbilical cord blood; EPIC, Human 
MethylationEPIC 850K Bead chip; T1, first trimester; T2, second trimester; T3, third trimester; RBC, red blood cells
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Table 1.2: Experimental studies of Pb exposure showing DNA methylation effects. 
Reference Experimental 
model 




of Pb and route 
Findings 
Li et. al.78  PC12 cells 2 and 7 days 2 and 7 days 50, 250 and 500 nM 
(0.0103, 0.0517, 
0.103 ppm) 
Hypomethylation of the APP promoter. 
Changes in the levels of global methylation and 
expression of DNMT1  
Bihaqi et. al.99 Monkey Birth to 400 
days of age 
Brain; 6, 12, 
and 23 years 
1.5 mg/kg/day (1.5 
ppm/day) 
Infant formula  
Reduction in levels of proteins involved in DNA 
methylation and histone modification  






2.1, 16, 32 ppm 
Drinking water 
Hypermethylation at the 2.1 ppm and 
hypomethylation at higher Pb levels; sex-effect 
driven by males 
Montrose et. 
al.84 




Brain; 10mo 2.1, 16, 32 ppm 
Drinking water 
Prenatal Pb exposure resulted in 
hypomethylation at three of the IAPs in the 
brain, and these changes were dose-
dependent and sex-specific.  







2.1 and 32 ppm 
Drinking water 
All statistically significant CpGs within each 
exposure group compared to control were 
hypomethylated 








~1000 differentially methylated cytosines for 
each tissue- and sex-specific comparison, 
mostly hypomethylated; hundreds of tissue- 












Thousands of sex-specific differentially 
methylated cytosines in the blood and liver of 
Pb-exposed animals; including gnomically 
imprinted loci 
Senut et. al.79 hESC 0 to 19 days 47 days 0.4μM (8 μg/dL), 
0.8μM (16 μg/dL), 
1.2μM (24 μg/dL), 
1.5μM (32 μg/dL), 
1.9μM (40 μg/dL) 
Pb induced rapid changes in the global DNA 
methylation patterns of undifferentiated and 
differentiating hESCs in a dose-dependent 
manner, mostly hypomethylated 
Note: PC12, pheochromocytoma cells; hESC, human embryonic stem cells; ppm, parts per million 
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Figure 1.1: DNA cytosine methylation and demethylation pathway. 
Passive demethylation occurs when DNA replicates in the absence of DNA 
methyltransferases (DNMTs) (blue dashed arrows). Active methylation (red solid 
arrows) involves DNMTs covalently bonding a methyl group to the 5’-carbon of cytosine. 
Active demethylation (solid purple arrows) occurs when TETs hydroxylate 5-
methylcytosines (5mC) to form 5-hydroxymethylcytosines (5hmC); further oxidation 
produces 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). Base excision repair 
(BER) pathways and targeted demethylation can remove 5fC and 5caC. Alternatively, 
thymine DNA glycosylase (TDG)-mediated BER can restore unmethylated cytosines 
through active demethylation. 5mC silences regulatory functions, whereas 5hmC is 





Figure 1.2: Conceptual model summarizing the dissertation aims.  
Hypotheses from the three aims work together to examine the effects of environmental 
factors on epigenetics perturbations and adverse neurodevelopmental outcomes. Each 
aim is indicated by colors (Aim 1 = blue, Aim 2 = purple, Aim 3 = green). Biomarkers 






Chapter 2 Trimester-Specific Associations of Prenatal Lead (Pb) Exposure with 
Infant Cord Blood DNA Methylation at Birth 
Abstract 
Gestational exposure to lead (Pb) adversely impacts offspring health through 
multiple mechanisms, one of which is the alteration of the epigenome including DNA 
methylation. This study aims to identify differentially methylated CpG sites associated 
with trimester-specific maternal Pb exposure in umbilical cord blood (UCB) leukocytes. 
Eighty-nine mother-child dyads from the Early Life Exposure in Mexico to Environmental 
Toxicants (ELEMENT) longitudinal birth cohorts with available UCB samples were 
selected for DNA methylation analysis via the Infinium MethylationEPIC BeadChip, 
which quantifies methylation at >850,000 CpG sites. Maternal blood lead levels (BLLs) 
during each trimester (T1: 6.56±5.35µg/dL; T2: 5.93±5.00µg/dL; T3: 6.09±4.51µg/dL), 
bone Pb (patella: 11.8±9.25µg/g; tibia: 11.8±6.73µg/g), a measure of cumulative Pb 
exposure, and UCB Pb (4.86±3.74µg/dL) were measured. After quality control 
screening, data from 786,024 CpG sites were used to identify differentially methylated 
positions (DMPs) and regions (DMRs) by Pb biomarkers using separate linear 
regression models, controlling for sex and estimated UCB cell-type proportions. We 
identified three DMPs associated with maternal T1 BLL, two with T3 BLL, and two with 
tibia bone Pb. We identified one DMR within PDGFRL associated with T1 BLL, one 
located at chr6:30095136-30095295 with T3 BLL, and one within TRHR with tibia bone 
Pb (adjusted p-value<0.05). Pathway analysis identified 15 overrepresented gene 
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pathways for differential methylation that overlapped among all three trimesters with the 
largest overlap between T1 and T2 (adjusted p-value<0.05). Pathways of interest 
include nodal signaling pathway and neurological system processes. These data 
provide evidence for differential methylation by prenatal Pb exposure that may be 
trimester-specific.  
Introduction 
 Lead (Pb) is a ubiquitous environmental pollutant found in air, soil, water and 
food. Human exposures mainly occur through ingestion and inhalation, and Pb can be 
stored long-term in teeth and bones. Pb is a potent neurotoxicant that alters brain 
development resulting in abnormal cognition and behaviors. Early life Pb exposure also 
increases the risk for developing a variety of adverse health outcomes later in life, 
including Alzheimer’s, attention-deficit/hyperactivity disorder, cardiovascular disease, 
and intellectual deficits 1-5. The Institute for Health Metrics and Evaluation (IHME) 
estimated in 2017 that Pb exposure accounted for almost 2 percent of total all-cause 
mortality and at least 2.5 million years of healthy life lost (disability-adjusted life years 
(DALYs)) worldwide due to idiopathic developmental intellectual disability  6, but this 
may be an underestimate 7.   
The health effects of prenatal Pb exposure can be framed with the 
Developmental Origins of Health and Disease (DOHaD) theory 8, which links early-life 
exposures to the development of disease and adverse health effects later in life. The 
placenta is not an effective barrier against Pb, and since bone reabsorption increases 
during pregnancy, Pb is released into the bloodstream from where it can reach the fetus 
potentially causing abnormalities in development 9-13. The fetus may be exposed to 
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stored Pb in bone from the mother’s previous exposures nearly decades prior as well as 
to concurrent Pb exposure circulating through the blood. 
It has been hypothesized that toxicant exposures, including Pb, may result in 
epigenetic modifications during sensitive developmental periods, thereby impacting 
gene regulation and subsequent development and later life health outcomes. Epigenetic 
modifications, which include DNA methylation, are mitotically heritable and regulate 
gene expression without altering the underlying DNA sequence. DNA methylation 
occurs primarily in cytosine-guanine (CpG) dinucleotides, which are enriched in regions 
called islands, typically located in promoter regions of genes 14,15. Establishment of DNA 
methylation patterns occurs in early gestation and disturbances during this period may 
result in DNA methylation variations that are propagated through mitosis to new cells 
and developing organs thus affecting gene expression in a wide range of tissues 
associated with various developmental physiological processes 16.  
We and others have provided evidence for the impact of early-life Pb exposure 
on the epigenome in animal and human studies. In mice, dams were exposed to one of 
three doses of Pb acetate in water prior to mating through weaning, and the offspring 
were followed through adulthood and compared to unexposed mice. Lead was 
associated with altered DNA methylation in offspring tail tips immediately following 
cessation of exposure (3 weeks of age) at two metastable epialleles17. Altered DNA 
methylation by Pb was also observed in offspring brain (10 months of age) at 
environmentally-responsive retrotransposons18.  In a human birth cohort, we quantified 
DNA methylation at four genes in 247 umbilical cord blood (UCB) leukocyte DNA 
samples. Biomarkers of prenatal Pb exposure (maternal tibia: 9.82 (SD=9.45) µg/dL, 
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maternal patella: 14.4 (SD=14.8) µg/dL, UCB: 6.49 (SD=3.52) µg/dL) were associated 
with percent DNA methylation in neonates in long interspersed elements 1 (LINE-1), as 
well as growth-related genes (IGF2 and HSD11B2) providing evidence for maternal 
cumulative Pb burden influencing the epigenome of a developing fetus 19. Lastly, the 
U.S. prospective pregnancy cohort, Project Viva conducted an epigenome-wide 
analysis on 268 UCB samples to evaluate the association between prenatal maternal 
Pb exposure (mid-to-late gestation Pb in erythrocytes averaged 1.22 (SD=0.63) µg/dL) 
and DNA methylation 20. Results identified sex-specific differentially methylated CpG 
sites by Pb exposure with more found in females (n=38) than males (n=2). 
Mechanistically, metal exposures such as Pb increase oxidative stress and can cause 
oxidative DNA damage which inhibits the ability of methyltransferases to bind to DNA; 
this leads to hypomethylation at some loci 21-23. Additionally, Pb exposure has been 
shown to alter expression and function of epigenetic machinery (i.e., DNA 
methyltransferases (DNMTs)). Several human and animal studies suggest DNA 
methylation changes from developmental Pb exposure are due to altered DNMT 
expression and activity 21,24-27.   
Despite mounting evidence for Pb’s effect on the epigenome, no studies have 
specifically investigated the association between genome-wide DNA methylation and Pb 
exposure during each of the three trimesters of pregnancy, as well as cumulative 
gestational Pb exposure estimated by maternal patella and tibia measures. We 
hypothesize that prenatal Pb exposure will be significantly associated with changes in 
DNA methylation patterns across the genome at birth and that these changes will differ 
depending on the timing of exposure.  A whole genome approach will assist researchers 
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in gaining valuable insight into the effects of prenatal Pb exposure on gene regulation 
and help to identify potential biomarkers of interest specific to each trimester and 
cumulative exposure. Here, we performed Pb exposure assessment in multiple 
biomarkers and DNA methylation profiling in UCB samples from 89 mother-infant pairs 
enrolled in the Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) 
project, a longitudinal birth cohort. 
Methods 
Study population 
The Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) 
project has utilized a series of longitudinal birth cohorts to investigate the influence of 
exposure to Pb and other toxicants – in utero and in childhood – on sensitive periods of 
development. This project is based on three sequentially recruited cohorts comprising of 
1643 mother-infant pairs, some of whom have been followed for over 20+ years 28. The 
present study uses data and biological samples from the second and third birth cohorts, 
for which 1530 women were originally enrolled, and 1012 mother-infant pairs were 
followed up after birth. Women were recruited from 1997-2000 and 2001-2005, from the 
Mexican Social Security Institute hospital in Mexico City. Eligibility and exclusion criteria 
are as previously described 28,29. For all recruited mother-child pairs, data collected 
include sex, gestational age, socioeconomic status, anthropometry data, and other 
environmental exposures. Families were followed-up at multiple timepoints from infancy 
through adolescent years. For the current study, we selected 97 ELEMENT participants 
from the second and third cohorts who had archived UCB samples from which we could 
isolate DNA. The final study comprised of 89 mother-infant dyads whose epigenetic 
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data passed downstream quality control (QC). Characteristics of these 89 participants 
compared to all women of cohorts 2 and 3 that had least one Pb biomarker 
measurement (n=1214) and their children are represented in Table 2.1A Appendix.   
At the time of enrollment, all mothers were informed about the study; those who 
agreed to participate read and signed a letter of informed consent about the original 
study. The original research protocol and all amendments to the study protocol were 
approved by the Ethics Committees of the National Institutes of Public Health of Mexico, 
participating hospitals, and the Internal Review Board at all participating institutions 
including the University of Michigan. 
Pb exposure assessment and genomic DNA isolation 
UCB was collected within 12 hours after birth. Cohort 2 blood lead levels (BLLs) 
from each trimester and UCB were measured using inductively coupled plasma mass-
spectrometry (ICP-MS, Thermo Finnigan, Bremen, Germany) at the University of 
California, Santa Cruz, as described previously 30. Cohort 3 BLLs in maternal venous 
blood from each trimester and UCB were measured at the Trace Metal Laboratory of 
the American British Cowdry Hospital using graphite furnace atomic absorption 
spectrometry (instrument model 3000; PerkinElmer, Norwalk, CT, USA).  
Bone Pb was measured in maternal left patella (trabecular bone) and mid-shaft 
of the left tibia (cortical bone) 1-month post-partum as an indicator of cumulative Pb 
exposure during pregnancy using a spot-source 109Cd K-shell X-ray fluorescence (K-
XRF) instrument. The technical specifications and validation of this instrument is 
described in detail elsewhere 31. Analysis of means and standard deviations once 
weekly for quality control and calibration measures did not disclose any significant shifts 
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in precision or accuracy. Tibia and patella bone Pb values below the limit of detection 
(i.e., negative values) were dropped from subsequent analyses resulting in 73 patella 
bone Pb and 46 tibia bone Pb measures. 
DNA was isolated from nucleated UCB cells using Qiagen kits and standard 
protocols for blood DNA isolation. Nucleic acid yield and purity were assessed first 
using a NanoDrop spectrophotometer (ThermoFisher Scientific), and doubled stranded 
DNA was also quantified via a Qubit fluorometer. All DNA samples were stored at -80oC 
until later use. 
Epigenetic analysis 
All genomic DNA samples were bisulfite converted (500 ng) using the Zymo EZ 
DNA Methylation kit (Zymo Research) and the recommended incubation conditions and 
methods for downstream Infinium analysis. In short, this treatment converts 
unmethylated cytosines to uracils while leaving methylated cytosines intact. DNA 
methylation was quantified at 863,904 CpG sites following hybridization to the Infinium 
MethylationEPIC BeadChip (Illumina) 32. Beadchips were processed and scanned on 
the Illumina iScan at the University of Michigan (UM) Advanced Genomics Core using 
the Infinium Methylation EPIC kit.  
We used a preprocessing pipeline for the resulting raw EPIC data based on a 
functional normalization method 33 within the ‘minfi’ package in R 34. The pipeline 
included several steps: loading raw image files, linking to phenotypic information, 
dropping probes with SNPs within query sites, removing poor quality samples (>5% 
failed probes) and poorly detected probes (p-value>1e-6 when comparing to 
background), normalizing the data to correct for background signal and dye bias, 
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checking and correcting for batch effects (by slide and array), and removing CpG sites 
on the X and Y chromosomes. After QC and normalization, 786,024 CpG sites and 89 
samples passed all QC measures and were subsequently used in statistical analysis. 
Estimates of cell-type composition (T lymphocytes (CD4T, CD8T), B cells, NK 
cells, monocytes, granulocytes, and nucleated red blood cells) for each sample was 
performed using an established method based on UCB cell-type specific differentially 
methylation regions. Cell-type proportions were adjusted for in downstream statistical 
analysis to avoid confounding by cell-type composition 35. Beta-values and M-values 
(log2 ratio of the intensities of methylated probes versus unmethylated probes) were 
then calculated from the processed data and used in statistical analysis 36. 
Statistical analysis 
All statistical analyses were performed in the R Project for Statistical Computing 
(version 3.4.3). Analyses were performed to identify differentially methylated loci by Pb 
exposure. Pb biomarkers tested were maternal BLLs at each trimester, UCB Pb levels, 
and Pb levels in maternal patella and tibia, which were treated as non-transformed 
continuous variables. Bone and UCB Pb levels were normally distributed. Trimester-
specific Pb measures were right-skewed yet all biomarker concentrations were 
biologically plausible and relevant to this study population. As such the relationships 
between maternal BLLs and DNA methylation were tested with and without BLL outliers.  
We performed bivariate analyses relating Pb biomarkers and covariates (e.g., cell-type 
proportions, gestational age, maternal age, maternal education, household income 
category) to identify potential confounders. We also performed singular value 
decomposition to identify covariates associated with principal components of the DNA 
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methylation data. We then chose potential confounding variables to include in the final 
statistical models of site-specific DNA methylation data that were associated with both 
Pb and DNA methylation. We also retained several variables that had a large effect on 
DNA methylation but were not also associated with Pb (i.e., infant sex, cell type 
proportions). In models with BLLs, offspring sex and estimated cell-type compositions of 
granulocytes and nucleated red blood cells (nRBC) 35  were included. Models with bone 
Pb measures as the predictor of interest additionally included maternal age and cohort. 
Other covariates available in this study population, including gestational age, were not 
considered as confounders because they were neither associated with prenatal Pb 
exposure nor DNA methylation in our study sample.  
Differentially methylated positions (DMPs) by Pb were identified using the ‘limma’ 
package 37,38. Briefly, linear regression models were run for each CpG site using M-
values, which are the logit ratio of intensities of methylated probes versus unmethylated 
probes, with one Pb exposure biomarker as the predictor of interest and the 
aforementioned covariates included. Limma calculates fold-change in methylation, t-
statistics, and p-values by applying empirical Bayes smoothing to the standard errors.  
To account for multiple testing, we used the false discovery rate (FDR) method 39, and 
consider DMPs with corrected p-value (q-value) <0.05 to be statistically significant. For 
comparison purposes between studies, we also report estimates (β) from the same 
regression analysis with betas (non-transformed methylation values) as the outcome. 
We used the statistical package DMRcate to test associations between each Pb 
exposure variable and differential methylation at the regional level across the entire 
genome 40. The Gaussian kernel bandwidth lambda values used was the default of 
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1000, and two CpG sites were considered the minimum consecutive loci to be included 
in a differentially methylated region (DMR). DMRs with FDR<0.05 were statistically 
significant.  
 We used LRpath, a multiple-comparison enrichment testing tool that uses 
logistic regression to test for gene sets that have higher significance values by raw p-
value than expected at random 41, to identify gene pathways enriched for hyper- or 
hypo-methylation by Pb exposure. It considers CpG sites in known genes, their 
respective log fold changes by Pb from linear regression models, and associated p-
values.  
Results 
Descriptive statistics of ELEMENT study data 
 Among the 89 mothers included in this analysis, 41 (46%) had male infants 
(Table 2.1). The mean age of women at offspring birth was 26.4 (SD=4.8) years. The 
average gestational age at birth was 39.0 (SD=1.1) weeks. The mean (SD) maternal 
BLLs averaged over all three trimesters was 6.18 (4.51) µg/dL, with the first trimester 
(T1) mean of 6.56 (5.35) µg/dL, second trimester (T2) mean of 5.93 (5.00) µg/dL, and 
third trimester (T3) mean of 6.09 (4.51) µg/dL. Maternal BLLs between the trimesters 
were highly correlated (r>0.63) according to a Spearman’s rank-order correlation test. 
Average Pb concentration in patella was 9.42 (10.28) µg/g and tibia was 7.51 (9.46) 
µg/g. UCB Pb levels were measured to represent offspring Pb exposure at birth and 
averaged 4.86 (3.74) µg/dL. Geometric means of BLL among women in this study were 
more than four times higher than women of childbearing ages within a similar time 
period in the United States according to NHANES (1999-2002 and 2003-2006) 42.  
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Sources of Pb exposure in Mexico City during this time included the use of traditional 
lead-glazed ceramics for cooking, and Pb in gasoline which was not phased out in full 
until 1997 43. Pregnant women in countries such as Malaysia, India, Iran, Malta, and 
Bangladesh continue to have exposures similar or up to two-and-a-half times greater on 
average than that of the women in this study44-48. 
 We compared participants included in this analysis with all ELEMENT mother-
infant pairs from the same cohorts (2 and 3). Demographics and Pb biomarker 
concentrations were not statistically different between the subset and the entire study 
(Table 2.1A Appendix) with the exception of gestational age which was slightly higher 
in the subset with DNA methylation data.  
CpG-site specific analysis and pathways analysis 
We found that DNA methylation levels at three CpG sites demonstrated 
significant associations (FDR<0.05) with T1 BLLs, one CpG with T3 BLLs, and two with 
tibia bone Pb levels (Table 2.2). There were no statistically significant DMPs in 
analyses with maternal BLLs in T2, UCB Pb, or maternal patella bone Pb. Of the three 
statistically significant DMPs with the maternal BLLs during T1, the sites mapped to 
RAB5A, EXT1, and a non-genic region (chr8:12615485). The DMPs in RAB5A and 
EXT1 had less DNA methylation (-0.22% and -0.02%, respectively) per 1-µg/dL 
increase in maternal T1 BLLs. In contrast, the non-genic region (chr8:12615485) was 
hypermethylated by Pb (0.35% per µg/dL of T1 BLL). The DMP by T3 maternal BLLs 
was hypomethylated (-0.52% per µg/dL BLL) and in a DNase I hypersensitivity site 
(chr1:160839299). Maternal tibia bone Pb associated DMPs were hypermethylated in 
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LNFN1 (0.37% per µg/g bone Pb) and hypomethylated in a non-genic region located at 
chr6:792305 (-0.21% per µg/g bone Pb).  
LRpath analysis was conducted to test for gene sets enriched with differential 
methylation by each Pb biomarker. After multiple-comparisons correction, there were 
109 gene sets enriched with T1 BLLs, 76 with T2 BLLs, 28 with T3 BLLs, and 12 with 
UCB Pb levels, as well as 15 with patella and 68 with tibia bone measures that met a q-
value cut-off of 5% (Table 2.2A Appendix). Differently methylated genes associated 
with Pb exposure across all three trimesters and at birth were more likely to be enriched 
in gene pathways involved in detection of chemical stimulus, sensory perception and 
smell, immunoglobin binding, transmembrane receptor activity, and olfactory receptor 
activity. Four pathways were statistically significant (q-value<0.05) among all blood Pb 
variables, with 35 uniquely overlapping between T1 and T2, four uniquely overlapping 
between T2 and T3, none matching between T1 and T3 only, and two matching 
between T1 and at birth UCB (Figure 2.1). There were only four matching pathways 
when comparing results from models of tibia and patella bone Pb measures (Figure 
2.2A Appendix).  
Significant pathways from Gene ontology (GO) and Kyoto encyclopedia of genes 
and genomes (KEGG) pathways related to neurological development included 
neurological system processes associated with T1 (q-value =2.87E10-6) and T2 (q-
value=1.77E10-3) BLLs and tibia bone Pb (q-value =5.65E10-9). Nodal system pathway 
was also associated with T1 (q-value =1.40E10-3) and T2 (q-value =1.36E10-3) BLLs. 




We tested for differentially methylated regions by Pb exposure for each trimester 
using DMRcate, which combines data from at least 2 consecutive CpG sites. DMRcate 
identified one region of differential methylation with T1 BLLs, one region with T3 BLLs, 
and one region with tibia bone Pb levels. No regions were identified with T2 BLLs, UCB 
Pb, or patella bone Pb. The region identified in T1 that was differentially methylated 
included 4 CpG sites in a region that is located between chr8:17433625-17433761 and 
is within the promotor of PDGFRL (Figure 2.2). The region identified in T3 included 12 
CpG sites located at chr6:30095136-30095295 (Figure 2.3). Tibia bone Pb was 
associated with a region with 4 CpG sites within the promotor of TRHR (Figure 2.4). 
None of the DMPs identified before encompassed these regions. 
Conclusion 
We performed an epigenome-wide DNA methylation analysis using DNA 
extracted from nucleated UCB cells and the Illumina MethylationEPIC beadchip in 89 
mother-infant pairs to identify differentially methylated genes by trimester-specific and 
cumulative Pb exposure biomarkers. To our knowledge, this is the first genome-wide 
DNA methylation study to investigate the association of DNA methylation at birth with 
prenatal Pb exposure at each of the three trimesters of pregnancy, as well as 
cumulative prenatal Pb exposure in maternal patella and tibia bones. We found that 
maternal BLLs during T1 and T3, as well as maternal tibia bone Pb levels, were 
associated with differential methylation at several CpG sites in UCB.  
Epidemiological studies of Pb exposed pregnant women have reported BLLs 
below 5µg/dL can have adverse impacts on neurodevelopment, manifesting for example 
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as decreased scores in the neonatal behavioral neurological assessment test49. 
Maternal BLLs under 10µg/dL have been associated with  a 3.5-6 point decrease in the 
Mental Development Index, a measure of IQ using the Bayley Scales of Infant 
Development, in 12-month-old infants (n=146) 29. Although the inverse association 
between prenatal Pb exposure and neurodevelopment is known, whether epigenetic 
perturbation is one of the mechanisms underlying this association is not known.  
In the epigenome-wide analysis performed here, the statistically significant DMPs 
and DMRs associated with biomarkers of prenatal Pb exposure annotated to several 
genes involved in neurodevelopment or neurologic function.  In this study, DNA 
methylation levels at three CpG sites were significantly associated with maternal T1 
BLLs, for which one is in a DHS within the first exon of RAB5A, a Ras-related protein. 
DHS are regulatory regions of the genome often located at transcription start sites 
where the DNA is accessible for transcription factor binding. RAB5A is an important 
mediator of endocytic pathways due to its role in intracellular membrane trafficking and 
fusion and localizing early endosomes 50-53. Evidence from an in vitro study indicates 
that loss of RAB5A activity may perturb endosomal dynamics and may underlie 
neuronal dysfunction and degeneration in various motor neuron and neurodegenerative 
diseases 54. The second CpG site associated with T1 BLLs is located at chr8:12615485, 
a DHS that is also classified to be within an enhancer region (according to FANTOM5 
55) but unclassified to date in terms of the specific gene(s) it may regulate. The third 
CpG site is in a DHS, a suspected enhancer, and is within 200 base pairs of the 
transcription start site of EXT1, exostosin glycosyltransferase 1. EXT1 has a primary 
role in the biosynthesis of heparan sulfate, which is known to regulate various biological 
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processes such as cell proliferation, growth factor signaling, and embryonic 
development, specifically mammalian neuronal development 56-59.  
Maternal T1 Pb exposure was also associated with differential methylation in 
UCB at the regional level, identified by analyzing consecutive probes. We observed a 
region of 4 CpG sites located at chr8:17433625-17433761 within 200 base pairs of the 
transcription start site of PDGFRL, platelet derived growth factor receptor-like protein. 
This gene encodes a known tumor suppressor that inhibits the growth of colorectal 
cancer cells in vitro; the function of this gene in development, if any, is not yet known 60. 
We observed one association between DNA methylation and T3 BLL. The CpG 
site associated with T3 BLLs is located at chr1:160839299 in an intergenic region within 
a DHS.  In the regional analysis, there was one differentially methylated region that was 
statistically associated with maternal T3 Pb exposure. It annotated to chr6: 30095136-
30095295 with 12 methylation sites within an intergenic region with no known regulatory 
function.  
DNA methylation levels at two CpG sites were significantly associated with tibia 
bone Pb, a measure of cumulative Pb exposure throughout and before pregnancy. The 
first is within a DHS located in the gene LRFN1, Leucine Rich Repeat and Fibronectin 
Type III Domain Containing 1. LRFN proteins promote neurite outgrowth and synapse 
formation in hippocampal neurons and have a role in the developing nervous system 
with involvement in the regulation and conservation of excitatory synapses 61-63. The 
second is located within a CpG island at chr6:792305 of no known regulatory function to 
date. We identified one region of differential methylation associated with tibia bone Pb 
located in the TRHR gene, thyrotropin-releasing hormone receptor, on chr8:110098835-
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110098870 within 800 base pairs of the transcription start site. This receptor signals 
synthesis, secretion, and bioactivity of the thyroid stimulating hormone within the 
pituitary gland in the brain by activating the phosphatidylinositol-calcium-protein kinase 
C transduction pathway 64,65. We did not identify associations between patella Pb and 
DNA methylation. Pb in tibia has a residence time of 25-30 years66 while patella Pb has 
a half-life ranging from months to years67. While both serve as proxies for gestational Pb 
exposure, differences in half-life and bioavailability (i.e., following bone turnover) may 
influence the relationship between maternal bone Pb and fetal exposure dose 
throughout pregnancy.    
We hypothesized that the greatest number of DMPs by Pb would be identified for 
T1, yet only a few significant results were obtained for T1, along with T3 and bone Pb. 
During early gestation, there are two major events influencing epigenetic programming: 
(1) post-fertilization there is a massive wave of demethylation to trigger embryonic 
developmental; (2) following, there is a subsequent re-methylation that shapes the 
epigenome in first cell lineages 68,69. These events occur during early T1, and as such 
environmental perturbation during T1 could lead to epigenetic reprogramming that is 
propagated across all germ layers and tissues. Differentiation, which is critical for 
nervous system development, also occurs during T1 70. Throughout the remainder of 
fetal development, dividing somatic cells are methylated via maintenance epigenetic 
machinery 16. Thus, while gestational exposures are expected to have the most 
dramatic effects on the DNA methylome across tissues, subtle changes can still occur in 
mid- to late-gestation that may be tissue-specific.  
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Our study is one of a growing body of literature that shows associations between 
gestational Pb exposure and offspring DNA methylation in rodent models and humans 
19,20,71-75. While the DMPs and DMRs identified in this study by T1 and T3 maternal BLL 
and maternal bone Pb were not the same as those previously reported in other cohorts, 
collectively these studies show that Pb exposure and DNA methylation vary by timing of 
exposure, sex, and population. A rural Bangladesh birth cohort study with high 
environmental Pb exposure performed epigenome-wide DNA methylation profiling using 
the Infinium HumanMethylation450K BeadChip (450K) on UCB and assessed its 
association with prenatal Pb exposure measured in maternal urine at 8 weeks’ gestation 
and in maternal erythrocytes at 14 weeks gestation (n=127) 76. This study identified nine 
loci associated with urine Pb and two loci with erythrocyte Pb. Another study, a U.S. 
prospective pregnancy cohort, Project Viva, with relatively low levels of Pb exposure 
(mean maternal erythrocyte Pb, 1.22±0.63μg/dL) conducted an epigenome-wide 
analysis using 450K on 268 UCB samples to evaluate the association between prenatal 
Pb exposure measured on average at 27.9 weeks’ gestation and DNA methylation 20. 
Their results identified four CpG sites in all newborns, as well as sex-specific CpG sites 
with more found in females (n=38) than males (n=2), associated with prenatal Pb. 
Differences in findings from these cohorts and ELEMENT could be due to differences in 
exposure levels between the cohorts, participant racial/ethnic background, sex 
differences, timing of Pb exposure assessment, and statistical power to detect true 
associations. Even so, our study adds to the previous evidence that prenatal Pb 
exposure is associated with altered DNA methylation with likely small effect sizes, and 
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this potential mechanism of toxicity or biomarker of response to exposure should be 
studied in larger cohorts and/or in consortiums. 
While the mechanism by which Pb perturbs DNA methylation is not entirely 
known, several studies provide evidence for direct or indirect changes in DNMT 
expression and activity by Pb. DNMTs add methyl groups to CpG sites; if DMNTs fail to 
add methyl marks during cellular replication, DNA can become passively demethylated 
77,78. Pb exposure has been shown to increase reactive oxygen species which inhibits 
the DNMT binding to DNA causing hypomethylation at some but not all loci 21-23,79,80. 
Additionally, several studies have provided evidence for Pb exposure effects on DMNT 
expression and function which could result in either increases or decreases in 
methylation 21,24-27.  
Our study had several strengths including Pb exposure assessment at multiple 
time periods during gestation, epigenome-wide assessment of DNA methylation, a 
prospective study design, and rich data on key covariates. At the same time, our study 
has limitations.  First, due to the sample size, we were unable to perform a sex-specific 
analysis to determine how sex may influence the relationship between DNA methylation 
and developmental Pb exposure. We were also underpowered to detect all ‘true’ 
differentially methylated genes by Pb exposure, especially those with small effect sizes. 
Secondly, although epigenomic changes in early gestation would be expected to 
propagate across all tissues, it is still important to consider tissue-specificity when 
conducting differential methylation studies. While brain is the primary tissue of interest 
in terms of Pb toxicity, blood-based epigenetic measures are typically necessary in 
longitudinal epidemiological studies. Cross-tissue studies should be conducted to better 
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understanding the biological connection between our findings in UCB with DNA 
methylation in the brain 81. The Toxicant Exposures and Responses by Genomic and 
Epigenomic Regulators of Transcription (TaRGET II) consortium is currently promoting 
efforts towards understanding the role of environment in disease susceptibility as a 
function of epigenomic perturbations across target and surrogate tissue using mouse 
models (i.e. blood and brain), which will provide insights on cross-tissue, inter-
interindividual variation of epigenomic marks 82. Finally, although DNA methylation 
changes would be expected to alter gene expression, we are unable to test this 
hypothesis; storage conditions of archived UCB samples in this cohort did not allow for 
RNA isolation. 
In conclusion, we found that T1, T3, and the cumulative measure in tibia of 
gestational Pb exposure were associated with several statistically-significant changes in 
DNA methylation. Five of the six CpG sites identified within the study were located 
within DHS which are important functional regions for gene regulation. There was no 
statistically significant differential methylation by T2 BLL, cord blood Pb, and patella 
bone Pb. Our findings are of importance because prenatal Pb exposure has been 
previously associated with adverse neurodevelopmental outcomes, but whether 
epigenetic mechanisms contribute to these long-term effects is not well characterized. 
Pb still remains a widespread environmental health problem. Dietary changes and 
micronutrient supplementation during pregnancy could play an essential role in 
neutralizing epigenomic perturbations due to environmental Pb exposure 83-85 , and the 
concentration of Pb in circulation can also be reduced by dietary supplementation (i.e. 
to calcium) 86. Many public health promotion efforts are centered on primary prevention 
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of Pb exposure in early childhood even though gestation is also a critical developmental 
period when Pb can affect long-term health. Our results suggest that prenatal Pb 
exposure may modify DNA methylation profiles at birth, and this should be explored as 
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Tables and Figures 
 
Table 2.1: Characteristics of ELEMENT mother-infant pairs with UCB DNA methylation 
data. 
Characteristics No. Mean ± SD or N (%) Range 
 Mothers 
   
    Age (yrs.) 89 26.4 ± 4.81 18.0 - 37.0 
    Blood lead (µg/dL) 
   
        First Trimester (T1) 69 6.56 ± 5.35 0.90 - 35.8 
        Second Trimester (T2) 74 5.93 ± 5.00 0.80 - 38.2 
        Third Trimester (T3) 76 6.09 ± 4.51 0.90 - 34.0 
        Average All Trimesters 77 6.18 ± 4.51 1.17 - 33.1 
    Bone lead (µg/g) 
   
        Patella 73 11.8 ± 9.25 0.20 - 42.0 
        Tibia 46 11.8 ± 6.73 0.40 - 28.8 
    Household Income 77   
        Lowest  12 (15.6)  
        Low-Middle  31 (40.3)  
        Middle  20 (26.0)  
        Middle-High  9 (11.6)  
        Highest  5 (6.5)  
    Maternal education (total yrs.) 89 11.0 ± 2.39 3.00 - 17.0 
 Children 
   
    UCB lead (µg/dL) 86 4.86 ± 3.74 0.00 - 19.5 
    Gestational age (wks.) 87 39.0 ± 1.09 36.0 - 41.0 
    Male (%) 89 41 (46.0) 
 




Table 2.2: Statistically significant DMPs (q<0.05) by first trimester maternal BLL, third 
trimester maternal BLL, and maternal tibia Pb. 
Pb  
Biomarker 
Probe ID Gene 
Name 
Chr Pos β 
estimate  
P-Value Q-Value 
T1 BLL cg17138393 RAB5A chr3 19988887 -0.000221 5.46E-08 0.0227 
cg03390844  chr8 12615485 0.00348 5.78E-08 0.0227 
cg00984923 EXT1 chr8 119124069 -0.000235 1.49E-07 0.0390 
T3 BLL cg01328348  chr1 160839299 -0.00519 1.81E-08 0.0142 
Tibia Pb cg00002033 LRFN1 chr19 39798481 0.00367 3.57E-08 0.0281 
cg03463208  chr6 792305 -0.00205 7.23E-08 0.0284 
Note: Results from the analysis are shown for CpG sites associated with Pb biomarker levels below q-
value of 0.05 from models adjusted for sex and estimated cell-type proportions (granulocytes and 
nucleated red blood cells). The p-values and q-values are obtained from the analyses using methylation 
expressed as M-values as the outcome variable and reported association estimates (β) are from analysis 






Figure 2.1: Venn diagram of functional annotations (q-value<0.05) associated with 
maternal Pb exposure compared across all three trimesters (first trimester, T1; second 





















Figure 2.2: Differentially methylated region (DMR) by maternal blood Pb concentrations 
in T1 located within 200 base pairs of the transcription start site of PDGFRL 
(chr8:17433625-17433761). Linear regression modeling, treating Pb exposure as a 
continuous variable, adjusted for sex and estimated cell-type proportions. DNA 
methylation (beta value) is plotted for each sample at six CpG sites in the region 
included four sites of the statistically significant DMR. Exposure quartile ranges are 
represented from light red to dark red with quartile 4 (Q4), representing the top 25% 
most Pb exposed during T1, being the most methylated at each of the four CpG sites 


















































































































































































































































Figure 2.3: DMR by maternal blood Pb concentrations in T3 at chr6:30095136-
30095295 includes 12 CpG sites within an intergenic region with no known regulatory 
function. This DMR was selected from a linear regression modeling, treating Pb 
exposure as a continuous variable, adjusting for sex and estimated cell-type 
proportions. DNA methylation (beta value) is plotted for each sample at the twelve CpG 
sites in the DMR. Exposure quartile ranges are represented from light red to dark red 
with Q4, representing the top 25% most Pb exposed during T3, being the most 


















































































































































































































































































































































































































































































































Figure 2.4: DMR by maternal tibia bone Pb located within 800 base pairs of the 
transcription start site of TRHR (chr8:110098835-110098870). The DMR was identified 
by a linear regression model, treating Pb exposure as a continuous variable, and 
adjusting for sex and estimated cell-type proportions, maternal age, and cohort. DNA 
methylation (beta value) is plotted for each sample for the four CpG sites in the DMR. 
Exposure quartile ranges are represented from light red to dark red with Q4, 
representing the top 25% most Pb exposed when cumulative Pb is measured in tibia, 










































































































































Table 2.1A: Comparison of all ELEMENT cohort 2 and 3 participants with subset of 
ELEMENT included in the current study. 
 
 ELEMENT Subset** All ELEMENT** 
Characteristics No. Mean ± SD or N (%) No. Mean ± SD or N (%) P-Value 
Mothers        
    Age (yrs.) 89 26.4 ± 4.81 1213 26.1 ± 5.34 0.34  
    Blood lead (µg/dL)        
        First Trimester (T1) 69 6.56 ± 5.35 594 5.77 ± 4.03 0.19 
        Second Trimester (T2) 74 5.93 ± 5.00 616 5.20 ± 3.93 0.11 
        Third Trimester (T3) 76 6.09 ± 4.51 575 5.54 ± 4.13 0.12 
        Average All Trimesters 77 6.18 ± 4.51 643 5.53 ± 3.51 0.13 
    Bone lead (µg/g)        
        Patella 72 11.8 ± 9.25 894 12.3 ± 8.69 0.41 
        Tibia 46 11.8 ± 6.73 666 11.4 ± 7.70 0.46 
    Household Income 77  688  0.91 
        Lowest  12 (15.6)   117 (17.0)   
        Low-Middle  31 (40.3)   251 (36.5)   
        Middle  20 (26.0)   213 (31.0)   
        Middle-High  9 (11.6)   82 (11.9)   
        Highest  5 (6.5)   25 (3.6)   
    Education (total yrs.) 89 11.0 ± 2.39 1212 10.8 ± 2.99 0.22 
Children        
    UCB lead (µg/dL) 86 4.86 ± 3.74 462 4.45 ± 3.00 0.74 
    Gestational age (wks.) 87 39.0 ± 1.09 1196 38.8 ± 1.57 0.03* 
    Male (%) 89 41 (46.0) 1202 621 (51.7) 0.36 
Note: SD, standard deviation; UCB, umbilical cord blood 
* p-value < 0.05 using Wilcox signed-rank test 
** Participants for the current study were a subset of mother-child pairs from Cohorts 2 and 3 of 
ELEMENT that had archived cord blood samples for DNA methylation analysis. Here we are comparing 
their characteristics to those of all ELEMENT women and their newborns from the same cohorts (cohorts 
2 and 3) that had at least one Pb biomarker available (n=1214). 
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Table 2.2A: Statistically significantly enriched functional annotations using LRpath (q-value<0.05) from epigenome-wide 
analysis of DNA methylation and biomarkers of Pb. 
Biomarker Name Database Direction Coeff. P-Value Q-Value 
T1 detection of chemical stimulus involved in sensory perception GOBP up 1.31 1.8E-21 1.1E-17 
detection of chemical stimulus GOBP up 1.28 6.6E-21 2.0E-17 
sensory perception of chemical stimulus GOBP up 1.23 2.1E-19 4.0E-16 
detection of stimulus involved in sensory perception GOBP up 1.23 2.6E-19 4.0E-16 
odorant binding GOMF up 1.59 4.0E-18 4.5E-15 
detection of chemical stimulus involved in sensory perception of smell GOBP up 1.23 1.7E-17 2.1E-14 
olfactory receptor activity GOMF up 1.20 5.0E-17 2.8E-14 
detection of stimulus GOBP up 1.10 3.2E-17 3.3E-14 
sensory perception of smell GOBP up 1.18 1.6E-16 1.4E-13 
intracellular GOCC down -0.69 7.0E-15 2.7E-12 
organelle GOCC down -0.68 3.8E-15 2.7E-12 
intracellular part GOCC down -0.68 1.2E-14 3.0E-12 
membrane-bounded organelle GOCC down -0.62 2.8E-13 5.4E-11 
intracellular organelle GOCC down -0.61 7.3E-13 1.1E-10 
sensory perception GOBP up 0.91 2.4E-13 1.8E-10 
Olfactory transduction KEGG up 1.30 1.0E-12 2.2E-10 
intracellular membrane-bounded organelle GOCC down -0.58 9.8E-12 1.3E-09 
G-protein coupled receptor activity GOMF up 0.86 1.7E-11 6.3E-09 
type I interferon receptor binding GOMF up 1.74 3.1E-10 7.0E-08 
IgG binding GOMF up 1.79 3.0E-10 7.0E-08 
bitter taste receptor activity GOMF up 1.63 4.3E-10 8.2E-08 
cytoplasm GOCC down -0.50 1.5E-09 1.7E-07 
transmembrane receptor activity GOMF up 0.71 1.6E-09 2.6E-07 
transmembrane signaling receptor activity GOMF up 0.71 2.2E-09 3.1E-07 
positive regulation of peptidyl-serine phosphorylation of STAT protein GOBP up 1.71 6.5E-10 4.4E-07 
taste receptor activity GOMF up 1.52 3.7E-09 4.7E-07 
regulation of peptidyl-serine phosphorylation of STAT protein GOBP up 1.68 1.0E-09 6.2E-07 
serine phosphorylation of STAT protein GOBP up 1.61 1.9E-09 1.1E-06 
G-protein coupled receptor signaling pathway GOBP up 0.72 2.2E-09 1.1E-06 
organelle part GOCC down -0.49 1.7E-08 1.7E-06 
signaling receptor activity GOMF up 0.66 2.1E-08 2.4E-06 
neurological system process GOBP up 0.70 6.1E-09 2.9E-06 
cytoplasmic part GOCC down -0.48 3.5E-08 2.9E-06 
intracellular organelle part GOCC down -0.47 4.3E-08 3.3E-06 
receptor activity GOMF up 0.62 3.5E-08 3.3E-06 
molecular transducer activity GOMF up 0.62 3.5E-08 3.3E-06 
immunoglobulin binding GOMF up 1.51 5.6E-08 4.9E-06 
 63 
detection of chemical stimulus involved in sensory perception of bitter 
taste 
GOBP up 1.44 2.8E-08 1.2E-05 
cell GOCC down -0.55 1.9E-07 1.3E-05 
cell part GOCC down -0.54 2.5E-07 1.6E-05 
natural killer cell activation involved in immune response GOBP up 1.51 4.0E-08 1.6E-05 
detection of chemical stimulus involved in sensory perception of taste GOBP up 1.37 1.1E-07 4.1E-05 
signal transducer activity GOMF up 0.57 6.0E-07 4.9E-05 
nucleus GOCC down -0.44 1.0E-06 6.1E-05 
sensory perception of bitter taste GOBP up 1.35 2.6E-07 9.3E-05 
endonuclease activity, active with either ribo- or deoxyribonucleic acids 
and producing 3'-phosphomonoesters 
GOMF up 1.41 4.4E-06 3.4E-04 
cellular component organization or biogenesis GOBP down -0.47 1.8E-06 6.1E-04 
primary metabolic process GOBP down -0.42 1.9E-06 6.1E-04 
endodeoxyribonuclease activity, producing 5'-phosphomonoesters GOMF up 1.54 8.7E-06 6.1E-04 
organic substance metabolic process GOBP down -0.42 2.2E-06 6.7E-04 
Regulation of autophagy KEGG up 1.53 6.7E-06 7.1E-04 
cellular component organization GOBP down -0.46 3.8E-06 1.1E-03 
response to exogenous dsRNA GOBP up 1.28 4.2E-06 1.2E-03 
metabolic process GOBP down -0.40 5.2E-06 1.4E-03 
nodal signaling pathway GOBP up 1.54 5.5E-06 1.4E-03 
organic cyclic compound binding GOMF down -0.42 2.3E-05 1.5E-03 
humoral immune response GOBP up 0.95 7.3E-06 1.8E-03 
cellular metabolic process GOBP down -0.39 9.2E-06 2.1E-03 
sensory perception of taste GOBP up 1.15 9.7E-06 2.1E-03 
localization GOBP down -0.44 9.6E-06 2.1E-03 
protein binding GOMF down -0.37 3.8E-05 2.3E-03 
endodeoxyribonuclease activity, producing 3'-phosphomonoesters GOMF up 1.49 3.9E-05 2.3E-03 
Taste transduction KEGG up 1.31 3.5E-05 2.5E-03 
heterocyclic compound binding GOMF down -0.40 4.7E-05 2.7E-03 
macromolecular complex GOCC down -0.40 6.2E-05 3.4E-03 
oxygen binding GOMF up 1.14 6.6E-05 3.5E-03 
RIG-I-like receptor signaling pathway KEGG up 1.21 7.9E-05 3.9E-03 
Staphylococcus aureus infection KEGG up 1.26 9.1E-05 3.9E-03 
nitrogen compound metabolic process GOBP down -0.40 1.8E-05 3.9E-03 
negative regulation of lipopolysaccharide-mediated signaling pathway GOBP up 1.58 2.1E-05 4.2E-03 
defense response to bacterium GOBP up 0.86 2.1E-05 4.2E-03 
protein complex GOCC down -0.42 9.3E-05 4.7E-03 
cytokine activity GOMF up 0.80 9.7E-05 5.0E-03 
macromolecule localization GOBP down -0.56 3.3E-05 6.3E-03 
pattern binding GOMF up 1.31 1.8E-04 8.5E-03 
polysaccharide binding GOMF up 1.31 1.8E-04 8.5E-03 
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macromolecule metabolic process GOBP down -0.36 5.2E-05 9.6E-03 
phosphatidylcholine binding GOMF down -2.48 2.2E-04 9.8E-03 
B cell proliferation GOBP up 1.04 6.2E-05 1.1E-02 
cellular macromolecule metabolic process GOBP down -0.35 7.4E-05 1.3E-02 
sperm principal piece GOCC down -2.59 2.7E-04 1.3E-02 
heterocycle metabolic process GOBP down -0.39 8.3E-05 1.4E-02 
regulation of type I interferon-mediated signaling pathway GOBP up 1.21 8.6E-05 1.4E-02 
regulation of lipopolysaccharide-mediated signaling pathway GOBP up 1.37 9.1E-05 1.5E-02 
organic substance biosynthetic process GOBP down -0.38 9.3E-05 1.5E-02 
cytosol GOCC down -0.41 3.3E-04 1.5E-02 
cellular aromatic compound metabolic process GOBP down -0.38 1.1E-04 1.6E-02 
cellular nitrogen compound metabolic process GOBP down -0.37 1.0E-04 1.6E-02 
cellular biosynthetic process GOBP down -0.37 1.2E-04 1.6E-02 
negative regulation of serine-type endopeptidase activity GOBP up 1.52 1.2E-04 1.6E-02 
negative regulation of serine-type peptidase activity GOBP up 1.52 1.2E-04 1.6E-02 
Drug metabolism - cytochrome P450 KEGG up 1.10 4.7E-04 1.7E-02 
nuclear part GOCC down -0.38 4.0E-04 1.7E-02 
biosynthetic process GOBP down -0.36 1.4E-04 1.9E-02 
T cell activation involved in immune response GOBP up 1.00 1.7E-04 2.2E-02 
extracellular space GOCC up 0.41 5.5E-04 2.2E-02 
organic cyclic compound metabolic process GOBP down -0.36 2.0E-04 2.6E-02 
nucleic acid binding GOMF down -0.38 6.2E-04 2.7E-02 
complement receptor activity GOMF down -2.68 6.8E-04 2.8E-02 
protein localization GOBP down -0.52 2.4E-04 3.1E-02 
lipopolysaccharide binding GOMF up 1.23 8.4E-04 3.4E-02 
catalytic activity GOMF down -0.32 9.3E-04 3.6E-02 
positive regulation of peptidyl-serine phosphorylation GOBP up 0.98 3.1E-04 3.8E-02 
defense response to other organism GOBP up 0.63 3.3E-04 4.1E-02 
regulation of gene expression GOBP down -0.39 4.0E-04 4.7E-02 
cellular macromolecule biosynthetic process GOBP down -0.37 3.9E-04 4.7E-02 
nucleobase-containing compound metabolic process GOBP down -0.34 4.3E-04 4.9E-02 
regulation of cellular macromolecule biosynthetic process GOBP down -0.40 4.3E-04 4.9E-02 
Drug metabolism - other enzymes KEGG up 1.13 1.6E-03 5.0E-02 
T2 olfactory receptor activity GOMF up 1.21 3.1E-17 3.6E-14 
detection of chemical stimulus involved in sensory perception GOBP up 1.15 5.2E-17 1.9E-13 
detection of chemical stimulus involved in sensory perception of smell GOBP up 1.17 6.1E-17 1.9E-13 
sensory perception of chemical stimulus GOBP up 1.11 1.3E-16 2.0E-13 
sensory perception of smell GOBP up 1.14 1.3E-16 2.0E-13 
detection of chemical stimulus GOBP up 1.11 2.8E-16 3.5E-13 
detection of stimulus involved in sensory perception GOBP up 1.10 5.7E-16 5.8E-13 
odorant binding GOMF up 1.47 5.0E-15 2.8E-12 
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intracellular GOCC down -0.65 1.2E-12 9.5E-10 
intracellular part GOCC down -0.63 2.8E-12 1.1E-09 
Olfactory transduction KEGG up 1.30 7.2E-12 1.5E-09 
detection of stimulus GOBP up 0.93 1.8E-12 1.5E-09 
organelle GOCC down -0.61 8.7E-12 2.2E-09 
IgG binding GOMF up 1.89 5.9E-12 2.2E-09 
G-protein coupled receptor activity GOMF up 0.88 2.0E-11 5.7E-09 
intracellular organelle GOCC down -0.55 2.8E-10 5.4E-08 
immunoglobulin binding GOMF up 1.62 8.6E-10 2.0E-07 
cytoplasm GOCC down -0.52 3.3E-09 5.1E-07 
sensory perception GOBP up 0.78 9.2E-10 7.0E-07 
membrane-bounded organelle GOCC down -0.51 6.0E-09 7.6E-07 
intracellular membrane-bounded organelle GOCC down -0.46 8.6E-08 9.4E-06 
transmembrane receptor activity GOMF up 0.65 1.6E-07 3.0E-05 
transmembrane signaling receptor activity GOMF up 0.65 2.5E-07 4.1E-05 
Systemic lupus erythematosus KEGG up 1.15 5.7E-07 6.1E-05 
organelle part GOCC down -0.42 1.5E-06 1.4E-04 
type I interferon receptor binding GOMF up 1.56 1.3E-06 1.8E-04 
signaling receptor activity GOMF up 0.60 1.4E-06 1.8E-04 
intracellular organelle part GOCC down -0.42 2.6E-06 2.2E-04 
G-protein coupled receptor signaling pathway GOBP up 0.63 3.5E-07 2.4E-04 
cytoplasmic part GOCC down -0.41 3.4E-06 2.6E-04 
receptor activity GOMF up 0.56 3.2E-06 3.3E-04 
molecular transducer activity GOMF up 0.56 3.2E-06 3.3E-04 
cell GOCC down -0.49 1.0E-05 7.1E-04 
protein binding GOMF down -0.41 1.0E-05 9.7E-04 
cell part GOCC down -0.47 1.7E-05 1.1E-03 
complement binding GOMF up 1.45 1.5E-05 1.3E-03 
nodal signaling pathway GOBP up 1.51 2.2E-06 1.4E-03 
neurological system process GOBP up 0.58 3.2E-06 1.8E-03 
Staphylococcus aureus infection KEGG up 1.17 4.0E-05 2.8E-03 
opsonin binding GOMF up 1.55 3.7E-05 3.0E-03 
signal transducer activity GOMF up 0.49 3.9E-05 3.0E-03 
Antigen processing and presentation KEGG down -1.74 7.2E-05 3.8E-03 
humoral immune response GOBP up 0.92 7.6E-06 3.9E-03 
regulation of humoral immune response GOBP up 1.17 8.9E-06 4.2E-03 
positive regulation of peptidyl-serine phosphorylation of STAT protein GOBP up 1.41 9.5E-06 4.2E-03 
localization GOBP down -0.45 1.4E-05 5.6E-03 
regulation of peptidyl-serine phosphorylation of STAT protein GOBP up 1.38 1.8E-05 7.0E-03 
negative regulation of heart contraction GOBP down -2.59 3.0E-05 1.1E-02 
cation-transporting ATPase complex GOCC down -2.42 2.0E-04 1.2E-02 
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natural killer cell activation involved in immune response GOBP up 1.28 3.7E-05 1.2E-02 
single-multicellular organism process GOBP down -0.42 3.6E-05 1.2E-02 
2 iron, 2 sulfur cluster binding GOMF up 1.29 2.1E-04 1.5E-02 
epithelial cilium movement GOBP down -2.56 6.5E-05 2.0E-02 
serine phosphorylation of STAT protein GOBP up 1.28 8.7E-05 2.5E-02 
cellular component organization or biogenesis GOBP down -0.39 9.9E-05 2.7E-02 
defense response to bacterium GOBP up 0.79 1.1E-04 2.8E-02 
regulation of complement activation GOBP up 1.21 1.2E-04 2.9E-02 
blood microparticle GOCC up 0.84 6.2E-04 3.4E-02 
WASH complex GOCC up 1.35 7.1E-04 3.6E-02 
beta-amyloid metabolic process GOBP down -2.40 1.5E-04 3.7E-02 
iron-sulfur cluster assembly GOBP up 1.33 1.7E-04 3.9E-02 
metallo-sulfur cluster assembly GOBP up 1.33 1.7E-04 3.9E-02 
multicellular organism development GOBP down -0.41 1.9E-04 4.0E-02 
negative regulation of blood circulation GOBP down -2.25 2.0E-04 4.0E-02 
regulation of protein activation cascade GOBP up 1.18 1.9E-04 4.0E-02 
intramolecular oxidoreductase activity, transposing C=C bonds GOMF up 1.44 6.0E-04 4.0E-02 
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GOBP down -2.29 2.5E-04 4.3E-02 
cellular component organization GOBP down -0.36 2.7E-04 4.3E-02 
macromolecule localization GOBP down -0.50 2.6E-04 4.3E-02 
anatomical structure development GOBP down -0.38 2.3E-04 4.3E-02 
organic substance transport GOBP down -0.52 2.4E-04 4.3E-02 
defense response to other organism GOBP up 0.63 2.5E-04 4.3E-02 
negative regulation of calcium ion transmembrane transporter activity GOBP down -2.37 2.7E-04 4.3E-02 
calcium ion transport from endoplasmic reticulum to cytosol GOBP down -2.29 2.5E-04 4.3E-02 
ferrous iron binding GOMF up 1.26 7.0E-04 4.4E-02 
Regulation of autophagy KEGG up 1.14 1.2E-03 5.0E-02 
T3 olfactory receptor activity GOMF up 0.97 4.1E-09 4.5E-06 
IgG binding GOMF up 1.74 8.0E-09 4.5E-06 
immunoglobulin binding GOMF up 1.50 5.1E-08 1.9E-05 
detection of chemical stimulus involved in sensory perception of smell GOBP up 0.91 7.5E-09 4.6E-05 
sensory perception of smell GOBP up 0.87 3.3E-08 1.0E-04 
Olfactory transduction KEGG up 0.95 1.4E-06 2.9E-04 
detection of chemical stimulus involved in sensory perception GOBP up 0.81 2.3E-07 4.6E-04 
sensory perception of chemical stimulus GOBP up 0.77 5.9E-07 7.9E-04 
detection of chemical stimulus GOBP up 0.78 6.5E-07 7.9E-04 
G-protein coupled receptor activity GOMF up 0.67 3.7E-06 1.0E-03 
Systemic lupus erythematosus KEGG up 1.06 1.0E-05 1.1E-03 
detection of stimulus involved in sensory perception GOBP up 0.76 1.2E-06 1.2E-03 
ferrous iron binding GOMF up 1.29 1.2E-05 2.4E-03 
2 iron, 2 sulfur cluster binding GOMF up 1.28 1.2E-05 2.4E-03 
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iron-sulfur cluster assembly GOBP up 1.29 3.9E-06 3.0E-03 
metallo-sulfur cluster assembly GOBP up 1.29 3.9E-06 3.0E-03 
WASH complex GOCC up 1.36 4.0E-06 3.1E-03 
G-protein coupled nucleotide receptor activity GOMF up 1.34 9.8E-05 1.4E-02 
G-protein coupled purinergic nucleotide receptor activity GOMF up 1.34 9.8E-05 1.4E-02 
transmembrane signaling receptor activity GOMF up 0.50 2.0E-04 2.5E-02 
transmembrane receptor activity GOMF up 0.49 2.2E-04 2.5E-02 
sarcoplasmic reticulum calcium ion transport GOBP down -1.99 3.7E-05 2.5E-02 
odorant binding GOMF up 0.93 2.8E-04 2.7E-02 
4 iron, 4 sulfur cluster binding GOMF up 1.06 2.9E-04 2.7E-02 
cellular defense response GOBP down -1.79 5.0E-05 3.0E-02 
signaling receptor activity GOMF up 0.46 5.0E-04 4.3E-02 
purinergic nucleotide receptor activity GOMF up 1.17 6.0E-04 4.5E-02 
nucleotide receptor activity GOMF up 1.17 6.0E-04 4.5E-02 
UCB Pb IgG binding GOMF up 1.55 2.0E-08 2.3E-05 
immunoglobulin binding GOMF up 1.37 3.6E-07 2.0E-04 
endodeoxyribonuclease activity, producing 5'-phosphomonoesters GOMF down -2.61 8.7E-06 3.3E-03 
olfactory receptor activity GOMF up 0.76 1.5E-05 4.3E-03 
2 iron, 2 sulfur cluster binding GOMF up 1.20 7.7E-05 1.7E-02 
Chemokine signaling pathway KEGG down -1.26 1.0E-04 1.8E-02 
Olfactory transduction KEGG up 0.79 1.7E-04 1.8E-02 
Ribosome KEGG up 1.04 3.1E-04 2.2E-02 
chemokine activity GOMF down -1.83 1.6E-04 3.0E-02 
endodeoxyribonuclease activity, producing 3'-phosphomonoesters GOMF down -2.42 2.3E-04 3.8E-02 
ferrous iron binding GOMF up 1.18 2.7E-04 3.9E-02 
transcriptional activator activity, RNA polymerase II distal enhancer 
sequence-specific binding 
GOMF up 1.15 3.2E-04 4.0E-02 
Tibia olfactory receptor activity GOMF down -2.11 2.8E-29 3.1E-26 
sensory perception of smell GOBP down -1.90 3.2E-24 6.5E-21 
detection of chemical stimulus involved in sensory perception GOBP down -1.89 2.3E-24 6.5E-21 
detection of chemical stimulus involved in sensory perception of smell GOBP down -1.94 1.1E-24 6.5E-21 
Olfactory transduction KEGG down -2.57 2.0E-22 4.2E-20 
sensory perception of chemical stimulus GOBP down -1.80 3.2E-23 4.9E-20 
detection of chemical stimulus GOBP down -1.80 5.6E-23 6.8E-20 
detection of stimulus involved in sensory perception GOBP down -1.78 1.3E-22 1.3E-19 
G-protein coupled receptor activity GOMF down -1.45 1.3E-19 7.4E-17 
detection of stimulus GOBP down -1.51 9.7E-19 8.4E-16 
sensory perception GOBP down -1.32 1.7E-16 1.3E-13 
transmembrane signaling receptor activity GOMF down -1.12 2.9E-14 1.1E-11 
transmembrane receptor activity GOMF down -1.11 4.0E-14 1.1E-11 
signaling receptor activity GOMF down -1.06 2.6E-13 5.9E-11 
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G-protein coupled receptor signaling pathway GOBP down -1.10 2.4E-13 1.6E-10 
receptor activity GOMF down -0.95 1.1E-11 1.8E-09 
molecular transducer activity GOMF down -0.95 1.1E-11 1.8E-09 
neurological system process GOBP down -1.01 9.2E-12 5.7E-09 
signal transducer activity GOMF down -0.91 4.9E-11 6.9E-09 
odorant binding GOMF down -1.44 3.2E-10 4.0E-08 
intracellular GOCC up 0.73 3.4E-10 2.6E-07 
binding GOMF up 0.74 3.1E-09 3.5E-07 
intracellular part GOCC up 0.63 2.6E-08 1.0E-05 
system process GOBP down -0.72 7.2E-08 4.0E-05 
organelle GOCC up 0.57 1.8E-07 4.1E-05 
membrane-bounded organelle GOCC up 0.55 2.2E-07 4.1E-05 
intracellular organelle GOCC up 0.51 9.8E-07 1.2E-04 
intracellular membrane-bounded organelle GOCC up 0.51 8.9E-07 1.2E-04 
cellular metabolic process GOBP up 0.55 9.8E-07 5.0E-04 
cytoplasm GOCC up 0.46 7.3E-06 8.0E-04 
cellular macromolecule metabolic process GOBP up 0.54 1.9E-06 8.7E-04 
palmitoyl-CoA hydrolase activity GOMF down -1.52 2.3E-05 2.3E-03 
integral component of membrane GOCC down -0.43 3.8E-05 3.7E-03 
protein binding GOMF up 0.45 5.0E-05 4.7E-03 
macromolecule metabolic process GOBP up 0.49 1.1E-05 4.8E-03 
clathrin-coated endocytic vesicle membrane GOCC up 1.48 5.9E-05 5.0E-03 
intrinsic component of membrane GOCC down -0.41 8.1E-05 6.2E-03 
organic substance metabolic process GOBP up 0.47 1.5E-05 6.3E-03 
LRR domain binding GOMF down -1.38 8.9E-05 7.8E-03 
neurotransmitter receptor activity GOMF up 1.91 9.7E-05 7.8E-03 
acyl-CoA hydrolase activity GOMF down -1.37 1.0E-04 7.8E-03 
metabolic process GOBP up 0.46 2.3E-05 9.0E-03 
primary metabolic process GOBP up 0.46 2.5E-05 9.1E-03 
CoA hydrolase activity GOMF down -1.34 1.3E-04 9.2E-03 
cellular response to ATP GOBP up 2.24 2.8E-05 9.6E-03 
clathrin-coated endocytic vesicle GOCC up 1.37 1.4E-04 1.0E-02 
organic cyclic compound binding GOMF up 0.46 1.6E-04 1.1E-02 
mitochondrial respiratory chain complex IV assembly GOBP down -1.15 4.0E-05 1.2E-02 
mitochondrial respiratory chain complex IV biogenesis GOBP down -1.15 4.0E-05 1.2E-02 
heterocyclic compound binding GOMF up 0.45 2.0E-04 1.2E-02 
clathrin-coated vesicle membrane GOCC up 1.30 2.1E-04 1.3E-02 
respiratory chain complex IV assembly GOBP down -1.06 6.0E-05 1.7E-02 
nitrogen compound metabolic process GOBP up 0.46 6.4E-05 1.8E-02 
membrane part GOCC down -0.36 3.4E-04 2.0E-02 
interferon-gamma-mediated signaling pathway GOBP up 1.63 7.5E-05 2.0E-02 
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nucleus GOCC up 0.37 4.2E-04 2.3E-02 
cytochrome complex assembly GOBP down -0.98 9.7E-05 2.5E-02 
organelle part GOCC up 0.34 5.5E-04 2.8E-02 
G-protein coupled nucleotide receptor activity GOMF up 2.59 6.7E-04 3.3E-02 
purinergic nucleotide receptor activity GOMF up 2.39 5.9E-04 3.3E-02 
G-protein coupled serotonin receptor activity GOMF up 2.25 6.2E-04 3.3E-02 
nucleotide receptor activity GOMF up 2.39 5.9E-04 3.3E-02 
G-protein coupled purinergic nucleotide receptor activity GOMF up 2.59 6.7E-04 3.3E-02 
serotonin receptor activity GOMF up 2.22 7.1E-04 3.4E-02 
intracellular organelle part GOCC up 0.34 7.6E-04 3.6E-02 
nucleic acid metabolic process GOBP up 0.47 1.7E-04 4.1E-02 
establishment of localization GOBP up 0.48 1.9E-04 4.4E-02 
enzyme binding GOMF up 0.63 1.1E-03 5.0E-02 
Patella detection of chemical stimulus involved in sensory perception of bitter 
taste 
GOBP down -1.95 9.7E-08 3.0E-04 
sensory perception of bitter taste GOBP down -1.91 9.8E-08 3.0E-04 
detection of chemical stimulus involved in sensory perception of taste GOBP down -1.87 1.9E-07 3.9E-04 
bitter taste receptor activity GOMF down -2.02 3.8E-07 4.3E-04 
taste receptor activity GOMF down -1.90 9.9E-07 5.6E-04 
sensory perception of taste GOBP down -1.65 1.5E-06 2.3E-03 
olfactory receptor activity GOMF up 0.98 9.2E-06 3.5E-03 
detection of chemical stimulus involved in sensory perception of smell GOBP up 0.99 7.6E-06 9.3E-03 
endonuclease activity, active with either ribo- or deoxyribonucleic acids 
and producing 3'-phosphomonoesters 
GOMF down -1.76 3.5E-05 1.0E-02 
Olfactory transduction KEGG up 0.87 7.7E-05 1.6E-02 
dipeptidase activity GOMF up 1.67 8.2E-05 1.9E-02 
endodeoxyribonuclease activity, producing 3'-phosphomonoesters GOMF down -1.84 1.3E-04 2.3E-02 
IgG binding GOMF up 1.75 1.4E-04 2.3E-02 
sensory perception of smell GOBP up 0.92 3.7E-05 3.8E-02 
Taste transduction KEGG down -1.61 4.1E-04 4.4E-02 
Note: T1, first trimester; T2, second trimester; T3, third trimester; UCB, umbilical cord blood; GOBP, Gene Ontology Biological Process; GOMF, 
Gene Ontology Molecular Function; GOCC, Gene Ontology Cellular Component; KEGG, Kyoto Encyclopedia of Genes and Genomes; Coeff, 
coefficient 
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Figure 2.3A: Venn diagram of functional annotations from LRPath analysis (q-






Chapter 3 Prenatal Lead (Pb) Exposure and Peripheral Blood DNA Methylation 
(5mC) and Hydroxymethylation (5hmC) in Mexican Adolescents from the 
ELEMENT Birth Cohort 
Abstract 
Gestational lead (Pb) exposure can adversely impact offspring health through 
multiple mechanisms, including epigenomic alterations via DNA methylation (5mC) and 
hydroxymethylation (5hmC), an intermediate in oxidative demethylation. Most current 
methods do not distinguish between 5mC and 5hmC limiting insights into their individual 
roles. The goal of this study is to identify the association of trimester-specific (T1, T2, 
T3) prenatal Pb exposures with 5mC and 5hmC levels at multiple cytosine-phosphate-
guanine (CpG) sites within gene regions previously associated with prenatal Pb 
exposure (HCN2, NINJ2, RAB5A, TPPP) in whole blood leukocytes of children ages 11-
18 years. Participants from the Early Life Exposure in Mexico to Environmental 
Toxicants (ELEMENT) birth cohorts were selected (n=144) for pyrosequencing analysis 
following oxidative or standard sodium bisulfite treatment. This workflow directly 
quantifies total methylation (5mC+5hmC) and 5mC only; 5hmC is estimated by 
subtraction. Participants were 51% male and mean maternal blood lead levels (BLL) 
were 6.43±5.16 µg/dL in T1, 5.66±5.21 µg/dL in T2, and 5.86±4.34 µg/dL in T3. 5hmC 
levels were calculated for HCN2 (mean±SD, 2.04±4.30%), NINJ2 (2.66±5.11%), RAB5A 
(0.64±0.80%), and TPPP (0.45±8.01%). 5mC levels were measured in HCN2 
(81.3±9.63%), NINJ2 (G/C:38.6±7.39%; G/G: 67.3±9.83%), RAB5A (1.40±1.20%), and 
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TPPP (92.5±8.03%). Several significant associations between BLLs and 5hmC/5mC 
were reported: T1 maternal BLLs with 5mC in HCN2 (β=-0.43, p=0.02) and 5hmC in 
NINJ2 (β=0.49, p=0.003); T2 BLL with 5mC in HCN2 (β=0.37, p=0.03) and 5hmC in 
NINJ2 (β=0.27, p=0.008); and T3 BLL with 5mC in HCN2 (β=0.50, p=0.01) and NINJ2 
(β=-0.35, p=0.004) and 5hmC in NINJ2 (β=0.45, p<0.001). 5mC was negatively 
correlated with gene expression (Pearson r=-0.5, p-value=0.005) within NINJ2, whereas 
5hmC was positively correlated (r=0.4, p-value=0.04). These findings suggest there is 
variable 5hmC in human whole blood and that prenatal Pb exposure is associated with 
gene-specific 5mC and 5hmC levels at adolescence, providing evidence to consider 
5hmC as a regulatory response mechanism to environmental exposures. 
Introduction 
The Developmental Origins of Heath and Disease (DoHAD) hypothesis 1 
postulates that in utero exposures, including environmental contaminant exposures 
such as lead (Pb), can permanently modify an organism’s molecular biology, 
physiology, and metabolism, potentially leading to myriad effects on cognition, growth, 
maturation, and metabolic risk 2. Pb is a widely abundant environmental pollutant known 
to be a potent neurotoxicant, even at low levels. Pregnancy is a vulnerable time period 
for Pb exposure as both current and past maternal Pb exposure may impact the 
developing fetus. Animal and human studies have provided evidence for the impact of 
early-life Pb exposure on the epigenome 3-8.  
Epigenetic modifications are mitotically heritable molecular changes that regulate 
gene expression without altering the underlying DNA sequence. DNA 5-methylcytosine 
(5mC) is the addition of a methyl group covalently bound to the 5’-carbon of Cytosine; in 
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mammals this typically occurs on a Cytosine adjacent to a Guanine, referred to as a 
CpG site 9, 10. During demethylation, 5mC is oxidized into 5-hydroxymethylcytosine 
(5hmC), an intermediate of oxidative demethylation that can remain as a stable 
modification 11, 12. 5hmC perturbations in the brain have been reported in several early-
life neurologic disorders and later-life neurodegenerative disorders in both human and 
animal studies. 13-16. Levels of 5hmC vary with tissue, where brain contains the highest 
levels; blood contains the lowest levels but 5hmC is still detectable at modest levels 17-
21. Recent studies suggest that the functional roles of 5hmC are distinct from 5mC 22. 
5mC and 5hmC undergo dynamic changes during early gestation that disseminate 
through mitosis to new cells and developing organs, potentially persisting throughout 
the life span. These modifications are important for gene regulation, including in the 
nervous system, and have implications for learning and memory from early 
development, adolescence, and into adulthood 13, 23-25. Most current methods, including 
the gold standard sodium bisulfite sequencing, collectively measure 5mC and 5hmC 
without distinguishing between the two. This has limited our ability to identify whether 
environmental exposures alter 5mC, 5hmC, or both and what the implications are for 
early-life neurodevelopment and long-term health. 
Pregnancy is a key starting point to investigate the association between 
environmental contaminants and epigenetic modifications leading to health outcomes in 
offspring. An important mechanism by which developmental exposures can affect long-
term disease risk is through the disruption of normal epigenetic processes, thereby 
impacting gene regulation and subsequent chronic outcomes 26. A study prenatally 
exposing dams, which are genetically invariant mice 93% identical to C57BL/6J strain, 
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to physiologically relevant doses of Pb (2.1 ppm, 16 ppm, and 32 ppm in water) two 
weeks prior to mating through lactation until weaning at postnatal day 21 assessed DNA 
total methylation via pyrosequencing at four Intracisternal A particle (IAP) elements in 
the brain 27. IAPs are a class of murine retrotransposons that are environmentally 
responsive 28. Prenatal Pb exposure reduced DNA methylation at three of the IAPs in 
the brain with dose-dependent and sex-specific effects compared to control mice. A 
study exposing rodents to 0.2% Pb acetate in water postnatally reported 
hypomethylation and initial transient 8-hydroxy-2’-deoxyguanosine (oxo8dG) 
accumulation in the cerebral cortex, a neurodegeneration biomarker 29. A U.S. 
prospective human pregnancy cohort, Project Viva, with low Pb exposure (averaging 
1.22 ± 0.63 µg/dL in erythrocytes) conducted an epigenome-wide analysis on 268 
umbilical cord blood samples to evaluate the association between maternal Pb 
exposure and DNA methylation, and identified sex-specific differentially methylated CpG 
sites 7. Using a similar epigenome-wide approach but with a moderately to highly 
exposed population, we identified differentially methylated genes in 89 umbilical cord 
blood leukocyte DNA samples from the Early Life in Mexico to Environmental Toxicants 
(ELEMENT) cohort that varied by trimester of exposure 6. Although these and several 
other studies provide evidence for associations between Pb exposure and DNA 
methylation profiles in humans and animals, only total methylation was assessed.  
Only one study has considered intermediates (5hmC) in these adverse 
environmental associations with prenatal Pb, which may have implications for 
understanding the association between prenatal exposures and adverse health 
outcomes. That study provided some evidence for associations between prenatal Pb 
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and 5hmC in umbilical cord blood at the regional level through a modified epigenome-
wide method called hMeDIP-450K chip 30. They identified both sex-independent and 
sex-specific differentially methylated and hydroxymethylated regions, where sex-
dependent associations were more common in 5mC compared to 5hmC. 
Mechanistically, Pb-induced oxidative stress results in the accumulation of α-
ketoglutarate (α-KG) 31, a co-factor for ten-eleven translocation (TET) enzymes which 
are involved in the oxidation of 5mC to 5hmC 32, 33. Thus, Pb may increase activity of 
TET enzymes and increase 5hmC across the genome 32. 
We hypothesized that prenatal Pb exposure would alter epigenetic programming 
of 5mC and 5hmC within genes involved in neurological function, and that this can be 
detected in adolescent-aged samples. We leveraged the ELEMENT longitudinal birth 
cohort with rich data on prenatal Pb exposure and offspring follow-up through 
adolescence, including whole blood leukocyte DNA and prenatal Pb exposure 
biomarkers, to investigate whether Pb is associated with programming of 
neurocognitive-related genes between the ages of 11-18 years in offspring whole blood 
leukocytes. We utilized oxidative-bisulfite (oxBS) pyrosequencing to profile both 5mC 
and 5hmC in adolescent blood leukocyte DNA at four neurocognitive-related genes 
HCN2, NINJ2, RAB5A, and TPPP that were associated with prenatal Pb exposure in 





Participants are from the second and third cohorts of the ELEMENT project, a 
series of longitudinal birth cohorts originally designed to investigate the influence of Pb 
exposure – in utero and in childhood – on child growth and neurodevelopment. Mothers 
were recruited between 1997-2000 (second cohort) and 2001-2005 (third cohort) from 
the Mexican Social Security Institute hospital in Mexico City. Eligibility and exclusion 
criteria are as previously described 34, 35. Data collected include sex, gestational age, 
household socioeconomic status, anthropometry, and other environmental exposures at 
multiple follow-up visits from infancy through adolescence. For the current study, 144 of 
the ELEMENT participants were selected that were followed-up through the 2015 study 
visit and had an adolescent blood sample for DNA isolation (Figure 3.1). Participants 
with prenatal and adolescent Pb measures and/or previous cord blood DNA methylation 
analysis were prioritized for the adolescent epigenetic analysis 6. 
Prior to participation, all mothers were informed about the study; those who 
agreed to participate read and signed a letter of informed consent about the original 
study. Children also provided informed consent prior to participation in the adolescent 
follow-up visits. The research protocol and all amendments to the study were approved 
by the Ethics Committees of the National Institutes of Public Health of Mexico, 
participating hospitals, and the Internal Review Board at participating institutions 
including the University of Michigan. 
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Pb exposure assessment and genomic DNA isolation 
Cohort 2 maternal venous blood lead levels (BLLs) from each trimester were 
measured using inductively coupled plasma mass-spectrometry (ICP-MS, Thermo 
Finnigan, Bremen, Germany) at the University of California, Santa Cruz, as described 
previously 36. Cohort 3 trimester-specific maternal BLLs were measured using graphite 
furnace atomic absorption spectrometry (instrument model 3000; PerkinElmer, Norwalk, 
CT, USA) at the Trace Metal Laboratory of the American British Cowdry Hospital. 
Perinatal maternal bone Pb levels were also measured in the left patella (trabecular 
bone) and mid-shaft of the left tibia (cortical bone) 1-month post-partum as an indicator 
of cumulative Pb exposure during pregnancy using a spot-source 109Cd K-shell X-ray 
fluorescence (K-XRF) instrument. The technical specifications and validation of this 
instrument are described in detail elsewhere 37. Tibia and patella bone Pb measures 
were dropped if their associated uncertainty levels were greater than 10 µg/g (n=1) and 
15 µg/g (n=0), respectively. Next, any negative tibia (n=27) and patella (n=20) bone Pb 
measurements were re-coded as positive values with random numbers in a uniform 
distribution between 0 and the limit of detection. Whole blood samples were collected 
during the 2015 follow-up visit conducted when the children were between the ages of 
11-18 years old, and blood was stored frozen at -80oC. DNA was isolated from blood 
leukocytes using Qiagen kits and standard protocols for blood DNA isolation. Nucleic 
acid yield and purity were assessed first using a NanoDrop spectrophotometer 
(ThermoFisher Scientific), and double-stranded DNA was also quantified via a Qubit 
fluorometer. All DNA samples were stored at -80oC. 
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Candidate gene selection 
 CpG sites that mapped back to four genes relevant to neurological function were 
selected as candidates from an epigenome-wide study of prenatal Pb exposure 
conducted with a subset of ELEMENT children in umbilical cord blood 6 and adolescent 
whole blood DNA (unpublished): HCN2 (cg06657917), NINJ2 (cg19692784, 
cg14911689, cg05578102), RAB5A (cg17138393), and TPPP (cg25353752; probe IDs 
from the Infinium  MethylationEPIC BeadChip). RAB5A DNA methylation in umbilical 
cord blood 6 and TPPP DNA methylation (unpublished) in adolescent whole blood were 
inversely associated with  T1 maternal BLLs and were selected for the current targeted 
analysis. HCN2 and NINJ2 were selected because T1 BLLs were associated with 
greater than 5% change in methylation (unpublished; hypermethylated in HCN2 and 
hypomethylated in NINJ2) in both umbilical cord blood and adolescent whole blood 
leukocytes, and these genes are involved in gestational neurological and/or cognitive 
development, for which mutations or disruptions in function have been associated with 
neuronal activity 38, and neurite outgrowth and regeneration 39. EXT1 and LRFN1 were 
additionally reported as significant in the original umbilical cord blood epigenome-wide 
study but were not included in this study because 1) we were unable to design primers 
to bind to the desired region in EXT1 and 2) LRFN1 was not associated with first 
trimester BLLs, which was the original research question during the development of this 
study. 
DNA 5mC and 5hmC quantification 
 Pyrosequencing primers for HCN2, NINJ2, RAB5A, and TPPP were designed 
using the PyroMark Assay Design Software 2.0 Methylation Analysis (CpG) Assay 
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(Appendix Table 3.1A). Primers were designed to target a specific CpG site within a 
region reported to be differentially methylated with first trimester Pb exposure in 
umbilical cord blood and/or adolescent whole blood (see Candidate gene selection). 
ELEMENT genomic DNA samples were oxidative and/or bisulfite treated according to 
the NuGen TrueMethyl oxBS Module protocol (Cat. #0414-32) and Zymo EZ DNA 
Methylation kit (Cat. #D5003). Briefly, 1µg of input genomic DNA was dissolved in 
nuclease-free water to 50µl, and each genomic DNA sample was divided into two 
aliquots 40. Each aliquot underwent independent, parallel treatments and were either 
oxidative bisulfite converted with the NuGen TrueMethyl oxBS Module or Zymo EZ DNA 
Methylation kit. The yield and purity of treated samples were quantified using a 
NanoDrop spectrophotometer.  
The target loci within HCN2, NINJ2, RAB5A, and TPPP were amplified in both 
bisulfite and oxidative bisulfite converted samples. PCR products were verified using the 
QIAxcel automated DNA electrophoresis. DNA methylation levels were quantified using 
the PyroMark Q96 ID instrument (Qiagen). Targeted pyrosequencing captured six CpG 
sites within a CpG island of HCN2, eight within a DNase hypersensitivity region of 
NINJ2, eleven within a DNase hypersensitivity region in the first exon of RAB5A, and 
four within the third exon of TPPP. CpG site #6 with NINJ2 was dropped since 90% of 
samples failed at this location, leaving seven CpG sites for NINJ2 from downstream 
analysis. Sequencing the bisulfite converted samples quantifies the total level of 5mC + 
5hmC, while sequencing the oxidative bisulfite treated samples quantifies total levels of 
5mC. Thus, 5hmC levels were quantified by subtracting the results from the oxidative 
bisulfite converted samples (5mC) from the bisulfite converted sample (5mC + 5hmC). It 
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should be noted that because 5hmC is based on a calculation, the difference can 
sometimes be negative at sites with zero or low levels of methylation as a consequence 
of random noise 41, 42. It should be noted that less than 1.4% of all 5hmC values were 
less than -10%. For quality control, plates were run with Qiagen EpiTect bisulfite 
converted unmethylated (0%) and methylated (100%) human methylation standards 
(Cat. #59665 & #59655). OxBS triplicates of eight samples were included for quality 
control. OxBS triplicate standard deviations of NINJ2 (variably methylated) and TPPP 
(highly methylated) in quantified 5mC averaged 2.11 and 2.28 respectively at each CpG 
site captured. Measures of 5mC were precise with <10% coefficient of variation, 
whereas the measures of methylation utilizing the standard bisulfite method was more 
precise with <5% coefficient of variation. DNA samples were randomized across 
experimental batches which consisted of four plates for each gene. Paired oxBS and BS 
conversion samples were always in the same batch. All data that failed internal quality 
control checks within the PyroMark software were excluded from analysis (HCN2: 5mC 
n=3, 5hmC n=7; NINJ2: 5mC n=7, 5hmC n=9; RAB5A: 5mC n=1, 5hmC n=1; TPPP: 
5mC n=2, 5hmC n=3). 
Estimates of cell-type composition (CD4+ and CD8+ T lymphocytes, B cells, 
natural killer [NK] cells, monocytes, granulocytes) for each sample were performed 
using an established method based on adult cell-type specific differentially methylated 
regions using data from the Infinium EPIC array for each sample 43. 
A methylation quantitative trait locus (MeQTL) was identified within NINJ2 and 
was found to be correlated with a SNP (C/G; rs34038797) within the pyrosequenced 
region 44. Genotyping was performed on genomic DNA from all 144 samples using the 
 81 
PyroMark Q96 ID instrument (Qiagen). Pyrosequencing SNP primers for NINJ2 were 
designed using the PyroMark Assay Design Software 2.0 Genotyping (SNP) Assay 
(Appendix Table 3.1A). Primers were designed to target the rs34038797 SNP.  
Gene expression analysis via RNA sequencing 
 For a subset of participants (n=70), next generation sequencing of RNA (“RNA-
seq”) was conducted to obtain relative expression data for all genes and utilized data 
from the four genes that are the focus of this paper. Following collection of whole blood 
into EDTA-containing tubes, white blood cells were extracted, preserved in RNALater, 
and stored frozen (-80oC) until further processing. RNA was isolated via the All-Prep kit 
(Qiagen). Quality and quantity were assessed via a Bioanalyzer Tapestation (Agilent). 
Libraries were prepared with Universal Plus mRNA-Seq with Human globin AnyDeplete 
(NuGEN Technologies, Inc.) which removes globin transcripts that are highly abundant 
in blood samples. Library preparation and sequencing were performed at the University 
of Michigan Advanced Genomics Core. Paired-end 50 cycle sequencing on an Illumina 
HiSeq 4000 was performed. Quality of the raw reads data for each sample was checked 
using FastQC (version 0.11.3). The Tuxedo Suite software package was used for 
alignment 45-47. Briefly, reads were aligned to the reference mRNA transcriptome (hg19) 
using TopHat (version 2.0.13) and Bowtie2 (version 2.2.1.) followed by a second round 
of post-alignment quality control in FastQC, which allows at most three mismatches. 
One sample was dropped due to low alignment rates. All samples used in downstream 
analysis (n=69) had at least 16.8 million good quality aligned reads with alignment rates 
averaging 60%. Prior to analysis, read counts were normalized by the trimmed mean of 
M-values method 48.  
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Statistical analysis 
All statistical analyses were performed in the R Project for Statistical Computing 
(version 3.6.1). Summary statistics were first calculated. Pb variables analyzed include 
maternal BLLs at each trimester (T1, T2, T3), bone Pb levels in maternal patella and 
tibia, and BLL measured at the adolescent follow-up visit, which were all treated as 
continuous variables. Bivariate analyses between Pb exposure variables and covariates 
(e.g., cell-type proportions, adolescent sex, maternal age at birth and adolescent age at 
time of sample collection, pyrosequencing plate (i.e., batch), height-for-age z-score, 
BMI-for-age z-score, weight, etc.) was performed. Potential confounding variables that 
were associated with both prenatal Pb and DNA methylation - adolescent age and 
adolescent BLL - were identified for inclusion in final statistical models of site-specific 
DNA methylation data. While not associated with Pb, sex and experimental plate were 
also included in statistical models due to their biological effect on DNA methylation and 
effect on the technical measurement of DNA methylation, respectively. A random 
intercept for each participant was included in all models to account for autocorrelation 
from matched 5mC and 5hmC percentages for each individual. Lastly, in models of 
NINJ2 methylation, C/C individuals had 0% regional methylation as expected since the 
SNP converts the CpG site to a CpC site, resulting in the inability to methylate the locus 
and ensuing regional methylation changes. Thus, C/C individuals were dropped from 
analysis and genotype (G/G or G/C) was included as a covariate. 
A mixed-effects model was run treating 5mC and 5hmC values as repeated 
measures of a single outcome variable – DNA methylation, given that 5mC and 5hmC 
are both measured at each CpG site and the values for these two marks are dependent 
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upon each other both biologically and statistically 49. To determine if Pb exposure 
modifies the balance between the DNA modification categories (5mC and 5hmC), an 
interaction term between prenatal Pb measures and a dichotomous variable signifying 
whether the outcome measure is 5hmC or 5mC was included in the statistical model. 
Since there was evidence for an interaction between Pb and type of DNA methylation, 
we next used separate mixed-effects regression models treating CpG sites as repeated 
measures to estimate associations between prenatal Pb and 5mC and associations 
between prenatal Pb and 5hmC, separately. To assess potential sex-specific effects on 
the association between prenatal Pb and DNA 5mC and 5hmC, identical models were 
run as described above but stratified by sex. The lme4 and lmerTest packages within 
the statistical program R were used for these analyses and a p-value<0.05 was 
considered significant. Finally, RNAseq normalized read counts of HCN2, NINJ2, 
RAB5A, and TPPP were log-transformed and compared to 5mC% and 5hmC% from 
pyrosequencing. We used Pearson’s product-moment correlation to quantify the 
strength of the relationship between these expression and epigenetics. P-values<0.05 
were considered significant. The ggplot2 R package was used to plot results. 
Due to outliers in many of the Pb biomarkers, a sensitivity analysis was 
performed. In this analysis, we re-ran the models excluding outliers for BLLs or bone Pb 
measures. Outliers were defined as ±3D from the mean. We excluded 4, 5, 1, 3 and 5 
outliers that were all 3 SD greater than the means for T1 BLL, T2 BLL, T3 BLL, tibia 




Population parameters and phenotypic data 
 Among the 144 children in the analytic sample, 73 (51%) were male (Table 1). 
The mean age of the offspring was 14.0 years, ranging from 11.1 years up to 17.7 years 
of age. The mean maternal BLLs averaged over all three trimesters was 5.98 (SD=4.34) 
µg/dL, with a first trimester (T1) mean of 6.43 (SD=5.16) µg/dL, second trimester (T2) 
mean of 5.66 (SD=5.21) µg/dL, and a third trimester mean of 5.86 (SD=4.32) µg/dL. 
Maternal BLLs between the trimesters were highly correlated (r>0.67, p<10-6) according 
to a Spearman’s rank-order correlation test. Bone Pb measures represent long-term Pb 
accumulation since the half-life of Pb in bone can be decades. Average Pb 
concentration measured in one-month post-partum maternal patella was 11.4 (SD=9.45) 
µg/g and tibia was 9.19 (SD=6.88) µg/g. Current adolescent BLL was 3.29 (SD=4.44) 
µg/dL, which was moderately correlated (r>0.34, p<0.0001) with maternal trimester-
specific Pb exposures. Genotyping of study participants at rs34038797 SNP revealed 
27 individuals with G/G genotype, 83 G/C, and 34 C/C. Participants included in this 
analysis were compared with all ELEMENT mother-infant pairs from the same cohorts 
(2 and 3). Characteristics of offspring and Pb biomarker concentrations were not 
statistically different between the subset included in this analysis and the entire sample 
(Table 3.1) with the exception of adolescent age at follow-up which was slightly lower in 
the subset.  
5mC and 5hmC within candidate regions  
To measure the levels of DNA 5mC and 5hmC at HCN2, NINJ2, RAB5A, and 
TPPP loci, we performed parallel BS and oxBS conversion of DNA samples from the 
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adolescent ELEMENT samples. Both 5mC and 5hmC were measured at each gene loci 
in all adolescent whole blood DNA samples. The mean percentages of 5hmC across 
genetic regions were measured at 2.04% (SD=4.31) in HCN2, 3.00% (SD=6.37) for G/C 
samples in NINJ2 and 1.47% (SD=5.86) in G/G NINJ2, 0.64% (SD=0.80) in RAB5A, 
and 0.45% (SD=8.01) in TPPP (Figure 3.2, Appendix Table 3.2A). Percent 
measurements of 5hmC in blood at each locus were detectable, but much lower than for 
5mC, with 13 participants displaying average 5hmC measures at or above 10% in at 
least one gene. 5mC was measured at 81.3% (SD=9.63) in HCN2, 38.6% (SD=7.39) for 
G/C samples NINJ2 and 67.3% (SD=9.83) in G/G NINJ2, 1.41% (SD=1.21) in RAB5A 
and 92.5% (SD=8.03) in TPPP.  
Association of prenatal Pb with 5mC and 5hmC  
Next, an interaction term was used to determine if prenatal Pb exposure is 
associated with 5mC and 5hmC in the same or a different manner. In a repeat 
measures model with the paired 5mC and 5hmC measures as outcomes, several 
interaction terms were statistically significant. In one example, as prenatal Pb exposure 
increases, there was a decrease in the slope between 5mC and 5hmC in whole blood, 
signifying a shift towards a greater proportion of 5hmC compared to 5mC in NINJ2. This 
shift towards 5hmC was reflected in the significant negative interaction terms between 
DNA modification category and Pb exposure (p<0.001 for all Pb exposure measures) 
(Appendix Table 3.3A). Similarly, the 5mC and 5hmC proportions in HCN2 shift 
towards increased 5mC at higher Pb exposure measures when analyzing T1 BLLs, T2 
BLLs, T3 BLLs, and patella bone Pb (not tibia bone Pb), which was reflected in the 
significant positive interaction terms (p≤0.001). Interestingly, TPPP 5mC and 5hmC 
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proportions shifted towards 5mC at higher patella bone Pb levels (p<0.03) but shifted 
towards 5hmC at higher tibia bone Pb measures (p<0.03). There was no significant 
interaction between Pb and type of DNA methylation and also no significant main effect 
of Pb in the model of RAB5A. 
Since there was evidence for differences in the association between Pb and DNA 
methylation by type of methylation at several genes, the association between each Pb 
exposure biomarker and 5mC or 5hmC at each gene was tested separately. For each 
unit increase (1 µg/dL) in maternal BLL during T1, there was a 0.43 (95% CI: 0.07, 0.78) 
increase in % 5mC in HCN2 (p=0.02) and a 0.49 (95% CI: 0.17, 0.80) increase in % 
5hmC within the NINJ2 locus (p=0.003) (Figure 3.3, Appendix Table 3.3A). DNA 5mC 
levels within HCN2 demonstrated a positive association with T2 BLLs (β=0.37 (95% CI: 
0.04, 0.69), p=0.03), but within NINJ2 it was 5hmC levels that were associated with T2 
BLLs (β=0.27 (95% CI: 0.07, 0.47), p=0.008) (Appendix Table 3.3A). Similarly, T3 
maternal BLLs were associated with an increase in HCN2 5mC (β=0.50 (95% CI: 0.10, 
0.90), p=0.01) but a decrease in NINJ2 (β=-0.35 (95% CI: -0.60, -0.11), p=0.004). T3 
BLL were also associated with an increase in NINJ2 5hmC levels (β=0.45 (95% CI: 
0.21, 0.68), p<0.001) (Figure 3.3, Appendix Table 3.3A). There were no observed 
significant associations between trimester-specific Pb measures and 5mC or 5hmC of 
RAB5A or TPPP. We next investigated whether patella or tibia bone Pb measures of 
cumulative gestational exposure were associated with either 5mC or 5hmC at each 
locus. A 1 µg/g increase in patella bone Pb was associated with a significant increase in 
5hmC (β=0.17 (95% CI: 0.07, 0.27), p<0.001) and a non-significant decrease in 5mC 
(β=-0.27 (95% CI: -0.56, 0.03), p=0.08) in NINJ2 (Appendix Table 3.3A). However, 
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patella Pb and tibia Pb were not significantly associated with 5mC or 5hmC in HCN2, 
RAB5A, or TPPP.  
The results of the sensitivity analysis excluding outliers for trimester-specific 
BLLs and bone Pb measures demonstrated associations with DNA 5mC and 5hmC in 
the same direction for each exposure-outcome relationship that were statistically 
significant in models including all subjects (Appendix Table 3.3A). After outliers were 
removed, associations remained significant for T1 BLLs and 5mC in HCN2, and for T1, 
T2, and T3 BLLs and patella bone Pb and 5hmC in NINJ2, while associations of T2 and 
T3 BLLs with 5mC in HCN2 remained positive but were no longer statistically 
significant. However, the estimate for T3 BLLs and 5mC in NINJ2 changed from a 
significant inverse association to a null association (β=–0.01; 95% CI: –0.79, 0.77) after 
one outlier for this exposure was excluded from the analysis.  
Sex-specific estimates  
To investigate whether trimester-specific or cumulative (bone) Pb exposure 
biomarkers were associated with male or female-specific alterations in 5mC and/or 
5hmC at HCN2, NINJ2, RAB5A, and TPPP loci (Table 3.2), we performed sex-stratified 
models. For HCN2, associations between 1 µg/dL increases in T2 and T3 BLLs and 
5mC were positive for females and null for males (e.g., T2: β=0.82 (95% CI: 0.25, 1.38) 
vs. β=0.02 (95% CI: –0.41, 0.45), respectively) while associations with 5hmC were 
negative for females and positive for males (e.g., T3 BLLs, β=-0.30 (95% CI: -0.62, 
0.03) vs. β=0.12 (95% CI: -0.11, 0.36), respectively). Associations with 5mC and 5hmC 
in HCN2 were not notably different by sex. For NINJ2, T2 BLLs were positively 
associated with 5hmC in females, while the association was close to the null for males 
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(β=0.48 (95% CI: 0.10, 0.86) vs. β=0.07 (95% CI: –0.20, 0.34), respectively). 
Associations of 5mC in NINJ2 with T1 BLLs and patella Pb were negative for females 
and close to the null for males, but confidence intervals overlapped; otherwise, effect 
estimates were similar by sex. Consistent with the results for RAB5A in males and 
females combined, associations with 5mC and 5hmC were consistently null for both 
groups. For TPPP, patella Pb was positively associated with 5mC and negatively 
associated with 5hmC in males (β=0.16 (95% CI: 0.05, 0.27) and β=-0.14 (95% CI: -
0.29, 0.02), respectively) while corresponding estimates were close to the null in 
females (β=-0.04 (95% CI: -0.16, 0.08) and β=0.04 (95% CI: -0.08, 0.15), respectively). 
The sex-stratified sensitivity analysis results excluding outliers for trimester-specific 
BLLs and bone Pb measures demonstrated effect estimate changes (Appendix Table 
3.4A). In HCN2, the magnitude of the association between 1 µg/dL increases in T1 
BLLs and 5mC became more positive in females by 0.42% (β =0.83 (95% CI: 0.08, 
1.59), whereas males remained unchanged. All other associations with 5mC and 5hmC 
in HCN2 were not notably different in the sensitivity analysis. In NINJ2, T1 BLLs were 
more negatively associated with 5mC by 0.64%, whereas the association among 
females was diminished (β=-0.66 (95% CI: -2.01, 0.68) and β=0.04 (95% CI: (-1.37, 
1.43), respectively). T2 BLLs changed directions to a positive association with 5mC in 
females (β=0.30 (95% CI: -0.88, 1.48)), whereas the male magnitude with 5hmC 
increased by 0.31% (β=0.38 (95% CI: -0.22, 0.99)). Patella Pb gained a negative 
association with 5mC and positive with 5hmC (β=-0.52 (95% CI: -1.03, -0.02), β=0.26 
(95% CI: 0.08, 0.44), respectively); otherwise, effect estimates were similar when 
outliers were included. Consistent with the results with RAB5A all other models, 
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associations with 5mC and 5hmC were consistently null. Similarly, TPPP sensitivity 
analysis by sex did not differ in magnitude from original sex-stratified models. 
5mC and 5hmC correlations with gene expression 
To compare quantified methylation levels with gene expression (normalized read 
counts), we compared DNA 5mC and 5hmC measures from the pyrosequencing 
method with a subset of individuals who had available RNA-seq data (used as 
normalized read counts; Figure 3.4 and Appendix Figure 3.1A). DNA 5mC was 
negatively correlated with NINJ2 expression (R=-0.5, p-value=0.005), whereas DNA 
5hmC was positively correlated with NINJ2 expression (R=0.4, p-value=0.04) (Figure 
3.4). RAB5A had similar directionality but was not statistically significant; 5mC was 
negatively correlated with expression (r=-0.1, p-value=0.4) and 5hmC was positively 
correlated (r=0.02, p=0.9). HCN2 (5mC: r=0.1, p-value=0.5; 5hmC: r=0.05, p-value=0.7) 
and TPPP (5mC: r=0.1, p-value=0.5; 5hmC: r=0.08, p-value=0.6) did not have 
statistically significant correlations. 
Conclusion 
Prenatal and early-life Pb exposures have been associated with altered DNA 
methylation patterns, which serve as potential mechanistic links among Pb-induced 
health effects 3, 5, 7, 8, 27, 50-52. The majority of studies, however, quantify total DNA 
methylation together, and fail to distinguish between 5mC and 5hmC. These include 
those based on sodium bisulfite conversion of DNA, which is unable to discriminate 
between 5mC and 5hmC with important implications for the interpretation of published 
epigenetic studies focused on Pb exposure to date. To our knowledge, this is the first 
epigenetic study to investigate the independent associations of DNA 5mC and 5hmC in 
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human blood samples with prenatal Pb exposure. Our study was strengthened by the 
inclusion of multiple biomarkers of early-life Pb exposure. 
First, by utilizing oxBS-pyrosequencing, we provide evidence for the presence of 
variable 5hmC in human whole blood. Second, we estimated the effect of prenatal Pb 
exposure on both 5mC and 5hmC of four genes with neurological functions selected 
from an epigenome-wide study of prenatal Pb exposure (HCN2, NINJ2, RAB5A, and 
TPPP). We observed associations between 5mC with T1, T2, and T3 BLLs in HCN2, in 
addition to T3 BLL and patella bone Pb in NINJ2, as well as show that T1, T2, T3 BLLs 
and cumulative gestational Pb exposure measured in patella bone are associated with 
5hmC levels in NINJ2. This supports the idea that prenatal Pb exposure stably alters 
gene-specific 5mC and 5hmC levels that can be detected into adolescence. Further, 
male- and female-specific associations of prenatal Pb exposure with both 5mC and 
5hmC were not notably different by sex. Lastly, we identified correlations between 5mC 
and 5hmC with gene expression in one of the genes, NINJ2.  
Our study provided estimates of 5mC and 5hmC in whole blood at four genes 
with varying methylation profiles. Levels of 5hmC in blood were relatively low with wide 
variability between individuals, consistent with prior research which estimates the 
highest levels of 5hmC are in brain tissue with lower levels estimated in tissues such as 
blood 19-21. A cross-sectional study of female neonates (n=48) and French-Canadian 
women aged 25–30y, 70–75y, and ≥90y (n=50 in each age group) reported that mean 
5hmC levels were highest in cord blood DNA and lowest in peripheral blood DNA from 
women in the two oldest groups, suggesting declining levels with age 53. Of note, we 
quantified average 5hmC levels as high as 10% within HCN2, NINJ2, and TPPP genes 
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for 13 individuals. Although, we also detected negative 5hmC values, which is an 
inherent limitation of the oxBS subtraction method when assessing gene-specific 5hmC 
via pyrosequencing. While brain is the tissue of interest in terms of Pb toxicity, surrogate 
epigenetic measures such as in blood are typically necessary in longitudinal 
epidemiological studies. Research has shown that there are widespread changes in 
5hmC occurring during human brain development, with sex-differences in 5hmC levels 
in fetal brain 24. Whether 5hmC levels in blood correlate with crucial 5hmC patterning in 
brain and if so, at which genes, is currently unknown but needs to be characterize to 
understand the implications of exposure-5hmC associations in surrogate tissues. 54. The 
Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of 
Transcription (TaRGET II) consortium is one research program that is conducting 
analyses of 5mC, 5hmC, and more in target and surrogate tissues (including brain and 
blood, respectively) from animals prenatally exposed to common environmental 
toxicants in order to understand the role that environment plays in disease susceptibility 
as a function of tissue-specific epigenomic perturbations 55.  
By using adolescent-age DNA methylation profiles, we observed evidence that 
Pb exposure may modify the balance between 5mC and 5hmC within total methylation. 
We detected a positive association between trimester-specific BLLs, but not bone Pb, 
with 5mC in HCN2. Further, increasing prenatal Pb exposure was associated with 
increases in 5hmC but decreases in 5mC in whole blood in NINJ2. For example, a 
1µg/dL increase in T3 BLLs was associated with lower 5mC but higher 5hmC in NINJ2. 
Although, the association between T3 BLLs and 5mC was null after an outlier was 
excluded. Metal exposures, such as Pb, cause increased oxidative DNA damage which 
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inhibits the ability of methyltransferases to interact with DNA, and these can result in 
hypomethylation at some loci 56-59. TET proteins are involved in the oxidation of 5mC to 
5hmC, and free radicals are known to interact with these proteins 32, 33. Pb-induced 
oxidative stress inhibits α-ketoglutarate dehydrogenase in the mitochondria resulting in 
the accumulation of α-ketoglutarate (α-KG), a co-factor for TET enzymes 31. Thus, we 
hypothesize that Pb exposure would increase activity of TET enzymes, resulting in 
genome-wide increases in 5hmC levels. The findings with NINJ2 reflect the hypothesis 
where increased 5hmC was associated with all Pb exposure measures, with or without 
Pb biomarker outliers included. In contrast, we identified a shift towards higher 5mC as 
Pb exposure increased for HCN2. This may be explained by interacting proteins that are 
required for HCN channel gating and kinetics. More studies are needed in 
understanding the interactions between DNA methylation and DNA oxidation. 
While both males and females are vulnerable to the adverse effects of Pb 
exposure, there is significant evidence that sex can influence the severity of Pb 
neurotoxicity 50, 60, 61. We observed some evidence for sex-specific associations, though 
based on magnitude, direction and CI overlap between male and female-specific effect 
estimates, it is not entirely conclusive. Our study would benefit from a larger sample 
size in order to draw such conclusions around sex-effects. These data are inconsistent 
with previous studies in humans and mice in which more Pb-associated methylated 
CpG sites were identified in females compared to males 50, 62. It is known that global 
DNA methylation profiles are dimorphic by sex when assessed in fetal, child, and adult 
human brain tissue 63 and influenced by hormones when assessed in brain tissue in rats 
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64. Thus, these interactions may influence an individual’s susceptibility to the effects of 
Pb. 
Within the a different cohort of the broader ELEMENT study, Sen et al., 2015a 
reported associations between  prenatal Pb exposure on 5hmC in umbilical cord blood 
30. Umbilical cord blood from 24 male and 24 female newborns were randomly selected 
from the 1st (<1.74 µg/dL) and 4th (>3.77 µg/dL) quartiles of Pb exposure, where 25% of 
their samples (5 males and 7 females) had BLLs in umbilical cord blood at or above 5 
µg/dL. Even though their sample size was relatively low, they observed significant 
associations between Pb and 5hmC as well as 5mC profiles measured with a modified 
epigenome-wide method, called hMeDIP-450K chip. Further, they categorized the 
differentially hydroxymethylated (DhMR) and differently methylated (DMR) regions into 
sex-independent and sex-specific DMRs. However, sex-dependent associations were 
more common in 5mC compared to 5hmC profiles. They concluded that differential 5mC 
was a better predictor for sex-specific effects of Pb exposure, whereas our stratified 
analysis identified 5hmC as the better predictor. None of their statistically significant 
DMRs or DhMRs overlapped with our candidate genes. These discrepancies could be 
due to a variety of reasons. 1) Our study benefitted from a larger samples size with 
greater variability of prenatal Pb exposure levels. 2) We assessed prenatal Pb on a 
continuous scale rather than low versus high Pb exposure. 3) Our Pb estimates were 
taken from prenatal exposures measured in the mothers during pregnancy versus an at 
birth measure in umbilical cord blood. Nonetheless, their effect sizes and directions 
were relatively similar for both 5hmC and 5mC associations with Pb, identifying both 
hyper- and hypo- changes in both DNA modifications. We both conclude that the 
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number of human studies assessing 5hmC is limited and that our studies provide 
promise for an increased understanding of Pb-induced epigenetic regulation in humans. 
Though we were limited to analyzing whole blood samples, results from this 
research provide preliminary evidence that Pb exposure may impact regulation of both 
5mC and 5hmC. Challenges in current developmental toxicology studies include 
determining whether persistent epigenetic alterations are due to global changes across 
all cells, altered cell-type proportions, or changes in specific cell types 65, 66. At this point 
in time, the stability of 5hmC within different blood cell-types is unknown 43. Therefore, it 
is possible that associations between prenatal Pb and gene-specific 5hmC alterations 
documented here are simply reflecting blood cell-type proportion shifts. The 
associations reported here between Pb and blood DNA methylation could be under or 
overrepresenting potential effects on the target tissue of interest for Pb toxicity – brain. 
However, additional studies have shown DNA methylation conservation among different 
tissue and cell-types 67, suggesting that differential methylation from whole blood can be 
a valid biomarker for tissues of interest at many genes. Future studies should consider 
cell and tissue type-specific impacts of perinatal Pb exposure to explain mechanisms 
and reveal biological pathways underlying the adverse outcomes of Pb exposure. 
Further, larger studies should incorporate oxBS based methodologies to study the sex-
specific impact of Pb and other environmental exposures on 5hmC and 5mC or employ 
methods that directly measure 5hmC (i.e. HMeDip-seq 68) to avoid negative 
measurements. Our study had a relatively wide range of Pb exposures, giving us the 
opportunity to investigate associations relevant to populations with a range of 
exposures. Although this project measures 5mC and 5hmC levels in only a few selected 
 95 
loci, it demonstrates the utility of oxBS pyrosequencing as a quantitative and high-
throughput method to estimate 5hmC levels at specific regions that does not require 
antibodies.  
In terms of gene regulation, we were able to detect statistically significant 
correlations within NINJ2, where increases in gene expression were associated with 
hypomethylation and hyper-hydroxymethylation. This follows previous research that has 
shown that increased levels of 5mC are associated with decreased transcription factor 
binding at promoter/enhancer sites and suppression of transcription 69; whereas, 5hmC 
is associated with increases in gene expression 70, 71. We were unable to detect these 
same correlations within HCN2, RAB5A, and TPPP. Despite nearly half the samples 
having RNA available for RNA-seq, the use of these samples allowed for direct 
measurement of expression of each gene analyzed within this study. To further explore 
the idea that altered 5hmC in human blood impacts gene regulation, future studies 
should include a larger sample size, as well as investigate expression in individual cell-
types utilizing technologies such as single-cell RNA-seq.  
In conclusion, these data suggest that 1) prenatal Pb exposure differentially 
influences 5mC and 5hmC and does not seem to vary by sex, and 2) 5hmC is present 
and detectable in whole blood samples at variable levels. These modification-specific 
associations would not have been detected using methods based on standard sodium 
bisulfite treatment, demonstrating the utility of incorporating oxBS treatment in cohort 
studies. Prenatal Pb exposure results in a shift from 5mC to 5hmC in NINJ2, with the 
opposite shift seen in HCN2 (5hmC to 5mC), and these relationships were detected 
using all blood Pb biomarker measures. Prenatal Pb exposure has been previously 
 96 
associated with a decrease in IQ and adverse effects on neurobehavioral outcomes, but 
whether epigenetic mechanisms contribute to these long-term effects is not well 
characterized. Given the potential importance of Pb-induced DNA methylation 
perturbations on processes related to early neurodevelopment and potential late-onset 
delays (i.e., adulthood) in cognition 52, careful examination of Pb-induced 5mC and 
5hmC alterations may eventually improve our knowledge of the epigenetic pathways 
involved in neurodevelopment. Our results suggest the prenatal Pb exposure may 
modify both 5mC and 5hmC, and the relationship between these changes and 
neurodevelopment outcomes merits further study. This study and others are providing 
additional evidence around DNA 5hmC as being an environmentally responsive 
modification 17, 30. Altogether, it is vital for environmental studies to consider 5hmC as a 
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Tables and Figures 
Table 3.1: Characteristics of ELEMENT mother-offspring pairs with adolescent blood leukocyte DNA methylation data 
compared to all ELEMENT mother-infant pairs. 
 
 ELEMENT Subset** All ELEMENT** 
Characteristics No. Mean ± SD or N (%) Min Max No. 
Mean ± SD 
or N (%) Min Max 
P-
Value 
 Mothers                   
    Age at birth (yrs.) 144 26.7 ± 5.42 14.0 39.0 1458 26.1 ± 5.35 14.0 44.0 0.200 
    Blood lead (µg/dL)        
      
        First Trimester 127 6.43 ± 5.16 0.90 35.8 594 5.77 ± 4.03 0.00 36.0 0.340 
        Second Trimester 130 5.66 ± 5.21 0.00 38.2 616 5.20 ± 3.93 0.00 38.0 0.430 
        Third Trimester 131 5.86 ± 4.34 0.00 34.0 575 5.54 ± 4.13 0.00 38.0 0.290 
        Average All Trimesters 133 5.98 ± 4.38 0.43 33.1 643 5.53 ± 3.51 0.00 33.0 0.410 
    Bone lead (µg/g)        
      
        Patella 140 11.4 ± 9.45 0.11 48.0 1252 11.0 ± 8.64 0.11 68.0 0.790 
        Tibia 122 9.19 ± 6.88 0.12 19.0 1104 9.20 ± 7.23 0.00 44.0 0.790 
 Adolescent children              
    Age at follow-up (yrs.) 144 14.0 ± 1.96 11.0 18.0 549 14.5 ± 2.10 10.7 18.1 0.002* 
    Male Sex 144 73 (51%)    546 268 (49%)    0.800 
    Blood Pb (µg/dL) 144  3.29 ± 4.44 0.00 41.0 404 3.09 ± 3.25 0.00 41.0 0.540 
    Weight (kg) 144 53.2 ± 12.2 25.9 95.0 554 54.9 ± 13.3 25.9 109.0 0.270 
    Height for Age Z-score 144 -0.23 ± 0.88 -2.30 -2.06 546 -0.29 ± 0.93 -2.84 3.32 0.430 
    BMI for Age Z-score 144 0.51 ± 1.25 -2.57 3.40 546 0.50 ± 1.25 -3.81 3.40 0.950 
Note: SD – standard deviation; N – number 
* p-value < 0.05 using Wilcox signed-rank test comparing entire ELEMENT cohort to the subset used in this current research. 
** Participants for the current study were a subset of mother-child pairs from Cohorts 2 and 3 of ELEMENT that had archived whole blood samples 
for DNA methylation analysis. Here we are comparing their characteristics to those of all ELEMENT mother-child pairs from the same cohorts (2 
and 3) with available data for each variable.  
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Table 3.2: Results from a sex-stratified sensitivity analysis of associations between Pb 
exposure biomarkers and DNA 5mC and 5hmC using a mixed-effects regression of 
repeated measures at multiple CpG sites of either 5mC or 5hmC. 
 
 Females Males 
 N Beta (95% CI) P-value N Beta (95% CI) P-value 
HCN2       
T1       
5mC 61 0.41 (-0.08, 0.90) 0.101 63 0.44 (-0.22, 1.10) 0.194 
5hmC 59 -0.11 (-0.34, 0.12) 0.356 61 -0.04 (-0.28, 0.20) 0.722 
T2       
5mC 63 0.82 (0.25, 1.38) 0.005 64 0.02 (-0.41, 0.45) 0.922 
5hmC 61 -0.35 (-0.66, -0.03) 0.031 62 0.12 (-0.17, 0.41) 0.407 
T3       
5mC 64 0.84 (0.26, 1.43) 0.005 64 0.06 (-0.62, -0.03) 0.865 
5hmC 62 -0.30 (-0.63, 0.03) 0.072 62 0.12 (-0.11, 0.36) 0.305 
Tibia       
5mC 65 0.15 (-0.22, -0.52) 0.433 54 -0.09 (-0.40, 0.23) 0.591 
5hmC 63 -0.10 (-0.30, 0.10) 0.320 52 -0.08 (-0.18, 0.02) 0.122 
Patella       
5mC 67 0.17 (-0.08, 0.41) 0.183 70 0.02 (-0.19, 0.22) 0.872 
5hmC 65 -0.08 (-0.21, 0.05) 0.212 68 0.04 (-0.03, 0.10) 0.323 
NINJ2*       
T1       
5mC 47 -0.27 (-0.73, 0.20) 0.260 45 -0.02 (-0.60, 0.57) 0.959 
5hmC 47 0.55 (0.06, 1.05) 0.029 45 0.24 (-0.32, 0.79) 0.402 
T2       
5mC 46 -0.18 (-0.54, 0.18) 0.325 47 -0.11 (-0.40, 0.19) 0.477 
5hmC 46 0.48 (0.10, 0.86) 0.014 47 0.07 (-0.20, 0.34) 0.617 
T3       
5mC 48 -0.25 (-0.60, 0.11) 0.169 45 -0.33 (-0.81, 0.16) 0.189 
5hmC 47 0.48 (0.11, 0.86) 0.012 45 0.29 (-0.17, 0.75) 0.221 
Tibia       
5mC 48 0.12 (-0.56, 0.80) 0.731 39 -0.28 (-0.95, 0.40) 0.422 
5hmC 48 0.10 (-0.15, 0.34) 0.449 39 0.11 (-0.09, 0.31) 0.273 
Patella       
5mC 50 -0.42 (-0.87, 0.03) 0.066 51 -0.10 (-0.52, 0.33) 0.657 
5hmC 50 0.20 (0.03, 0.36) 0.019 51 0.10 (-0.03, 0.24) 0.155 
RAB5A       
T1       
5mC 62 0.01 (-0.02, 0.03) 0.683 64 -0.01 (-0.04, 0.02) 0.631 
5hmC 62 -0.01 (-0.04, 0.04) 0.889 64 0.01 (-0.06, 0.08) 0.786 
T2       
5mC 64 -0.01 (-0.04, 0.02) 0.709 65 0.01 (-0.01, 0.03) 0.281 
5hmC 64 0.01 (-0.04, -0.06) 0.596 65 -0.02 (-0.05, 0.02) 0.450 
T3       
5mC 65 -0.01 (-0.05, 0.02) 0.360 65 0.02 (0.00, 0.05) 0.067 
5hmC 65 0.03 (-0.02, 0.08) 0.215 65 -0.03 (-0.09, 0.02) 0.241 
Tibia       
 106 
 Females Males 
 N Beta (95% CI) P-value N Beta (95% CI) P-value 
5mC 66 0.00 (-0.02, 0.02) 0.725 55 0.01 (-0.01, 0.02) 0.376 
5hmC 66 0.00 (-0.03, 0.03) 0.972 55 0.01 (-0.02, 0.01) 0.529 
Patella       
5mC 68 -0.01 (-0.02, 0.01) 0.444 71 0.01 (0.00, 0.01) 0.203 
5hmC 68 0.01 (-0.01, 0.03) 0.390 71 -0.01 (-0.03, 0.00) 0.144 
TPPP       
T1       
5mC 61 0.14 (-0.10, 0.38) 0.269 64 0.16 (-0.27, 0.60) 0.458 
5hmC 61 0.01 (-0.24, 0.25) 0.965 63 0.11 (-0.46, 0.68) 0.708 
T2       
5mC 63 0.03 (-0.31, 0.37) 0.865 65 0.11 (-0.15, 0.37) 0.415 
5hmC 63 0.22 (-0.08, 0.52) 0.151 64 -0.07 (-0.47, 0.32) 0.717 
T3    66   
5mC 64 0.17 (-0.15, 0.49) 0.297 65 0.46 (0.07, 0.85) 0.021 
5hmC 64 0.14 (-0.14, 0.42) 0.335 64 -0.41 (0.07, 0.85) 0.130 
Tibia       
5mC 65 -0.11 (-0.30, 0.08) 0.255 55 0.00 (-0.18, 0.18) 0.967 
5hmC 65 0.06 (-0.12, 0.23) 0.517 54 0.17 (-0.09, 0.43) 0.191 
Patella       
5mC 67 -0.04 (-0.16, 0.08) 0.556 71 0.16 (0.05, 0.27) 0.006 
5hmC 67 0.04 (-0.08, 0.15) 0.519 70 -0.14 (-0.29, 0.02) 0.085 
*NINJ2 models were also adjusted for genotype at rs34038797 (G/C). 
Note: In each sex-stratified mixed-effects regression model, represented in the different rows, the 
outcome is percentages of 5mC or 5hmC at all quantified CpG sites treated as repeated measures, and 




Figure 3.1: Data collection timeline from the ELEMENT birth cohort. 
Maternal whole blood samples were collected during the first trimester (T1), second 
trimester (T2), and third trimester (T3) and analyzed for blood Pb concentrations. 
Maternal bone Pb was measured one month postpartum as an indicator of cumulative 
exposure over the course of the gestational period. Adolescent whole blood samples 
were collected in offspring at a follow-up visit occurring once between the ages of 11-18 
years for blood Pb measures and DNA 5mC and 5hmC profiling. Covariate data 
including demographics and anthropometry were conducted at each stage with sample 
collection. 
 




















Figure 3.2 Boxplot depicting DNA 5hmC percent in human whole blood detected for 
females and males within HCN2 (n=137), NINJ2 (separated by SNP (rs34038797); G/G, 
n=27; G/C, n=83; C/C dropped from analysis (n=34)), RAB5A (n=143), and TPPP 






































Figure 3.3: DNA 5mC (yellow) and 5hmC (blue) percent levels by T1 (top row) and T3 (bottom row) maternal Pb 
exposure separated by male (dashed regression line) and female (solid regression line) for loci within HCN2 (left column) 
and NINJ2 (right column). Models were adjusted for sex, adolescent age, adolescent BLL, and batch; NINJ2 models were 
additionally adjusted for the SNP rs34038797. 
 
Note: T1, First trimester; T3, third trimester; BLL, blood lead level; M, males; F, females; DNAm, DNA methylation. Models were adjusted for sex, 
adolescent age, adolescent BLL, and batch; NINJ2 models were additionally adjusted for the SNP rs34038797 where C/C samples (n=34) were 
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Figure 3.4: Correlation coefficients between gene expression (normalized read counts) 
and 5mC% (left column) and 5hmC% (right column) from pyrosequencing in NINJ2 




























































Figure 3.1A: Correlations between gene expression and 5mC (left column) and 5hmC 
(right column) in HCN2 (top row; 5mC n=68, 5hmC n=66), TPPP (middle row; 5mC 
n=63, 5hmC n=61), and RAB5A (bottom row; 5mC n=70, 5hmC n=70). Regression line 
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Table 3.1A: Primer sequences for oxBS-pyrosequencing. 
Gene Primer Sequence 
HCN2 Forward 5’-TTTTTTGGTTAGATTGTATTGGTAGATGT-3’  
Reverse 3’-ACTCACCTCTCCAACCCCAATTTC-5’  
Sequencing 3’-CTCTCCAACCCCAATTTCC-5’ 
NINJ2 Forward 5’-AGGGTTTGATTTTTATTTTTTTTAAGGT-3’  
Reverse 3’-AACCCCATTCAACTTCCTC-5’  
Sequencing 3’-CCTCCCTCAAAAACTA-5’ 
NINJ2 Forward 5’-TGCAAATCCCCAAAGAGG-3’ 
SNP Genotyping Reverse 3’-CACCCTTGATCCTAGCACGTAC-5’ 
(rs34038797) Sequencing 3’-CCAGCCCGGCCTCGT-5’ 
RAB5A Forward 5’-GGAGGAGGAGAAAGGAAAGAG-3’  
Reverse 3’-AAACCCAAACTTCCTAACAACAAAACC-5’  
Sequencing 3’-AAAATAAAAATATATCTATAAC-5’ 
TPPP Forward 5’-AGGGTTAGGAGAGGTAAAAATAAGA-3’  





Table 3.2A: Average Percent (%) 5mC and 5hmC for each site, each gene, and number of samples with calculated 
negative 5hmC values per CpG site within HCN2, NINJ2, RAB5A, and TPPP. Bolded CpG site numbers indicate that 
these exact CpG sites were included on the Infinium EPIC array location of EPIC array probes. 
Gene CpG sitea N of 5mC 





% ± SD 
N of Neg 
Samples 
N of Samples 
with >10% 
5hmC 
HCN2 1 140 81.37 ± 9.53 137 3.15 ± 4.32 22 6 
  2 140 83.86 ± 8.42 137 2.79 ± 3.76 28 4 
  3 140 79.85 ± 7.78 137 2.19 ± 4.50 37 3 
  4 140 89.49 ± 6.80 137 1.79 ± 2.83 26 2 
  5 140 80.86 ± 8.76 137 1.46 ± 4.58 42 4 
  6 140 72.75 ± 7.80 137 0.17 ± 5.14 61 8 
  Average 140 81.31 ± 9.63 137 2.03 ± 4.31 31 3 
NINJ2a 1 27 61.87 ± 5.17 27 5.37 ± 5.75 4 5 
 SNP=GG 2 27 74.08 ± 4.80 27 1.11 ± 4.82 10 0 
  3 27 75. 92 ± 5.14 27 1.56 ± 7.21 10 3 
  4 27 72.34 ± 4.77 27 0.94 ± 4.33 11 1 
  5 27 73.27 ± 4.68 27 -0.47 ± 4.84 14 0 
  7 27 63.63 ± 4.84 27 2.64 ± 5.71 9 3 
  8 27 50.24 ± 4.38 27 -0.85 ± 6.15 16 3 
  Average 27 67.34 ± 9.83 27 1.47 ± 5.86 10 0 
NINJ2d 1 78 35.58 ± 5.32 78 5.47 ± 5.50 13 15 
 SNP=CG 2 78 42.19 ± 5.98 78 2.53 ± 5.98 21 7 
  3 78 43.15 ± 6.68 78 3.14 ± 6.62 26 9 
  4 78 41.25 ± 6.41  78 3.08 ± 6.19 20 14 
  5 78 40.96 ± 6.28 78 2.62 ± 6.53 24 9 
  7 77 37.22 ± 5.87 77 2.64 ± 6.24 26 10 
  8 78 30.42 ± 6.34 78 1.50 ± 6.98 27 4 
  Average 78 38.64 ± 7.39 78 3.00 ± 6.37 22 8 
RAB5A 1 143 1.62 ± 0.62 143 0.74 ± 0.91 26 0 
  2 143 1.40 ± 0.77 143 0.97 ± 0.94 17 0 
  3 143 1.03 ± 0.77 143 0.86 ± 0.99 26 0 
  4 143 1.36 ± 0.86 143 0.62 ± 1.08 39 0 
  5 143 0.37 ± 0.91 143 0.33 ± 1.38 30 0 
  6 143 0.16 ± 0.45 143 0.40 ± 0.98 17 0 
  7 143 0.18 ± 0.90 143 0.36 ± 1.36 10 0 
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  8 143 0.19 ± 0.55 143 0.41 ± 1.15 16 0 
  9 143 1.91 ± 1.10 143 1.46 ± 1.33 23 0 
  10 143 0.32 ± 2.44 143 0.19 ± 2.51 2 0 
  11 143 0.32 ± 1.00 143 0.82 ± 1.97 16 0 
  Average 143 1.41 ± 1.21  143 0.64 ± 0.80 17 0 
TPPP 1 141 90.30 ± 4.89 140 1.07 ± 5.27 57 6 
  2 140 93.80 ± 8.41 140 1.32 ± 11.85 49 21 
  3 142 94.42 ± 4.21 136 0.13 ± 5.34 57 9 
  4 142 90.53 ± 13.77 141 -1.15 ± 7.30 64 18 
  Average 142 92.48 ± 8.03 141 0.45 ± 8.01 55 7 
Note: SD – standard deviation, Avg – average, Neg – Negative, N – Number of samples;  
aCpG site number indicates the order of the CpG sites analyzed within the pyrosequencing region 
bPyrosequencing the oxidative bisulfite treated samples quantifies total percentage of 5mC.  
c5hmC percentages were quantified by subtracting the results from the oxidative bisulfite converted samples (5mC) from standard bisulfite 
converted sample (5mC + 5hmC). The difference can sometimes be negative at sites with zero or low levels of methylation as a consequence of 
random noise. 




Table 3.3A: Results from three different models assessing associations between prenatal Pb biomarkers and DNA 
methylation. For each Pb biomarker and gene combination, the first two rows display the effect estimates for Pb and for 
an interaction term between the prenatal Pb biomarker and a dichotomous variable signifying whether the outcome 
measure is for 5mC or 5hmC; these estimates are from a mixed-effects model with repeated measures of 5hmC and 5mC 
for each gene as the outcome variable. The third row is a mixed-effects model of 5mC data only; in this model outcomes 
are repeat measures of 5mC at each CpG site within the gene and the effect estimate for the Pb biomarker is shown. The 
fourth row is a model of 5hmC measures only. All three models adjusted for the following covariates: sex, adolescent age, 
adolescent BLL, and batch. Models were identical in the sensitivity analysis with outliers of Pb exposure excluded for the 
5mC only and 5hmC only models. 
 
 All observations Outliers excluded 
 N Betaa (95% CI) P-value P-int N Betaa (95% CI) P-value 
HCN2        
T1 Pb        
Main effect 120 0.05 (-0.12, 0.21) 0.582   NA NA 
Interaction 120 0.30 (0.16, 0.45)  <0.001  NA NA 
5mC 124 0.43 (0.07, 0.78) 0.018  122 0.58 (0.01, 1.06) 0.018 
5hmC 120 -0.04 (-0.18, 0.12) 0.649  118 -0.03 (-0.23, 0.18) 0.793 
T2 Pb        
Main effect 123 0.06 (-0.13, 0.24) 0.540   NA NA 
Interaction 123 0.28 (0.12, 0.45)  0.001  NA NA 
5mC 127 0.37 (0.04, 0.69) 0.026  123 0.41 (-0.16, 0.97) 0.156 
5hmC 123 -0.10 (-0.29, 0.09) 0.300  119 0.01 (-0.28, 0.25) 0.931 
T3 Pb        
Main effect 124 0.06 (-0.12, 0.25) 0.500   NA NA 
Interaction 124 0.32 (0.16, 0.49)  <0.001  NA NA 
5mC 128 0.50 (0.10, 0.90 0.014  127 0.39 (-0.06, 0.83) 0.091 
5hmC 124 -0.06 (-0.16, 0.05) 0.547  123 0.01 (-0.20, 0.22) 0.930 
Tibia        
Main effect 116 -0.03 (-0.15, 0.08) 0.553   NA NA 
Interaction 116 0.04 (-0.078, 0.15)  0.538  NA NA 
5mC 120 0.03 (-0.21, 0.26) 0.830  117 -0.02 (-0.29, 0.25) 0.878 
 116 
5hmC 116 -0.06 (-0.16, 0.05) 0.318  113 -0.07 (-0.20, 0.06) 0.286 
Patella        
Main effect 133 -0.01 (-0.09, 0.06) 0.724   NA NA 
Interaction 133 0.13 (0.05, 0.21)  0.001  NA NA 
5mC 137 0.10 (-0.06, 0.26) 0.211  133 0.12 (-0.08, 0.32) 0.245 
5hmC 133 -0.01 (-0.09, 0.06) 0.762  129 -0.01 (-0.10, 0.00) 0.908 
NINJ2b        
T1 Pb        
Main effect 92 0.41 (-0.02, 0.84) 0.063   NA NA 
Interaction 92 -0.82 (-1.06, -0.57)  <0.001  NA NA 
5mC 92 -0.26 (-0.59, 0.07) 0.126  90 -0.29 (-1.22, 0.64) 0.541 
5hmC 92 0.49 (0.17, 0.80) 0.003  90 0.36 (0.01, 0.71) 0.042 
T2 Pb        
Main effect 93 0.38 (0.24, 0.52) <0.001   NA NA 
Interaction 93 -0.68 (-0.87, -0.49)  <0.001  NA NA 
5mC 93 -0.19 (-0.40, 0.02) 0.073  92 0.01 (-1.00, 1.01) 0.990 
5hmC 93 0.27 (0.07, 0.47) 0.008  92 0.38 (0.03, 0.73) 0.034 
T3 Pb        
Main effect 93 0.46 (0.29, 0.63) <0.001   NA NA 
Interaction 93 -0.82 (-1.04, -0.60)  <0.001  NA NA 
5mC 93 -0.35 (-0.60, -0.11) 0.004  92 -0.01 (-0.79, 0.77) 0.984 
5hmC 93 0.45 (0.21, 0.68) <0.001  92 0.32 (0.03, 0.61) 0.030 
Tibia        
Main effect 87 0.13 (0.01, 0.26) 0.041   NA NA 
Interaction 87 -0.28 (-0.45, -0.10)  0.002  NA NA 
5mC 87 -0.08 (-0.55, 0.39) 0.741  85 -0.17 (-0.75, 0.40) 0.558 
5hmC 87 0.13 (-0.03, 0.28) 0.111  85 0.11 (-0.08, 0.30) 0.266 
Patella        
Main effect 101 0.20 (0.12, 0.28) <0.001   NA NA 
Interaction 101 -0.40 (-0.51, -0.29)  <0.001  NA NA 
5mC 101 -0.27 (-0.56, 0.03) 0.081  98 -0.36 (-0.73, 0.01) 0.056 
5hmC 101 0.17 (0.07, 0.27) <0.001  98 0.19 (0.07, 0.32) 0.003 
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RAB5A        
T1 Pb        
Main effect 126 -0.01 (-0.02, 0.01) 0.440   NA NA 
Interaction 126 0.01 (-0.01, 0.028)  0.421  NA NA 
5mC 126 0.01 (-0.01, 0.02) 0.454  122 -0.01 (-0.03, 0.02) 0.524 
5hmC 126 -0.01 (-0.04, 0.02) 0.610  122 0.00 (-0.04, 0.05) 0.909 
T2 Pb        
Main effect 129 -0.01 (-0.02, 0.01) 0.424   NA NA 
Interaction 129 0.01 (-0.01, 0.03)  0.251  NA NA 
5mC 129 0.01 (-0.01, 0.02) 0.344  124 0.00 (-0.04, 0.05) 0.817 
5hmC 129 -0.01 (-0.03, 0.02) 0.625  124 0.00 (-0.04, 0.04) 0.971 
T3 Pb        
Main effect 130 0.00 (-0.02, 0.02) 0.898   NA NA 
Interaction 130 0.01 (-0.02, 0.03)  0.635  NA NA 
5mC 130 0.01 (-0.01, 0.03) 0.416  129 0.01 (-0.01, 0.03) 0.414 
5hmC 130 -0.01 (-0.04, 0.03) 0.851  129 -0.01 (-0.05, 0.03) 0.687 
Tibia        
Main effect 122 0.01 (-0.00, 0.02) 0.193   NA NA 
Interaction 122 -0.01 (-0.03, -0.004)  0.160  NA NA 
5mC 122 0.00 (-0.01, 0.01) 0.826  119 0.00 (-0.01, 0.01) 0.945 
5hmC 122 0.01 (-0.01, 0.02) 0.591  119 0.01 (-0.02, 0.03) 0.505 
Patella        
Main effect 139 0.00 (-0.01, 0.01) 0.724   NA NA 
Interaction 139 0.00 (-0.01, -0.01)  0.976  NA NA 
5mC 139 0.00 (-0.01, 0.01) 0.919  134 0.00 (-0.01, 0.01) 0.606 
5hmC 139 0.00 (-0.02, 0.01) 0.697  134 0.01 (-0.01, 0.02) 0.503 
TPPP        
T1 Pb        
Main effect 124 -0.03 (-0.19, 0.13) 0.714   NA NA 
Interaction 124 0.14 (-0.06, 0.35)  0.174  NA NA 
5mC 125 0.11 (-0.09, 0.30) 0.281  121 0.15 (-0.13, 0.42) 0.305 
5hmC 124 0.03 (-0.20, 0.26) 0.793  120 0.05 (-0.28, 0.38) 0.771 
 118 
T2 Pb        
Main effect 127 0.00 (-0.17, 0.17) 0.979   NA NA 
Interaction 127 0.08 (-0.15, 0.31)  0.516  NA NA 
5mC 128 0.04 (-0.16, 0.23) 0.720  123 0.03 (-0.27, 0.33) 0.847 
5hmC 127 0.06 (-0.16, 0.28) 0.599  122 0.09 (-0.27, 0.45) 0.627 
T3 Pb        
Main effect 128 -0.09 (-0.27, 0.09) 0.350   NA NA 
Interaction 128 0.23 (-0.01, 0.47)  0.061  NA NA 
5mC 129 0.17 (-0.05, 0.39) 0.129  128 0.22 (-0.02, 0.45) 0.073 
5hmC 128 -0.02 (-0.27, 0.22) 0.857  127 -0.12 (-0.39, 0.15) 0.372 
Tibia        
Main effect 120 0.10 (-0.00, 0.20) 0.055   NA NA 
Interaction 120 -0.16 (-0.30, -0.01)  0.032  NA NA 
5mC 121 -0.06 (-0.19, 0.06) 0.342  118 0.38 (0.04, 0.71) 0.028 
5hmC 120 0.11 (-0.03, 0.26) 0.133  117 0.18 (0.00, 0.36) 0.049 
Patella        
Main effect 137 -0.05 (-0.12, 0.02) 0.162   NA NA 
Interaction 137 0.10 (0.01, 0.20)  0.032  NA NA 
5mC 138 0.05 (-0.04, 0.13) 0.263  133 0.21 (-0.28, 0.70) 0.404 
5hmC 137 -0.04 (-0.13, 0.06) 0.432  132 -0.05 (-0.18, 0.08) 0.443 
aPer 1 µg/dL change in maternal blood Pb at T1, T2, and T3, and 1 µg/g change in maternal bone Pb measured in tibia and patella 1-month 
postpartum. 
bNINJ2 models were controlled for genotype at rs34038797 and C/C samples (n=34) were dropped from the analysis. 
Note: N, number; p-int, p-value for intercept effect estimates; T1, first trimester; T2, second trimester; T3, third trimester; In each interaction and 
mixed-effects regression and sensitivity analyses, the outcome is percentages of 5mC or 5hmC at all quantified CpG sites treated as repeated 
measures, and models adjust for sex, adolescent age, adolescent BLL, and batch. 
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Table 3.4A: Results from a sex-stratified sensitivity analysis of associations between Pb exposure biomarkers and DNA 
5mC and 5hmC using a mixed-effects regression of repeated measures at multiple CpG sites of either 5mC or 5hmC, 
excluding outliers. 
 
  Females Males 
  N Betab (95% CI) P-value N Betab (95% CI) P-value 
HCN2             
T1           
5mC 59 0.83 (0.08, 1.59) 0.031 63 0.44 (-0.22, 1.10) 0.194 
5hmC 57 -0.19 (-0.55, 0.18) 0.312 61 -0.04 (-0.28, 0.20) 0.722 
T2           
5mC 60 0.83 (0.12, 1.54) 0.023 63 -0.01 (-0.86, 0.85) 0.988 
5hmC 58 -0.30 (-0.70, 0.09) 0.134 61 0.05 (-0.24, 0.34) 0.741 
T3           
5mC 63 0.74 (0.10, 1.39) 0.024 64 0.04 (-0.68, 0.75) 0.922 
5hmC 61 -0.21 (-0.57, 0.15) 0.247 62 0.08 (-0.17, 0.33) 0.523 
Tibia           
5mC 64 0.10 (-0.32, 0.52) 0.641 53 -0.17 (-0.54, 0.20) 0.367 
5hmC 62 -0.09 (-0.32, 0.13) 0.418 51 -0.10 (-0.21, 0.02) 0.096 
Patella           
5mC 65 0.21 (-0.10, 0.51) 0.187 68 0.00 (-0.29, 0.29) 0.998 
5hmC 63 -0.06 (-0.22, 0.11) 0.496 66 0.02 (-0.07, 0.11) 0.656 
NINJ2a             
T1           
5mC 46 0.03 (-1.37, 1.43) 0.97 44 -0.66 (-2.01, 0.68) 0.334 
5hmC 46 0.44 (-0.07, 0.96) 0.09 44 0.27 (-0.29, 0.82) 0.349 
T2           
5mC 46 0.30 (-0.88, 1.48) 0.615 44 -0.22 (-1.93, 1.48) 0.798 
5hmC 46 0.36 (-0.08, 0.80) 0.108 44 0.38 (-0.22, 0.99) 0.213 
T3           
5mC 47 -0.03 (-1.16, 1.10) 0.963 44 0.20 (-1.14, 1.54) 0.773 
5hmC 47 0.39 (-0.02, 0.80) 0.06 44 0.13 (-0.34, 0.61) 0.591 
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Tibia           
5mC 47 0.33 (-0.51, 1.16) 0.446 44 -0.51 (-1.43, 0.42) 0.283 
5hmC 47 0.14 (-0.17, 0.45) 0.369 44 -0.07 (-0.32, 0.18) 0.59 
Patella           
5mC 49 -0.52 (-1.03, -0.02) 0.042 44 -0.32 (-0.99, 0.35) 0.347 
5hmC 49 0.26 (0.08, 0.44) 0.006 44 0.00 (-0.22, 0.23) 0.978 
RAB5A             
T1           
5mC 59 -0.01 (-0.06, 0.03) 0.55 63 -0.01 (-0.04, 0.02) 0.633 
5hmC 59 0.01 (-0.06, 0.09) 0.717 63 0.01 (-0.04 0.02) 0.786 
T2           
5mC 60 -0.02 (-0.05, 0.02) 0.427 64 0.02 (-0.01, 0.06) 0.213 
5hmC 60 0.03 (-0.03, 0.09) 0.369 64 -0.02 (-0.09, 0.06) 0.679 
T3           
5mC 64 -0.02 (-0.06, 0.02) 0.39 66 0.03 (0.01, 0.06) 0.014 
5hmC 64 0.04 (-0.02, 0.09) 0.202 66 -0.05, -0.11, 0.01) 0.092 
Tibia           
5mC 65 0.00 (-0.02, 0.02) 0.951 54 0.00 (-0.01, 0.02) 0.599 
5hmC 65 -0.01 (-0.04, 0.03) 0.743 54 0.02 (-0.01, 0.05) 0.186 
Patella           
5mC 65 -0.01 (-0.02, 0.01) 0.315 69 0.00 (-0.01, 0.02) 0.544 
5hmC 65 0.02 (-0.01, 0.04) 0.206 69 0.00 (-0.02, 0.03) 0.95 
TPPP             
T1           
5mC 58 0.18 (-0.22, 0.59) 0.376 63 0.16 (-0.28, 0.60) 0.475 
5hmC 58 0.04 (-0.38, 0.46) 0.844 62 0.11 (-0.47, 0.70) 0.703 
T2           
5mC 59 -0.03 (-0.42, 0.36) 0.875 64 0.28 (-0.24, 0.81) 0.291 
5hmC 59 0.25 (-0.10, 0.60) 0.163 63 -0.05 (-0.74, 0.64) 0.885 
T3           
5mC 63 0.16 (-0.18, 0.49) 0.36 64 0.44 (0.07, 0.81) 0.021 
5hmC 63 0.11 (-0.19, 0.40) 0.484 63 -0.43 (-0.94, 0.07) 0.092 
 121 
Tibia           
5mC 64 -0.02 (-0.23, 0.19) 0.859 54 -0.09 (-0.30, 0.12) 0.387 
5hmC 64 0.04 (-0.16, 0.24) 0.694 53 0.31 (0.00, 0.61) 0.047 
Patella           
5mC 64 -0.06 (-0.21, 0.10) 0.479 69 0.21 (0.05, 0.36) 0.008 
5hmC 64 0.06 (-0.08, 0.20) 0.393 68 -0.21 (-0.41, 0.00) 0.051 
Note: N, number; T1, first trimester; T2, second trimester; T3, third trimester; In each mixed-effects sensitivity analysis, the outcome is 
percentages of 5mC or 5hmC (separated by rows) at all quantified CpG sites treated as repeated measures stratified by sex, and models adjust 
for adolescent age, adolescent BLL, and batch. 
aNINJ2 models were controlled for genotype at rs34038797 (G/C) and C/C samples (n=34) were dropped from the analysis. 




Chapter 4 DNA Methylation at Birth Potentially Mediates the Association between 
Prenatal Lead (Pb) Exposure and Neurodevelopmental Outcomes 
Abstract 
Early-life lead (Pb) exposure has been linked to adverse neurodevelopmental 
outcomes. Recent evidence has indicated a critical role of DNA methylation in cognition, 
and Pb exposure has also been shown to alter DNA methylation. However, it is still 
unknown whether DNA methylation plays a role in the pathological mechanism of this 
ubiquitous metal in cognitive development. This longitudinal study investigated the 
associations between trimester-specific (T1, T2, T3) maternal blood Pb concentrations, 
gene-specific DNA methylation percentages in umbilical cord blood at birth, and infant 
neurodevelopmental among 85 infants from the Early Life Exposure in Mexico to 
Environmental Toxicants (ELEMENT) study. Infant outcomes included the Mental 
Development Index (MDI), Psychomotor Development Index (PDI), and Behavioral 
Rating Scale (BRS) of Orientation/Engagement (ORIEN) and Emotional Regulation 
(EMOCI), assessed at ages 12 and 24 months. DNA methylation at a locus in CCSER1 
(probe ID cg02901723) mediated the association between T2 Pb exposure on 24-month 
ORIEN [indirect effect estimate 4.44, 95% CI (-0.09, 10.68), P=0.06] and EMOCI 
percentiles [3.62 (-0.05, 8.69), P=0.05]. Cg18515027 (GCNT1) DNA methylation 
mediated the association of T1 Pb exposure with 24-month EMOCI [-4.94 (-10.6, -0.77), 
P=0.01], and T2 Pb with the same outcome [-3.52 (-8.09, -0.36), P=0.02], but there was 
a positive indirect effect estimate between T2 Pb exposure and PDI scores at 24-
 123 
months [βIndirect = 1.25 (-0.11, 3.32), P=0.09]. The indirect effect was significant for 
cg19703494 (TRAPPC6A) DNA methylation in the association between T2 Pb exposure 
and 24-month MDI scores [1.54 (0, 3.87), P=0.05]. A positive significant effect of 
cg23280166 (VPS11) DNA methylation on the relationship between T3 maternal BLLs 
and EMOCI scores at 24 months of age [βIndirect = 2.43 (-0.16, 6.38), P=0.08]. These 
associations provide preliminary evidence for DNA methylation at some genes as a 
mediator between prenatal Pb and adverse cognitive outcomes in offspring. These 
findings may elucidate biological pathways that could serve as potential targets for 
interventions to disrupt Pb toxicity.  
Introduction 
Lead (Pb) is an abundant element and environmental pollutant found in air, soil, 
and water that has been used for thousands of years due to the ease of extraction from 
ores, relative abundance on earth, and low cost.  Examples of exposure sources 
common today include ingestion of contaminated water and lead-based paint in older 
homes. In some countries such as Mexico, Pb absorbing into food from lead-glazed 
ceramics used for food preparation and storage is another major source of exposure1. 
Pb is a cumulative toxicant that affects nearly all organs of which the brain is the most 
sensitive. Pb negatively impacts cognitive and behavioral functions, impairs learning 
and memory, decreases intelligence quotient (IQ), increases aggression, and may 
increase the risk for developing a variety of late-life neuropathological disorders 2-10. 
Despite major initiatives to reduce environmental exposures, epidemiological studies 
demonstrate that even low levels of Pb in blood affect IQ and behavior with major 
impacts on functioning 11-15. 
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During pregnancy, Pb from past exposures stored in maternal bone is released 
into the bloodstream, passes through the placenta, and reaches the developing fetus 16-
18. Gestational Pb exposure has been associated with lower scores on neonatal and 
infant neurobehavioral tests, even when exposure levels are below 5 μg/dL in maternal 
blood 5 and below 2 μg/dL in cord blood 19. In the Early Life Exposure in Mexico to 
Environmental Toxicants (ELEMENT) study, we previously reported that each unit of 
first trimester (T1) maternal blood Pb level (BLL, natural-log transformed ug/L) was 
associated with a decrease of 4.13 points on the Bayley Scales of Infant Development 
Mental Development Index (MDI) among 24-month old children 10. Another report 
provided evidence that lower MDI scores as early as 6 months of age were associated 
with late pregnancy maternal Pb exposures below 5 μg/dL 20. Mechanistically, the N-
methyl-D-aspartate (NMDA) receptor is particularly sensitive to developmental Pb 
exposure due to its important role in hippocampal-dependent spatial learning and 
memory 21. Studies have shown that developmental Pb exposure in rats alters NMDA 
subunits and signaling, which are associated with impaired hippocampal long-term 
potentiation representing a biological model of learning and memory 22-24. 
Developmental exposures including Pb may also impact phenotype through alterations 
in gene regulation via epigenetic modifications such as DNA methylation 25-27.  
Epigenetics is the study of mitotically heritable and potentially reversible changes 
in gene expression that are independent of the DNA sequence. DNA methylation (5mC) 
is the addition of a methyl group covalently bound to the 5’-carbon of Cytosine. In 
mammals, a methylated cytosine is typically adjacent to a Guanine by a phosphate, 
referred as a CpG site. The period of fetal development has been shown to be sensitive 
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to prenatal exposures, mainly because of the dramatic DNA methylation changes and 
reprogramming that takes places during embryogenesis 25, 26.There is current evidence 
for epigenetic modifications in various neurodevelopmental disorders related to deficits 
in language, cognition, motor skills, and other functional domains 28-31 Pb-induced 
oxidative stress may alter DNA methylation, which could then alter gene expression and 
contribute to toxicity 32. A growing number of studies have provided evidence for 
gestational Pb exposure influencing offspring epigenetic programming in murine studies 
at candidate genes 33, 34 and epigenome-wide 35. Further, in human studies epigenome-
wide platforms have helped to identify candidate gene pathways that were potentially 
impacted by prenatal Pb exposure 36-39.  Among these studies, we previously utilized the 
Infinium MethylationEPIC to profile DNA methylation at >850,000 CpG sites and 
reported statistically significant associations between maternal first- and third-trimester 
blood Pb levels and DNA methylation at several loci 38.  Whether epigenetic 
mechanisms play a role in the link between prenatal Pb exposure and childhood 
outcomes including neurodevelopmental delays remain to be assessed in an 
epidemiological study.  
Despite the consistent evidence for the inverse association between prenatal Pb 
exposure and cognitive and behavioral outcomes in childhood 5, 10, 19, 20, whether 
perturbation of DNA methylation is a mediator of Pb-induced neurotoxicity is largely 
unexplored. We hypothesized that DNA methylation differences in previously identified 
prenatal Pb-associated genes at birth in umbilical cord blood (UCB) mediate the 
association of trimester-specific maternal Pb exposure with neurodevelopmental 
outcomes within the first two years of life. We utilized the ELEMENT longitudinal 
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pregnancy cohort with rich data on trimester-specific Pb exposure and infant follow-up 
at 12 and 24 months of age to investigate this question. This longitudinal study builds 
upon our past ELEMENT study which reported an association between prenatal Pb 
exposure and reduced MDI score in infancy 10 and examines potential mediation of this 
association by DNA methylation. 
Methods 
Study population 
The ELEMENT study consists of three longitudinal pregnancy cohorts used to 
investigate the influence of Pb exposure – in utero and in childhood – on health 
outcomes during sensitive periods of development. The current study includes mother-
infant pairs with prenatal information from the second and third birth cohorts who were 
recruited at the Mexican Social Security Institute, Mexico City between 1997 and 2005. 
Eligibility and exclusion criteria are as previously described 40. Maternal variables 
collected include age, socioeconomic status, and IQ; child variables include sex, 
gestational age at birth, and neurodevelopmental and anthropometric assessments at 
multiple follow-up visits in infancy and childhood. For the current study, 85 ELEMENT 
participants were selected based on availability of: prenatal blood Pb measures,  
archived UCB from which we could isolate DNA that passed quality control checks for 
DNA methylation analysis, and neurodevelopmental assessments at 12 and 24 months 
of age 38. 
At time of recruitment, mothers were informed about the study and those who 
agreed to participate read and signed a letter of informed consent about the original 
study. Mothers also provided written, informed consent at each follow-up visit. The 
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Ethics Committees of the National Institutes of Public Health of Mexico, participating 
hospitals, and the Internal Review Board at all participating institutions including the 
University of Michigan, approved the research study protocol and all amendments. 
Pb concentrations, DNA isolation, and DNA methylation quantification 
Concentrations of Pb were measured in maternal venous blood collected during 
each trimester as previously described 38. Infant venous blood was collected in trace 
metal-free tubes at ages 12 and 24 months and immediately refrigerated until Pb 
analysis using atomic absorption spectrophotometry (Model 3000; Perkin Elmer, 
Wellesley, MA, USA) at the Center for Environmental Health Research American British 
Cowdray Hospital Trace Metal Laboratory in Mexico City. For quality control, Pb 
analysis was repeated by the Wisconsin Laboratory of Hygiene, and precision and 
accuracy were demonstrated (Pearson r>0.98; mean difference <1 ug/dL between inter-
laboratory replicates).  
DNA was isolated from UCB, bisulfite converted, and DNA methylation was 
quantified utilizing the Infinium MethylationEPIC BeadChip (Illumina) 41. Detailed 
description of the DNA isolation and data processing procedures is as previously 
described 38. The methylation level of each CpG site was calculated as beta-values 
ranging from 0 (unmethylated) to 1 (methylated).  CpG sites from Rygiel et. al., 2020 
were selected to be tested as mediators in this analysis that fit the following criteria: 
CpG site was associated with a trimester-specific BLL with p<1E-5 and effect size 
>|0.01| and CpG site annotated to a gene related to neurodevelopment, fetal growth, or 
neuronal growth. The top five CpG sites meeting these criteria from each trimester of 
BLL were selected: Trimester 1: RAB5A (EPIC probe ID: cg17138393), EXT1 
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(cg00984923), KDM6B (cg16049335), GCNT1 (cg18515027), RPS29 (cg03724407); 
Trimester 2: CHTF18 (cg26820233), PRDM16 (cg12267948), TAPBP (cg20603557), 
TRAPPC12 (cg08025337), ICAM5 (cg10604476); Trimester 3: GORASP2 
(cg02608914), TRAPPC6A (cg19703494), VPS11 (cg23280166), MTA1 (cg20482280), 
CCSER1 (cg02901723) (Appendix Table 4.1A). 
Child neurocognitive assessment  
Infant cognitive, motor, and behavioral development at 12 and 24 months was 
assessed by a trained personnel using the Bayley Scales of Infant Development II–
Spanish version (BSID-IIS) 42 using a standardized protocol described in a previous 
study by our research group 43. It is the most widely used test to identify young children 
with potential developmental delays. Researchers performing the test were blinded to 
the infant’s current and past Pb exposure results. Mental Development Index (MDI), 
Psychomotor Development Index (PDI), and Behavioral Rating Scale (BRS) of 
Orientation/Engagement (ORIEN) and Emotional Regulation (EMOCI) at 12 and 24 
months of age were the outcomes included in this longitudinal study (MDI-12, MDI-24, 
PDI-12, PDI-24, EMOCI-12, EMOCI-24, ORIEN-12, ORIEN-24). The BRS describes the 
child’s attention, social engagement, orientation, and motivation, and may partly explain 
variations in individual performance based on behavior when assessing the MDI and 
PDI scales. MDI and PDI are classified using standardized scores. The deviation of an 
individual’s score from that of the mean is used to classify developmental delay from 
this particular population: normal, mild delay, significantly delayed. Classification of 
developmental delay are as follows: normal (≥84), mild (≥75.4 and <84), significant 
delay (<75.4) for 12-month MDI and PDI scores; normal (≥85), mild (≥75.4 and <85), 
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significant delay (<75.4) for 24-month MDI and PDI scores. ORIEN assesses an infant’s 
state, affect, energy, interest, exploration, and responsiveness to an examiner, along 
with their behavior towards those measures. EMOCI is an assessment of the infant’s 
range of affect and emotional response to both success and failure on the assessment. 
Raw scores were converted to percentiles for each factor within each age group. The 
BRS outcomes were scored as percentiles, where lower scores reflecting more adverse 
behaviors. Specifically, BRS scores can be categorized as Within Normal Limits 
(26th percentile or above), Questionable (11th to 25th percentile), and Non-Optimal (at or 
below the 10th percentile). Percentiles Within Normal Limits were ≥70 for EMOCI-12, 
≥72 for ORIEN-12, ≥82 for EMOCI-24, and ≥71 for ORIEN-24; Questionable were 
between 49-69 for EMOCI-12, 57-71 for ORIEN-12, 33-81 for EMOCI-24, 27-70 for 
ORIEN-24; and Non-Optimal <46 EMOCI-12, <57 for ORIEN-12, <33 for EMOCI-24, 
<27 for ORIEN-24 for this particular study. To our knowledge, only one other study has 
assessed EMOCI and ORIEN in Pb exposed infants. Their study showed exposed 
infants had significantly lower scores in both EMOCI and ORIEN measures when 
compared to unexposed infants, but no other studies have used these specific 
measures 44. In our previous research with ELEMENT children (cohort 2), higher 
prenatal Pb exposure was associated with lower 24-month MDI scores 10; here we 
expanded to include 24-month PDI, ORIEN and EMOCI, as well as 12-month MDI, PDI, 
ORIEN and EMOCI.  
Covariates 
Maternal IQ was measured using a Spanish translated version of the Information, 
Comprehension, Similarities, and Block Design subtests of the Wechsler Adult 
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Intelligence Score 45. Additional information, such as infant weight, length, 
socioeconomic status, and other factors that could confound the relationship between 
Pb and infant development was collected. Z-scores by age and sex for length, weight 
and BMI were calculated by using the World Health Organization (WHO)/National 
Center for Health Statistics/CDC reference data 46, 47. For each UCB sample, estimates 
of cell-type proportions for T lymphocytes (CD4T, CD8T), B cells, NK cells, monocytes, 
granulocytes, and nucleated red blood cells were performed using an established 
method based on UCB cell-type specific differentially methylation regions 48.  
Statistical Analysis 
The R Project for Statistical Computing (version 3.6.1) was used to perform all 
statistical analyses. Descriptive statistics were calculated for continuous measures as 
means and standard deviations and for categorical measures as frequencies, including 
sex ratios, age of mothers, maternal IQ, socioeconomic status, gestational age, infant 
weight, infant length/weight/BMI-for-age Z-score, infant neurodevelopmental continuous 
measures (MDI, PDI, EMOCI, ORIEN) and Pb biomarkers. Pb variables analyzed 
include maternal BLLs at each trimester (T1, T2, T3) and infant BLLs at 12 and 24 
months of age, which were all treated as continuous variables. The neurodevelopmental 
measures at 12 and 24 months of age were considered the primary dependent 
variables and models as continuous scores. Maternal BLL measures at the T1, T2, and 
T3 were the primary exposure biomarkers. The DNA methylation data within the fifteen 
differentially methylated CpG sites from the UCB EPIC analysis were the mediators 
(Appendix Table 4.1A).  
.  
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Continuous variables’ distributions were visually checked for normality. Current 
BLL and maternal trimester BLLs were natural-log transformed in all models to fit 
normality assumptions. We first determined associations between prenatal Pb exposure 
variables and covariates (e.g., maternal age, offspring sex, length-for-age z-score, 
weight, socioeconomic status, cell-types, etc.). We examined Spearman’s rank-order 
correlations between continuous covariates including cell type estimates, Pb 
biomarkers, DNA methylation at each CpG site, and outcomes. We then chose potential 
confounding variables to include in final statistical mediation models that were 
associated with prenatal Pb, DNA methylation, and infant neurodevelopmental 
outcomes. Cell-types estimates were not correlated with the 15 CpG sites, exposures or 
outcomes; therefore, they were not included in downstream models. In final models we 
included potential confounders in these relationships (infant sex, maternal age at birth, 
maternal IQ at birth) and covariates that influence the outcome (infant BLL, infant weight 
and length-for-age z-scores, infant age at time of measurement). 
Pairwise multivariable linear regression analyses were performed to test the 
outcome model (i.e., exposure à outcome; observed neurodevelopment outcomes 
scores at each timepoint given trimester-specific Pb exposure) and mediator models 
(i.e., exposure à mediator; DNA methylation per CpG-site given trimester-specific Pb 
exposure). This research is building upon an observed statistically significant 
relationship between maternal T1 BLLs and 24-month MDI score in a larger set of 
ELEMENT participants 10. Our previous EWAS paper 38 reported associations between 
Pb and the CpG-site specific DNA methylation at the fifteen selected CpG sites. In order 
to explore the potential for epigenetics to be mediator and to estimate effect sizes of 
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mediation, this analysis was pursued even though the associations between exposure 
and outcome were not statistically significant at the 24-month timepoint in this subset of 
the ELEMENT cohort 49. Not all ELEMENT participants included in the original 
publication had archived samples to isolate DNA from at birth. Thus, this pilot study has 
a smaller sample size and lower statistical power compared to the original study.  
Mediation Models 
Mediation analyses were conducted to examine whether DNA methylation at 
each of the CpG sites mediated the association between prenatal Pb exposure and 
each neurodevelopmental outcome measure 50, 51. The analysis was performed using 
the algorithms previously proposed in Imai et. al. (2010). This incorporates the 
mediate() function within the mediation package (version 4.5.0) in R 52, 53.  In this 
setting, we utilize the counterfactual framework to define causal effects within mediation 
analysis, which relies on the following assumptions to estimate parameters:  
(1) No unmeasured confounding in the relationship between exposure and outcome;  
(2) No unmeasured confounding in the relationship between the mediator and 
outcome after adjusting for the exposure variable;  
(3) No unmeasured confounding for the relationship between the exposure and 
mediator; and  
(4) No subsequent effects that the exposure might have that may confound any 
mediator and outcome relationship. 
The total effect (βTotal), direct effect (βDirect), average casual mediation effect 
(ACME) (i.e. indirect; βIndirect), and the proportion mediated were calculated using quasi-
Bayesian Monte Carlo method with 2000 simulations. The βDirect represents the effect of 
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prenatal Pb exposure on each neurodevelopmental outcome while holding DNA 
methylation constant; βIndirect is the estimated effect of gestational Pb exposure 
operating through DNA methylation; βTotal is βDirect + βIndirect; the proportion mediated is 
the estimated proportion of the total effect of prenatal Pb exposure on each individual 
outcome measure due the mediator, DNA methylation (Figure 4.1). Regression 
estimates, 95% confidence intervals, and p-values were calculated for each effect 
estimate. Given the pilot nature of this study and current mediation methods having less 
power than typical statistical methods, ACME (i.e., βIndirect) with P-values<0.1 were 
considered statistically significant 54. 
If we were to adjust for multiple comparisons, considering our analysis to include 15 
independent tests (for each CpG site; the multiple exposure biomarkers and outcomes 
are correlated with each other and therefore are not considered completely independent 
tests), a p-value<0.003 would be considered statistically significant.   
Since this method assumes no exposure-mediator interactions, we performed a 
sensitivity analysis to test for exposure-mediator interactions. We re-ran all models with 
T2 BLLs as the predictor and EMOCI-24 as the outcome with an exposure-mediator 
(DNA methylation at each CpG site) interaction term included. We also re-ran any 
model that had a significant ACME with the interaction term included between the 
exposure and mediator. There was very limited evidence for interaction (i.e., p>0.05 for 
effect estimate of all interaction terms except one), and as such only results from the 




Participants include 85 mother-infant dyads from ELEMENT cohorts 2 and 3 with 
epigenetic, Pb exposure, and outcome data. Compared with all ELEMENT cohort 2 and 
3 participants that completed the BSID-II and BRS assessments and had at least one 
prenatal blood Pb measure, the subset including in this study did not significantly differ 
on maternal age at birth, trimester BLLs, IQ, socioeconomic status, or offspring sex, 
weight, weight/length/BMI-for-Z-score, 12-month BLL,12-month 
neurocognitive/behavioral outcomes, and 24-month neurocognitive outcomes; BLLs and 
BRS measures at 24 months were significantly higher in the subset (Table 4.1).  
Among the 85 mothers included in this analysis, the mean age at delivery was 
26.4 (standard deviation (SD)=4.8) years (Table 4.1). About 66% of participants were 
either low-middle or middle socioeconomic status. Concentrations of Pb were measured 
in maternal blood during the first trimester (T1) with a geometric mean of 5.27 
(geometric standard deviation (GSD)=1.93) μg/dL, second trimester (T2) geometric 
mean of 4.74 (GSD=1.96) μg/dL, and third trimester (T3) geometric mean of 4.98 
(GSD=1.93) μg/dL. Maternal BLLs between the trimesters were highly correlated 
(r>0.67) according to a Spearman’s rank-order correlation test. Infant whole blood Pb 
geometric mean was 3.92 (GSD=1.80) at 12 months and 3.49 (GSD=1.93) μg/dL at 24-
months of age, which were highly correlated (r=0.53) with each other and moderately 
correlated (r>0.22) with maternal trimester BLLs. 
At 12 months of age, the mean weight was measured at 9.35 kg (SD=1.03), whereas 
the 24-month infants averaged 11.90 kg (SD=1.40). Further, the length-for-age Z-score 
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as measured at -0.004 (SD=1.0) in 12-month children and 0.05 (SD=0.97) in 24-month 
infants, putting these children within the normal height range compared to children their 
age.  
Mean maternal IQ was measured at 93.9 (SD=19.5) points. At 12-months of age, 
mean MDI score was 95.1 (SD=8.33) points and PDI was 90.1 (SD=8.80) points; at 24-
months of age, MDI mean was 91.1 (SD=10.9) and PDI was 96.3 (SD=8.37). Mean 12-
month EMOCI percentile was 80.4 (SD=22.7) and ORIEN percentile was 85.7 
(SD=19.1). At 24-months of age, mean EMOCI percentile was 80.9 (SD=22.6) and 
ORIEN percentile was 77.9 (SD=27.3). Each neurodevelopmental score or percentile 
was highly correlated between individuals at 24-months of age (r>0.49), but only 
moderately correlated at 12 months (r>0.24).  
Mediation Analysis 
This study was conducted because we previously reported a significant inverse 
association between T1 BLL and MDI at 24-months in a larger set of ELEMENT children 
10. In this smaller subset of 85 ELEMENT children who also have DNA methylation data 
from birth, we also report inverse associations between prenatal Pb and MDI (24 mos.), 
PDI (12 and 24 mos.), EMOCI (24 mos.), and ORIEN (24 mos.). While none of these 
associations were significant at p<0.05 in this sub-cohort, we conducted pilot mediation 
analyses to estimate and report on effect sizes of the potential indirect effects from DNA 
methylation at neurologically-relevant genes. Thus, the indirect effects are of most 
interest to this analysis, and indirect effects with p<0.1 are considered statistically 
significant. If adjusting for multiple-comparisons, p<0.003 would be significant, and none 
of these pilot results meet that cut-off.  
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Exposure-outcome models showed that at the 12-month neurodevelopment 
timepoint, each one-unit increase in ln-transformed Pb measured at T1, T2, and T3 was 
associated with decreases in PDI scores 1.39, 2.01, and 1.83, respectively, but were 
not statistically significant (Appendix Table 4.2A, βTotal). This non-significant inverse 
relationship persisted at less magnitude at 24 months with the association between T2 
Pb levels and PDI scores measured at -0.27 (Appendix Table 4.3A, βTotal). T2 BLLs 
consistently had inverse associations with all neurodevelopmental outcomes at the 24-
month timepoint. Specifically, the strongest associations measured a 6.04% (P=0.14) 
decrease in EMOCI percentiles and a 5.20% (P=0.30) decrease in ORIEN percentiles 
with on one-unit change ln-transformed T2 BLLs (Appendix Table 4.3A, βTotal). For 
additional exposure-outcome estimates (βTotal) see Appendix Tables 4.2A (12-month 
outcomes) and 4.3A (24-month outcomes).  
Analyses estimating the indirect mediating effect of gene-specific DNA 
methylation on the association between trimester-specific BLLs and four different 
neurodevelopmental outcomes at two timepoints indicated ten statistically significant 
ACME (βIndirect, P<0.1) effect estimates out of a total of 360 mediation analyses (Figure 
4.2, Appendix Figure 4.1A). For each one-unit increase in ln-transformed Pb exposure 
during T2, there was a 0.53% (CI: 0.23, 0.83) increase in DNA methylation within a 
CCSER1 CpG site, cg02901723, at birth (P<0.001; Figure 4.3a βE-M). The association 
between ln-transformed T2 BLLs and EMOCI score at 24 months of age (βTotal) was -
6.05 (-13.97, 0.11) and the βDirect (conditional on cg02901723 DNA methylation as a 
mediator) was -9.68 (-18.37, -1.09), thus showing that the magnitude of the association 
between T2 BLLs on EMOCI score at 24 months of age became larger. βIndirect for the 
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EMOCI percent at 24 months of age increased by 3.62% (-0.05, 8.69) for each one-unit 
change in ln-transformed T2 BLLs that was mediated through cg02901723 methylation 
(P=0.05), and the estimate for proportion mediated between the exposure and outcome 
by cg02901723 DNA methylation was -49%. In other words, Pb exposure was 
associated with decreasing EMOCI score, while increasing DNA methylation at 
cg02901723 was associated with an increase in EMOCI score. When there is a larger 
magnitude of direct effect than total effect, or if the indirect effect is in the opposite 
direction as the direct effect, this suggests a suppressive effect by the mediator on the 
direct effect between exposure and outcome 55. Similarly, cg02901723 DNA methylation 
mediated the effect of T2 Pb exposure on 24-month ORIEN score [βIndirect = 4.44 (-0.09, 
10.68), P=0.06]. The estimated percent of the total effect of T2 Pb exposure on 24-
month ORIEN percentile due to the mediator, cg02901723 DNA methylation, is -54%. 
The ACME (βIndirect) for cg18515027 in the association between T1 and T2 Pb 
exposure and EMOCI score at 24 months of age was statistically significant (P=0.01, 
P=0.02). Further, cg18515027 was associated with T2 Pb and PDI scores at 12 months 
of age. Cg18515027 DNA methylation at birth increased by 0.42% (0.096, 0.75) with 
each one-unit increase in ln-transformed T2 BLLs (Figure 4.3b βE-M; P=0.012). 
Regressing 24-month EMOCI scores on cg18515027 DNA methylation showed an 
inverse association with EMOCI scores decreasing by 8.17 (-14.67, -1.65) for each one 
percent increase in DNA methylation (P=0.015). Cg18515027 DNA methylation 
mediated the effects of T1 Pb exposure on 24-month EMOCI [βIndirect = -4.94 (-10.6, -
0.77), P=0.01], and T2 Pb exposure [βIndirect = -3.52 (-8.09, -0.36), P=0.02]. The percent 
of the Pb-EMOCI relationship mediated by cg18515027 is estimated to be 69% for T1 
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BLLs and is reduced to 51% for T2 BLLs. In contrast, cg18515027 had a positive 
indirect effect between T2 Pb exposure and PDI scores at 24-months [βIndirect = 1.25 (-
0.11, 3.32), P=0.09] with -38% mediated through DNA methylation of cg18515027 
located within GCNT1. 
The indirect effect was significant for cg19703494 DNA methylation located 
within TRAPPC6a in the association between maternal T2 Pb exposure and 24-month 
MDI scores [βIndirect = 1.54 (0, 3.87), P=0.05] with an estimated -31% percent mediated 
by cg19703494. There was a significant effect of cg23280166 DNA methylation located 
within VPS11 on the relationship between T3 maternal BLLs and EMOCI scores at 24 
months of age [βIndirect = 2.43 (-0.16, 6.38), P=0.08] with -19% mediated. For additional 
mediation effect estimates (βTotal, βIndirect, βDirect, and proportion mediated) not mentioned 
above, see Appendix Tables 4.2A (12-month outcomes) and 4.3A (24-month 
outcomes). 
Discussion 
We conducted multiple mediation analyses in a subsample of 85 mother-child 
participants in the longitudinal study, ELEMENT, to begin to understand the potential for 
DNA methylation to be a mediator between gestational Pb exposure and offspring 
neurodevelopment. Specifically, we examined the association between maternal BLLs 
at each trimester with scores for four different domains of neurodevelopment at 12 and 
24 months of age and whether UCB DNA methylation at fifteen CpG sites statistically 
mediated these relationships (Figure 1). This study expands upon previous ELEMENT 
research reporting that maternal trimester-specific BLLs predicted offspring MDI and 
PDI scores 10 to include EMOCI and ORIEN scores, as well as to investigate DNA 
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methylation as a potential mediator. Using a significance cut-off of p<0.1 for the ACME, 
we report suggestive evidence for locus-specific mediation, primarily for relationships 
between maternal blood Pb levels and 24-month outcomes. We provide preliminary 
evidence for both mediating and suppressive roles of DNA methylation in these 
relationships, depending on the locus. The latter of which can be interpreted as DNA 
methylation at a given gene suppressing the effect of Pb on a neurodevelopmental 
outcome 55.  
Across trimesters, higher T2 maternal BLLs were most consistently associated 
(total effect) with lower childhood cognitive abilities at 24 months of age, though most 
were not statistically significant, likely to due to the sample size. Statistically significant 
indirect (mediation) effects by DNA methylation of cg02901723, cg18515027, and 
cg19703494 were also observed in models of T2 BLLs with neurodevelopmental 
outcomes. The majority of these indirect effects were in the opposite direction of direct 
effects (i.e., suppressive). When added to the model, cg02901723 DNA methylation 
suppressed the association between prenatal Pb exposure during T2 and ORIEN and 
EMOCI scores at 24 months of age. Cg02901723 (in the gene CCSER1, alias 
FAM190A) is frequently altered in human cancers, but recent studies have verified 
CCSER1 expression in the cerebellum is associated with attention deficit hyperactivity 
disorder 56, 57. 
DNA methylation of cg18515027 mediated associations between T1 and T2 BLL 
and EMOCI-24 (Figure 4.3b). In contrast, there was a suppressive effect of 
cg18515027 on the relationship between T2 BLLs and PDI-12 scores. The protein 
product of the gene associated with cg18515027 (GCNT1) behaves like a cell surface 
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marker to indicate whether a T-cell has received Notch signals 58. Notch signaling 
stimulates proliferative signaling during neurogenesis and plays an important role in 
regulation of embryonic development 59, 60. DNA methylation within cg19703494 
negatively mediated the association between T1 BLLs and T2 BLLs with MDI-24. The 
gene that this CpG site is in - TRAPPC6a - is part of the TRAPP complex that plays a 
major role in endoplasmic reticulum-Golgi transport, but little is known about 6a 
specifically. Interestingly, within the TRAPP family, TRAPP9 is associated with 
intellectual disability as well as microcephaly and problems with speech, and TRAPP11 
is involved in movement disorders, ataxia (nervous system degeneration), intellectual 
disability, and muscular dystrophy 61. Cg23280166 was a statistically significant 
mediator between Pb at T3 and EMOCI-24. This site is annotated to the gene VPS11, 
which encodes an essential protein of the endosomal pathway, and it is hypothesized 
that in neuronal cells abnormal VPS11 functioning would attenuate the degradation of 
plasma membrane receptors thereby contributing to progressive developmental delay 
62.  
During early gestation, neurogenesis occurs at an astonishing rate starting on 
embryonic day 42 and ending in mid-gestation 63, 64. By week 8, neuronal proliferation 
and migration beings. During T2, axons form branches (i.e., dendrites) and synapses 
with a cortical plate where cortical circuits are then organized 65-69. This timing is in line 
with inverse associations between T1 and T2 Pb exposure and neurodevelopment 
measures in children up to 24-months of age that have been reported by us and others 
5, 10. By the end of T2 and into T3, the human brain contains billions of neurons 69-71. In 
T3, these new cells can communicate, and the brain starts to exhibit neuronal 
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differentiation, axonal elongation, synapse formation and myelination 63, 64, 72-74. The 
timing of these developmental processes may explain why Pb exposure during late 
pregnancy also correlates with early-life lower cognition scores 19, 20.  
Development of the brain and nervous system in utero is a highly complex 
process, in which epigenetics plays a critical role. During gestation, a global 
reprogramming of epigenetic modifications in the embryo occurs making it the most 
vulnerable period to environmental perturbations 75. These changes can be propagated 
across germ layers within the developing fetus. It has been shown that during early 
neuronal differentiation, DNA methylation occurs at promoters to repress germ-line 
specific genes, while methylation loss at other promoters activates neuronal-specific 
genes 76-78. How these widespread reprogramming events relate to specific pathways of 
fetal neurodevelopment remains a key gap in research. It is particularly challenging, 
both scientifically and ethically, to research fetal development, but it is essential we 
enhance the understanding of mechanistic processes in order to both improve infant 
and maternal health, particularly in analyses of environmental exposures during 
pregnancy.  Prenatal and early postnatal Pb exposure have been shown in rodent and 
human studies to be associated with epigenetic changes in the offspring including in the 
brain 79, 80 and blood 33, 34, 38, 81, 82. Metals’ exposure, such as to Pb, causes indirect 
reactive oxygen species formation with thiol depletion resulting in oxidative stress, 
which might be a route to explain the DNA methylation changes by Pb 83-85. Pb-induced 
oxidative stress could result in oxidative damage of methylated cytosines and decrease 
the level of methylation.  
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Gestational epigenomic changes would be expected to propagate across all 
tissues, yet it is still important to consider tissue-specificity when conducting differential 
methylation research. UCB was the available tissue for at-birth DNA methylation 
profiling, but the most relevant tissue would ideally be brain, specifically the cortex, 
cerebellum, or hippocampus. We utilized a publicly available database with matched 
blood and adult brain DNA methylation profiles to infer the level of similarity between 
blood and brain at the CpG sites included in our study86. Of the 15 CpG sites analyzed, 
8 CpGs were available in the database. Of these, 5 CpGs were moderately to highly 
correlated between blood and the prefrontal cortex (cg14911689, cg26654770, 
cg01201512, cg06657917: r>0.72; cg26371957: r=0.44) and entorhinal cortex 
(cg14911689, cg26654770, cg01201512, cg06657917: r>0.79; cg26371957: r=0.48), 
and 3 CpGs with cerebellum cg14911689, cg26654770: r>0.70; cg01201512: r=0.52). 
UCB DNA methylation of 3 CpG-sites were not correlated with any brain regions 
(cg25353752, cg00002033, cg03463208). This comparison is limited since samples in 
the database were from adults and our study focuses on UCB and infants. Even so, 
correlations between blood and brain at 5 of the 8 CpGs within this study suggest they 
may be able to serve as biomarkers of effects in other tissues, and this should be 
validated in future studies. 
This pilot study is one of a growing number to consider DNA methylation as a 
mediator in the association between prenatal exposures and childhood phenotypes. For 
example, one study identified a positive mediating effect of gene-specific methylation on 
the association between non-syndromic cleft lip and/or palate and in utero Pb exposure. 
Pb exposure mediated 9.3% of the relationship between Pb and the outcome with a 
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statistically significant indirect effect (odds ratio) of 1.26 (95% CI: 1.05, 1.97) 87. Another 
study reported that gene-specific differential methylation explained 12-19% of the 202g 
lower birthweight among offspring of women who smoked during pregnancy versus non-
smokers 88. Finally, another study identified negative mediating effects of DNA 
methylation at 66 CpG sites on cognitive appraisal predicting high C-peptide secretion 
with 54 of those CpG sites being hypomethylated and 12 CpGs hypermethylated; DNA 
methylation explained 5.2-32.0% of the variance, depending on the site 89. In terms of 
this negative (i.e., suppressive) effect, we and others are hypothesizing that DNA 
methylation changes in response to some exposures may serve to protect against the 
impacts of that exposure. For example, while changes at some genes and/or biological 
pathways may be part of the mechanism leading to Pb’s toxicity, changes at another set 
of genes may mitigate some of the toxic impacts. We cannot prove causality based on 
the design of our study and its’ pilot nature. Future studies should confirm this 
hypothesis.  
There are several strengths within this study, including the longitudinal design 
with both exposure and outcome having multiple timepoint measurements allowing the 
assessment of windows of susceptibility during prenatal into postnatal 
neurodevelopment. The selection of genes was hypothesis-driven based on 
associations between prenatal Pb exposure and DNA methylation at birth in the same 
cohort in an epigenome-wide study 38; although, this could also be a limitation since 
additional genes that influence cognitive development were not examined here. DNA 
methylation was assessed in cord blood instead of brain. Due to the sample size limited 
by availability of DNA methylation data, we were unable to test whether sex differences 
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in the exposure-outcome or exposure-mediator-outcome relationships exist. Further, the 
small sample size limits our statistical power; therefore, we cannot conclude that the 
results presented here are not by chance alone as they did not withstand correction for 
multiple hypothesis testing. In a previous ELEMENT study by Hu et. al. (2006), the 
association between first trimester maternal BLLs and 24-month MDI scores was 
statistically significant (n=146). While we did not achieve statistical significance with the 
smaller subset included in this present study, the effect estimates (i.e., the total effects 
for the T2 and T3 BLL on MDI) were similar. The generalizability of this study may be 
limited to populations with similar racial-ethnic and socioeconomic backgrounds. 
Replication with a larger and more diverse study population is needed.  
Conclusions 
The results of this pilot study show that DNA methylation at several genes 
statistically mediates the association between T2 Pb exposure and neurodevelopmental 
scores at 24-months of age. This effect was independent from that of postnatal Pb 
exposure, and the strongest evidence for mediation was for DNA methylation of 
cg02901723 and cg18515027. At cg02901723, increasing methylation suppressed the 
influence of Pb on the outcome; whereas at cg18515027, increasing methylation 
mediated the association. Pb remains a global environmental problem. The majority of 
preventative measures focus on early childhood and often ignore prenatal exposure 
during embryonic development as an additional critical period affecting long-term health. 
Our study builds upon previous research on prenatal Pb exposure and its association 
with decreased childhood IQ, MDI, and adverse neurobehavioral outcomes; we provide 
preliminary data to consider epigenetic alterations as one of the biological mechanisms 
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contributing to these long-term effects. As designed, our study cannot prove causality, 
and we suggest future research on this topic that includes the genes that had evidence 
for mediation here (CCSER1, GCNT1, TRAPP6A, and VPS11). Identifying genes and 
their corresponding biological pathways involved in Pb’s neurotoxic effects is an 
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Tables and Figures 
Table 4.1: Characteristics of ELEMENT mother-infant pairs. Participant Pb biomarkers, DNA methylation data, and 
neurocognitive and behavioral outcome measures compared with outcome measures from the rest of the participants in 
the same ELEMENT cohorts.  
 ELEMENT subset for current study ELEMENT Cohorts 2 and 3  
Characteristics No. Mean ± SD or Percent (%) Range No. 
Mean ± SD or 
Percent (%) Range P-value 
Mothers 
Age at offspring birth 85 26.4 ± 4.81 18.0 - 37.0 642 26.6 ± 5.43 14.0 - 44.0 0.56 
Whole blood lead 
(μg/dL) 
  
    
  
  
        First Trimester* 69 5.27 ± 1.93 0.90 - 35.8 594 4.78 ± 1.89 0.00 - 35.8 0.23 
        Second Trimester* 74 4.74 ± 1.96 0.80 - 38.2 616 4.23 ± 1.99 0.00 - 38.2 0.15 
        Third Trimester* 76 4.98 ± 1.93 0.90 - 34.0 575 4.51 ± 1.92 0.00 - 38.1 0.13 
Maternal IQ 82 93.9 ± 19.5 34.0 - 139.0 581 90.4 ± 21.6 34.0 - 182.0 0.06 
Maternal SES 77 
 
  506 
  
0.82 
        Lowest 12 15.6   85 16.8 
 
  
        Low-Middle 31 40.3   189 37.4 
 
  
        Middle 20 26.0   150 29.6 
 
  
        Middle-High 9 11.7   60 11.9 
 
  
        Highest 5 6.49   22 4.3     
Offspring 
Male sex (%) 85 46.0   525 49.7 
 
0.43 
Whole blood lead 
(μg/dL) 
  
    
  
  
        12 months* 78 3.92 ± 1.80 0.90 - 19.7 466 3.85 ± 1.88 0.00 - 20.4 0.87 
        24 months* 79 3.49 ± 1.93 0.80 - 17.5 522 3.98 ± 1.84 0.80 - 36.8 0.03 + 
Neurological measures 
  




        12 months 
  
    
  
  
              MDI 85 95.1 ± 8.33 80.0 - 115.0 526 94.7 ± 8.95 60.0 - 116.0 0.83 
              PDI 85 90.1 ± 8.80 69.0 - 113.0 526 88.7 ± 8.75 50.0 - 113.0 0.34 
              EMOCI 84 80.4 ± 22.7 10.0 - 99.0 526 78.7 ± 22.2 6.00 - 99.0 0.99 
              ORIEN 84 85.7 ± 19.1 21.0 - 99.0 526 83.0 ± 20.4 9.00 - 99.0 0.34 
        24 months 
  
    
  
  
              MDI 85 91.1 ± 10.9 72.0 - 122.0 569 86.8 ± 11.5 52.0 - 122.0 0.01+ 
              PDI 85 96.3 ± 8.37 80.0 - 117.0 569 93.1 ± 10.2 61.0 - 121.0 0.01+ 
              EMOCI 85 80.9 ± 22.6 13.0 - 99.0 569 77.2 ± 23.1 11.0 - 99.0 0.10 
              ORIEN 85 77.9 ± 27.3 10.0 - 99.0 569 74.9 ± 26.9 1.00 - 99.0 0.17 
Weight (kg) 
  
    
  
  
        12 months 85 9.35 ± 1.03 7.50 - 11.7 523 9.27 ± 1.10 6.30 - 14.8 0.62 
        24 months 85 11.9 ± 1.40 9.40 - 15.5 567 12.0 ± 1.52 8.50 - 19.5 0.58 
Weight-for-age Z-score 
  
    
  
  
        12 months 85 -0.04 ± 0.91 -1.93 - 2.13 523 -0.09 ± 1.00 -2.96 - 4.05 0.39 
        24 months 85 -0.04 ± 0.94 -1.89 - 2.32 567 0.09 ± 1.02 -3.03 - 4.27 0.78 
Length-for-age Z-score 
  
    
  
  
        12 months 85 -0.004 ± 1.00 -2.47 - 2.31 523 -0.08 ± 1.14 -3.50 - 4.59 0.35 
        24 months 85 0.05 ± 0.97 -2.07 - 2.55 567 0.28 ± 1.11 -3.00 - 5.43 0.38 
BMI-for-age Z-score 
  
    
  
  
        12 months 85 0.01 ± 1.01 -2.49 - 2.24 523 -0.09 ± 1.17 -4.09 - 4.39 0.35 
        24 months 85 0.12 ± 1.00 -2.08 - 2.62 567 0.35 ± 1.15 -3.14 - 5.60 0.33 
* Geometric mean 
+ Statistically significant difference between current study population and entire ELEMENT cohort 
Note: SD, Standard deviation; MDI, Mental Development Index; PDI, Psychomotor Development Index; ORIEN, Orientation/Engagement 
percentile; EMOCI, Emotional Regulation percentile  
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Figure 4.1: Diagram showing the associations tested in the mediation analyses.  
Direct effect refers to the association from maternal trimester-specific (T1, T2, T3) Pb 
concentrations in blood and neurodevelopmental scores. Indirect effect refers to the 
association of maternal T1, T2, or T3 Pb BLLs on neurodevelopmental outcomes at 12 
and 24 months of age through CpG site-specific DNA methylation (DNAm) at birth. The 
total effect is the sum of the direct and indirect effects. Mediation effect is a proportion of 
the indirect effect compared to the total effect. Covariates included in the final model 
were potential confounders in these relationships (infant sex, maternal age at birth, 
maternal IQ at birth) and covariates that influence the outcome (infant BLL, infant weight 
and length-for-age z-scores, infant age at time of measurement). 
 
 
Note: T1, First trimester; T2, second trimester; T3, third trimester; BLL, blood lead level; CpG, cytosine-




Figure 4.2: P-values for the average casual mediation effect (ACME), representing the influence of prenatal Pb exposure 
at each trimester on neurodevelopmental outcomes at 24 months of age through umbilical cord blood DNA methylation at 
each gene. Models control for offspring sex, current BLL, current weight, length-for-age z-score, maternal IQ and maternal 


















































Figure 4.3: Relationship between ln-transformed T2 maternal BLLs, DNA methylation at 
a) cg02901723 (CCSER1) and b) cg18515027 (GCNT1), and 24-month-old infant 
EMOCI scores controlling for infant sex, current BLL, current weight, length-for-age z-











Table 4.1A: Gene mediators. Five differentially methylated CpG sites by prenatal Pb 
exposure at each trimester that were also in genes relevant to neurological function 
were selected from a previous epigenome-wide association study (Rygiel et al. 2020) to 











cg17138393 RAB5A chr3 19988887 -0.0221 
cg00984923 EXT1 chr8 119124069 -0.0235 
cg16049335 KDM6B chr17 7748444 0.236 
cg18515027 GCNT1 chr9 79074066 0.0870 
cg03724407 RPS29 chr14 50053250 -0.0236 
T2 
cg26820233 CHTF18 chr16 838206 -0.0386 
cg12267948 PRDM16 chr1 2986566 -0.0224 
cg20603557 TAPBP chr6 33281576 -0.0198 
cg08025337 TRAPPC12 chr2 3428370 0.154 
cg10604476 ICAM5 chr19 10403908 0.173 
T3 
cg02608914 GORASP2 chr2 171784720 -0.469 
cg19703494 TRAPPC6A chr19 45681672 0.1733 
cg23280166 VPS11 chr11 118938394 -0.0496 
cg20482280 MTA1 chr14 105936300 -0.457 
cg02901723 CCSER1 chr4 91049728 0.102 
*Note: Linear regression models were run for each CpG site using M-values (logit-transformed beta 
values) with each Pb biomarker, controlling for infant sex and cell-type proportions (granulocytes and 
nucleated red blood cells). P-values were obtained from the aforementioned analyses using methylation 
expressed as M-values. The estimates reported in this table are instead from analyses using beta-values 
as the outcome variable for ease of interpretation. CpG sites associated with Pb with P-values<1.0E-5 
and beta estimates >|0.01| that were also in neurologically-relevant genes were selected for the current 
analysis. Beta estimate represents change in DNA methylation percent per one unit (ug/dL) increase in 
Pb. T1, first trimester; T2, second trimester; T3, third trimester; EPIC, Infinium MethylationEPIC BeadChip 
(Illumina); CpG, cytosine-phosphate-guanine, Chr, chromosome; Pos, base pair position 
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Figure 4.1A: Average casual mediation effect (ACME) p-values of the influence of prenatal Pb exposure at each trimester 
and potential gene mediators on adverse neurodevelopmental outcomes at 12 months of age. Models control for offspring 
sex, current BLL, current weight, length-for-age z-score, maternal IQ and maternal age. Red dotted line is P<0.1, which is 















































Measure β Total (CI) 
β Total 
P-value β Indirect (CI) 
β Indirect 







EMOCI 2.95 (-6.96, 12.47) 0.56 -2.4 (-9.46, 4.12) 0.46 5.35 (-6.11, 16.41) 0.38 -24.92 
MDI 1.84 (-2.43, 5.93) 0.42 -1.21 (-4.18, 1.42) 0.37 3.04 (-1.85, 7.82) 0.24 -29.60 
ORIEN 4.5 (-3.95, 12.94) 0.34 -0.11 (-5.99, 5.82) 0.96 4.61 (-5.49, 14.35) 0.39 -1.27 
PDI -1.4 (-5.6, 2.76) 0.52 -0.57 (-3.42, 2.18) 0.67 -0.82 (-5.73, 3.97) 0.77 12.03 
ICAM5 
EMOCI 2.97 (-6.84, 12.62) 0.55 3.32 (-1.09, 9.14) 0.16 -0.35 (-11.21, 10.36) 0.97 39.06 
MDI 1.84 (-2.41, 5.96) 0.42 0.77 (-1.08, 2.94) 0.40 1.07 (-3.56, 5.68) 0.64 18.52 
ORIEN 4.52 (-4.05, 12.92) 0.32 1.85 (-2.15, 6.63) 0.36 2.67 (-6.98, 12.18) 0.57 22.46 
PDI -1.41 (-5.5, 2.77) 0.52 -0.42 (-2.55, 1.43) 0.65 -0.99 (-5.63, 3.63) 0.67 7.86 
GORASP2 
EMOCI 2.91 (-6.52, 12.73) 0.57 -0.08 (-2.19, 1.82) 0.95 2.99 (-6.46, 12.63) 0.55 0.38 
MDI 1.8 (-2.33, 6) 0.42 -0.12 (-1.87, 1.38) 0.86 1.93 (-1.93, 5.82) 0.36 2.52 
ORIEN 4.46 (-4.07, 13.08) 0.33 -0.13 (-2.82, 2.25) 0.91 4.59 (-3.49, 12.84) 0.30 0.34 
PDI -1.41 (-5.52, 2.76) 0.51 -0.02 (-0.75, 0.66) 0.98 -1.39 (-5.5, 2.76) 0.53 0.41 
TRAPPC6A 
EMOCI 2.92 (-6.63, 12.59) 0.57 -0.33 (-3.12, 1.86) 0.77 3.25 (-6.62, 13.29) 0.52 -0.81 
MDI 1.84 (-2.42, 5.96) 0.42 0.54 (-0.43, 2.14) 0.34 1.3 (-2.9, 5.57) 0.55 12.28 
ORIEN 4.5 (-3.99, 12.94) 0.34 0.09 (-2.11, 2.37) 0.94 4.41 (-4.24, 13.22) 0.34 0.51 
PDI -1.4 (-5.58, 2.76) 0.52 0.16 (-0.9, 1.42) 0.76 -1.55 (-5.81, 2.77) 0.49 -0.90 
VPS11 
EMOCI 2.96 (-6.99, 12.45) 0.56 -0.57 (-3.63, 1.44) 0.64 3.52 (-5.77, 12.93) 0.49 -1.45 
MDI 1.83 (-2.35, 6.02) 0.41 0.01 (-0.84, 0.86) 0.95 1.82 (-2.24, 5.95) 0.42 0.38 
ORIEN 4.5 (-3.96, 12.94) 0.34 -0.05 (-1.96, 1.65) 0.99 4.55 (-3.7, 12.9) 0.33 0.01 
PDI -1.39 (-5.59, 2.81) 0.51 -0.33 (-1.82, 0.71) 0.55 -1.06 (-5, 2.96) 0.64 7.89 
MTA1 
EMOCI 2.88 (-6.75, 12.7) 0.57 0.51 (-2.84, 3.94) 0.74 2.37 (-6.65, 11.42) 0.62 8.07 
MDI 1.8 (-2.31, 6.05) 0.42 0.22 (-1.4, 1.84) 0.77 1.58 (-2.22, 5.4) 0.44 9.85 
ORIEN 4.43 (-4.03, 13.1) 0.31 0.62 (-3.15, 4.38) 0.73 3.81 (-3.69, 11.35) 0.36 14.03 
PDI -1.41 (-5.56, 2.77) 0.51 0.02 (-0.73, 0.75) 0.98 -1.42 (-5.49, 2.65) 0.51 0.19 
CCSER1 
EMOCI 2.94 (-6.81, 12.57) 0.56 0.53 (-2.48, 4.01) 0.71 2.41 (-7.8, 12.71) 0.64 3.98 
MDI 1.84 (-2.42, 5.93) 0.42 0.49 (-0.61, 2.11) 0.40 1.35 (-2.96, 5.72) 0.54 10.52 
ORIEN 4.49 (-3.83, 12.97) 0.34 -0.6 (-3.71, 1.89) 0.64 5.08 (-3.84, 14.1) 0.27 -5.05 
PDI -1.41 (-5.47, 2.79) 0.51 -0.34 (-1.85, 0.78) 0.56 -1.07 (-5.39, 3.3) 0.63 6.30 
EXT1 
EMOCI 2.92 (-6.56, 12.66) 0.56 1.36 (-3.87, 7.39) 0.61 1.56 (-9.3, 12.12) 0.76 12.79 
MDI 1.82 (-2.27, 6.06) 0.41 0.73 (-1.49, 3.35) 0.52 1.09 (-3.55, 5.65) 0.65 18.78 
ORIEN 4.51 (-4.07, 12.96) 0.33 -1.03 (-6.02, 3.64) 0.65 5.54 (-3.98, 14.8) 0.28 -11.83 
PDI -1.41 (-5.5, 2.79) 0.52 0.43 (-1.82, 3) 0.71 -1.83 (-6.47, 2.73) 0.45 -7.16 
KDM6B 
EMOCI 2.93 (-6.73, 12.54) 0.57 -0.3 (-5.04, 4.16) 0.88 3.22 (-7.62, 14.02) 0.55 -3.18 
MDI 1.82 (-2.29, 6.03) 0.42 -0.46 (-2.59, 1.28) 0.60 2.29 (-2.34, 6.87) 0.33 -10.58 
ORIEN 4.48 (-3.78, 12.99) 0.33 -1.38 (-5.9, 2.26) 0.47 5.86 (-3.59, 15.25) 0.24 -15.79 
PDI -1.41 (-5.46, 2.78) 0.52 -0.61 (-2.76, 1.11) 0.50 -0.8 (-5.4, 3.76) 0.73 13.78 
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GCNT1 
EMOCI 2.93 (-6.71, 12.52) 0.56 -0.14 (-5.39, 4.91) 0.95 3.06 (-8.11, 14.04) 0.58 -1.34 
MDI 1.84 (-2.43, 5.96) 0.42 1.21 (-0.77, 3.64) 0.25 0.63 (-4.1, 5.27) 0.77 32.18 
ORIEN 4.49 (-3.92, 13.01) 0.34 -0.44 (-5.16, 3.92) 0.84 4.93 (-4.86, 14.54) 0.32 -5.10 
PDI -1.39 (-5.56, 2.77) 0.51 1.63 (-0.24, 4.21) 0.11 -3.02 (-7.67, 1.54) 0.19 -42.90 
RPS29 
EMOCI 2.93 (-6.7, 12.61) 0.57 0.07 (-4.12, 4.54) 0.96 2.86 (-7.44, 13.12) 0.60 0.85 
MDI 1.82 (-2.29, 6.04) 0.41 0.34 (-1.33, 2.3) 0.68 1.49 (-2.91, 5.9) 0.52 8.20 
ORIEN 4.49 (-3.86, 13.01) 0.34 0.66 (-2.81, 4.72) 0.70 3.82 (-5.18, 12.8) 0.43 7.73 
PDI -1.4 (-5.59, 2.79) 0.51 -0.23 (-2.12, 1.57) 0.78 -1.17 (-5.56, 3.23) 0.63 3.81 
CHTF18 
EMOCI 2.92 (-6.56, 12.67) 0.57 0.94 (-2.11, 4.86) 0.55 1.98 (-7.8, 11.99) 0.69 7.05 
MDI 1.83 (-2.36, 6.01) 0.42 -0.23 (-1.84, 1.25) 0.73 2.06 (-2.17, 6.38) 0.37 -3.18 
ORIEN 4.5 (-3.98, 13.02) 0.34 -0.27 (-3.46, 2.8) 0.84 4.77 (-3.83, 13.58) 0.31 -1.91 
PDI -1.39 (-5.59, 2.81) 0.51 -0.95 (-2.98, 0.27) 0.17 -0.44 (-4.55, 3.77) 0.86 23.93 
PRDM16 
EMOCI 2.9 (-6.71, 12.84) 0.56 2.68 (-1.47, 8.19) 0.21 0.22 (-10.02, 10.45) 0.97 28.61 
MDI 1.83 (-2.4, 5.99) 0.42 -0.44 (-2.62, 1.53) 0.64 2.28 (-2.21, 6.75) 0.35 -9.49 
ORIEN 4.5 (-3.93, 12.96) 0.34 0.13 (-3.96, 4.54) 0.94 4.36 (-4.77, 13.48) 0.38 1.67 
PDI -1.41 (-5.51, 2.76) 0.52 0.24 (-1.7, 2.43) 0.80 -1.65 (-6.12, 2.81) 0.49 -4.19 
TAPBP 
EMOCI 2.9 (-6.77, 12.81) 0.56 2.59 (-0.89, 7.59) 0.15 0.3 (-9.68, 10.31) 0.95 28.05 
MDI 1.82 (-2.31, 6.09) 0.42 1.03 (-0.51, 3.17) 0.20 0.79 (-3.55, 5.15) 0.73 27.24 
ORIEN 4.47 (-4, 13.22) 0.33 2.2 (-0.83, 6.54) 0.16 2.27 (-6.49, 11.05) 0.62 28.89 
PDI -1.4 (-5.59, 2.78) 0.51 -0.03 (-1.86, 1.87) 0.97 -1.37 (-5.78, 3.05) 0.56 -0.04 
TRAPPC12 
EMOCI 2.9 (-6.75, 12.74) 0.57 -1.5 (-7.68, 4.11) 0.60 4.4 (-6.99, 15.72) 0.44 -12.98 
MDI 1.83 (-2.41, 6.01) 0.42 0.76 (-1.63, 3.34) 0.53 1.07 (-3.81, 5.93) 0.67 19.49 
ORIEN 4.48 (-3.99, 13.01) 0.33 -0.24 (-5.53, 4.91) 0.94 4.72 (-5.29, 14.67) 0.36 -2.49 
PDI -1.41 (-5.55, 2.8) 0.51 -0.47 (-3.03, 1.93) 0.71 -0.94 (-5.82, 3.91) 0.72 9.80 
T2 
RAB5A 
EMOCI 2.58 (-6.96, 12.13) 0.60 -1.38 (-6.37, 2.96) 0.51 3.96 (-6.3, 14.14) 0.48 -11.94 
MDI 0.61 (-3.46, 4.64) 0.74 -0.54 (-2.63, 1.31) 0.54 1.14 (-3.21, 5.47) 0.61 -7.99 
ORIEN 2.34 (-6.05, 10.58) 0.58 0.19 (-3.74, 4.44) 0.91 2.15 (-6.91, 11.14) 0.64 1.90 
PDI -2.03 (-5.88, 1.75) 0.30 0.35 (-1.37, 2.35) 0.68 -2.38 (-6.56, 1.77) 0.26 -9.33 
ICAM5 
EMOCI 2.59 (-6.98, 12.23) 0.60 3.23 (-1.18, 8.85) 0.17 -0.64 (-11.24, 9.7) 0.94 38.48 
MDI 0.6 (-3.44, 4.65) 0.74 0.42 (-1.54, 2.56) 0.67 0.18 (-4.36, 4.63) 0.92 7.22 
ORIEN 2.37 (-5.97, 10.72) 0.59 2.4 (-1.55, 7.19) 0.25 -0.04 (-9.41, 9.11) 0.98 30.47 
PDI -2.03 (-5.9, 1.77) 0.31 0.01 (-1.99, 2) 0.99 -2.04 (-6.4, 2.23) 0.36 1.15 
GORASP2 
EMOCI 2.55 (-6.94, 11.78) 0.59 -0.07 (-1.79, 1.36) 0.94 2.62 (-6.91, 11.78) 0.58 0.15 
MDI 0.58 (-3.42, 4.67) 0.77 -0.14 (-1.65, 1.11) 0.83 0.72 (-3.14, 4.44) 0.71 4.12 
ORIEN 2.31 (-6.06, 10.53) 0.60 -0.19 (-2.37, 1.65) 0.84 2.5 (-5.74, 10.43) 0.54 0.33 
PDI -2.04 (-5.86, 1.73) 0.29 -0.05 (-0.88, 0.6) 0.89 -1.98 (-5.84, 1.73) 0.31 0.76 
TRAPPC6A 
EMOCI 2.55 (-6.91, 11.91) 0.59 -0.38 (-3.55, 2.3) 0.76 2.93 (-6.95, 12.81) 0.56 -1.87 
MDI 0.61 (-3.44, 4.64) 0.74 0.27 (-0.71, 1.59) 0.59 0.34 (-3.78, 4.53) 0.85 3.36 
ORIEN 2.34 (-6, 10.59) 0.58 0.11 (-2.44, 2.71) 0.93 2.23 (-6.46, 10.92) 0.61 0.94 
PDI -2.02 (-5.91, 1.83) 0.30 0.42 (-0.48, 1.8) 0.39 -2.44 (-6.35, 1.55) 0.21 -8.97 
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VPS11 
EMOCI 2.58 (-6.95, 12.15) 0.60 -0.05 (-1.94, 1.65) 0.95 2.63 (-6.8, 11.9) 0.58 0.11 
MDI 0.6 (-3.42, 4.55) 0.75 0.01 (-0.67, 0.69) 0.99 0.58 (-3.43, 4.52) 0.76 0.37 
ORIEN 2.33 (-5.97, 10.49) 0.58 0.03 (-1.43, 1.45) 0.98 2.3 (-6.01, 10.47) 0.58 0.33 
PDI -2.02 (-5.88, 1.86) 0.30 -0.04 (-1.04, 0.88) 0.92 -1.98 (-5.77, 1.75) 0.30 1.18 
MTA1 
EMOCI 2.52 (-6.95, 11.92) 0.61 0.87 (-1.3, 4) 0.45 1.65 (-7.58, 10.79) 0.71 8.21 
MDI 0.58 (-3.45, 4.6) 0.76 0.48 (-0.62, 1.93) 0.39 0.1 (-3.76, 3.93) 0.95 10.06 
ORIEN 2.3 (-6.08, 10.72) 0.59 1.14 (-1.47, 4.38) 0.38 1.15 (-6.74, 8.97) 0.77 16.84 
PDI -2.04 (-5.85, 1.73) 0.30 0.14 (-0.54, 1.14) 0.69 -2.18 (-6, 1.61) 0.25 -1.34 
CCSER1 
EMOCI 2.57 (-6.92, 12.04) 0.59 0.51 (-4.18, 5.44) 0.82 2.06 (-8.65, 12.53) 0.69 4.52 
MDI 0.6 (-3.42, 4.6) 0.74 0.14 (-1.86, 2.2) 0.88 0.46 (-4.08, 4.9) 0.83 1.77 
ORIEN 2.33 (-5.96, 10.49) 0.58 -1 (-5.6, 2.96) 0.62 3.33 (-6.06, 12.53) 0.48 -9.06 
PDI -2.03 (-5.88, 1.81) 0.31 0.16 (-1.75, 2.14) 0.86 -2.19 (-6.54, 2.07) 0.31 -3.50 
EXT1 
EMOCI 2.55 (-6.84, 11.83) 0.59 0.58 (-1.77, 3.68) 0.62 1.97 (-7.62, 11.66) 0.68 3.60 
MDI 0.59 (-3.41, 4.53) 0.76 0.5 (-0.4, 1.98) 0.34 0.09 (-3.94, 4.17) 0.95 7.28 
ORIEN 2.34 (-6, 10.6) 0.58 -0.01 (-2.34, 2.33) 0.99 2.35 (-6.1, 10.9) 0.60 0.29 
PDI -2.03 (-5.87, 1.76) 0.30 0.14 (-0.84, 1.34) 0.77 -2.18 (-6.08, 1.77) 0.27 -2.11 
KDM6B 
EMOCI 2.57 (-6.94, 12.05) 0.59 0.6 (-3.35, 4.84) 0.74 1.97 (-8.34, 12.09) 0.70 4.92 
MDI 0.59 (-3.4, 4.53) 0.76 -0.63 (-2.56, 0.94) 0.45 1.22 (-3.14, 5.5) 0.58 -8.25 
ORIEN 2.33 (-5.98, 10.43) 0.58 -0.93 (-4.82, 2.37) 0.58 3.26 (-5.79, 12.14) 0.48 -8.58 
PDI -2.04 (-5.87, 1.72) 0.29 -0.73 (-2.62, 0.75) 0.35 -1.31 (-5.48, 2.77) 0.54 21.84 
GCNT1 
EMOCI 2.56 (-6.98, 11.95) 0.60 -0.07 (-4.2, 3.79) 0.96 2.63 (-7.46, 12.74) 0.62 -0.52 
MDI 0.61 (-3.45, 4.64) 0.75 1.04 (-0.41, 3.09) 0.19 -0.42 (-4.64, 3.79) 0.87 21.13 
ORIEN 2.35 (-5.97, 10.72) 0.59 0.47 (-2.95, 4.03) 0.76 1.88 (-6.99, 10.76) 0.67 4.36 
PDI -2.01 (-5.89, 1.85) 0.30 1.25 (-0.11, 3.32) 0.09 -3.26 (-7.25, 0.73) 0.10 -37.47 
RPS29 
EMOCI 2.59 (-6.97, 12.05) 0.60 -0.49 (-3.17, 1.37) 0.64 3.07 (-6.25, 12.36) 0.53 -1.24 
MDI 0.6 (-3.39, 4.53) 0.75 0.11 (-0.6, 1.06) 0.78 0.49 (-3.51, 4.46) 0.80 1.08 
ORIEN 2.36 (-6.05, 10.7) 0.58 -0.24 (-2.29, 1.26) 0.77 2.6 (-5.66, 10.82) 0.55 -0.54 
PDI -2.03 (-5.88, 1.79) 0.31 -0.01 (-0.77, 0.71) 0.99 -2.01 (-5.85, 1.8) 0.30 0.15 
CHTF18 
EMOCI 2.55 (-6.93, 11.85) 0.59 0.65 (-2.95, 4.68) 0.71 1.9 (-8.18, 11.86) 0.71 4.89 
MDI 0.6 (-3.42, 4.61) 0.74 -0.11 (-1.76, 1.54) 0.88 0.72 (-3.56, 4.95) 0.73 -1.33 
ORIEN 2.35 (-5.99, 10.71) 0.58 -0.57 (-4.14, 2.7) 0.69 2.92 (-5.94, 11.68) 0.52 -5.04 
PDI -2.02 (-5.9, 1.85) 0.30 -0.8 (-2.67, 0.54) 0.26 -1.22 (-5.26, 2.78) 0.56 24.44 
PRDM16 
EMOCI 2.54 (-6.87, 11.78) 0.60 2.15 (-1.84, 7.19) 0.31 0.38 (-9.8, 10.5) 0.92 21.22 
MDI 0.61 (-3.42, 4.67) 0.74 -0.7 (-2.83, 1.12) 0.42 1.31 (-3.04, 5.62) 0.56 -12.07 
ORIEN 2.34 (-6.05, 10.59) 0.58 0.29 (-3.57, 4.5) 0.87 2.05 (-7, 11.03) 0.65 3.06 
PDI -2.03 (-5.89, 1.73) 0.29 0.63 (-1.02, 2.65) 0.47 -2.66 (-6.83, 1.46) 0.20 -16.73 
TAPBP 
EMOCI 2.55 (-6.86, 11.82) 0.60 0.91 (-2.2, 4.78) 0.57 1.64 (-8.29, 11.53) 0.74 7.02 
MDI 0.59 (-3.4, 4.52) 0.75 0.4 (-0.89, 2.03) 0.54 0.19 (-4.01, 4.37) 0.91 5.25 
ORIEN 2.33 (-5.94, 10.48) 0.58 0.86 (-1.88, 4.3) 0.54 1.47 (-7.25, 10.16) 0.73 7.80 
PDI -2.04 (-5.89, 1.73) 0.30 0.49 (-0.71, 2.1) 0.45 -2.52 (-6.53, 1.47) 0.20 -11.29 
 165 
TRAPPC12 
EMOCI 2.54 (-6.81, 11.84) 0.60 -0.54 (-3.73, 2.04) 0.66 3.08 (-6.69, 12.84) 0.53 -2.04 
MDI 0.61 (-3.49, 4.62) 0.75 0.67 (-0.39, 2.31) 0.21 -0.06 (-4.15, 4.02) 0.99 11.23 
ORIEN 2.34 (-6.02, 10.5) 0.58 0.1 (-2.42, 2.67) 0.92 2.24 (-6.38, 10.84) 0.60 1.15 
PDI -2.03 (-5.91, 1.78) 0.31 0.12 (-0.97, 1.34) 0.80 -2.15 (-6.13, 1.83) 0.29 -1.91 
T3 
RAB5A 
EMOCI 0.8 (-9.05, 10.75) 0.86 -0.17 (-3.68, 3.28) 0.92 0.97 (-8.99, 11.14) 0.84 -0.21 
MDI 2.32 (-1.99, 6.49) 0.29 -0.8 (-2.67, 0.39) 0.23 3.12 (-1.02, 7.36) 0.16 -18.09 
ORIEN 4.28 (-4.29, 12.92) 0.36 0.57 (-2.2, 3.83) 0.68 3.71 (-4.97, 12.57) 0.43 6.07 
PDI -1.82 (-5.91, 2.31) 0.38 -0.14 (-1.59, 1.2) 0.83 -1.69 (-5.77, 2.49) 0.43 2.36 
ICAM5 
EMOCI 0.84 (-9.47, 10.83) 0.86 3.62 (-0.56, 9.31) 0.11 -2.78 (-13.52, 7.61) 0.60 24.00 
MDI 2.31 (-1.88, 6.57) 0.30 0.14 (-1.77, 2.07) 0.87 2.17 (-2.5, 6.71) 0.34 2.78 
ORIEN 4.3 (-4.47, 12.95) 0.35 1.95 (-1.85, 6.51) 0.31 2.35 (-7.18, 11.58) 0.62 24.91 
PDI -1.83 (-5.9, 2.26) 0.37 -0.16 (-2.11, 1.67) 0.86 -1.67 (-6.2, 2.74) 0.46 4.73 
GORASP2 
EMOCI 0.79 (-9.05, 10.76) 0.86 0.14 (-1.82, 2.4) 0.88 0.65 (-8.98, 10.54) 0.89 0.99 
MDI 2.29 (-1.87, 6.42) 0.29 0.61 (-0.8, 2.29) 0.36 1.68 (-2.21, 5.65) 0.43 17.95 
ORIEN 4.26 (-4.23, 12.87) 0.36 0.53 (-1.08, 2.96) 0.55 3.73 (-4.6, 12.29) 0.42 4.75 
PDI -1.84 (-5.84, 2.24) 0.37 0.27 (-0.51, 1.44) 0.52 -2.11 (-6.05, 1.92) 0.30 -3.31 
TRAPPC6A 
EMOCI 0.79 (-9.03, 10.67) 0.86 -1 (-6.53, 4.01) 0.70 1.79 (-9.65, 12.77) 0.75 -4.95 
MDI 2.31 (-1.92, 6.58) 0.30 0.3 (-1.7, 2.41) 0.75 2.01 (-2.71, 6.58) 0.39 6.69 
ORIEN 4.28 (-4.32, 12.93) 0.36 -0.72 (-5.53, 3.69) 0.75 5 (-4.99, 14.6) 0.31 -8.60 
PDI -1.81 (-5.99, 2.25) 0.38 1.24 (-0.53, 3.49) 0.19 -3.05 (-7.55, 1.31) 0.17 -34.99 
VPS11 
EMOCI 0.82 (-9.16, 10.81) 0.85 -1.2 (-5.4, 2.12) 0.46 2.02 (-8.06, 12.24) 0.70 -3.53 
MDI 2.31 (-1.89, 6.52) 0.30 0.08 (-1.44, 1.69) 0.90 2.23 (-2.09, 6.59) 0.34 1.86 
ORIEN 4.28 (-4.36, 12.96) 0.36 0.21 (-2.91, 3.55) 0.88 4.07 (-4.78, 13.04) 0.40 2.34 
PDI -1.82 (-5.98, 2.25) 0.38 -0.69 (-2.52, 0.63) 0.31 -1.13 (-5.28, 3.06) 0.59 18.35 
MTA1 
EMOCI 0.76 (-8.93, 10.61) 0.86 1.71 (-0.71, 5.65) 0.21 -0.95 (-10.64, 8.9) 0.88 8.92 
MDI 2.29 (-1.81, 6.42) 0.30 0.94 (-0.21, 2.71) 0.14 1.35 (-2.7, 5.44) 0.53 26.40 
ORIEN 4.24 (-4.15, 12.78) 0.35 1.96 (-0.41, 5.65) 0.14 2.28 (-6.04, 10.75) 0.60 27.20 
PDI -1.83 (-5.92, 2.28) 0.37 0.32 (-0.71, 1.72) 0.53 -2.15 (-6.21, 1.95) 0.30 -5.34 
CCSER1 
EMOCI 0.81 (-9.14, 10.84) 0.85 0.62 (-3.54, 5.01) 0.75 0.19 (-10.49, 10.78) 0.95 2.17 
MDI 2.31 (-1.9, 6.53) 0.30 -0.07 (-1.91, 1.68) 0.93 2.37 (-2.13, 6.88) 0.30 -1.43 
ORIEN 4.27 (-4.16, 12.91) 0.36 -1.27 (-5.41, 2.1) 0.47 5.54 (-3.75, 14.75) 0.24 -14.16 
PDI -1.83 (-5.91, 2.28) 0.38 -0.03 (-1.81, 1.67) 0.96 -1.8 (-6.17, 2.58) 0.43 1.64 
EXT1 
EMOCI 0.78 (-8.92, 10.66) 0.85 -0.01 (-1.95, 1.74) 1.00 0.8 (-8.85, 10.63) 0.86 0.71 
MDI 2.3 (-1.81, 6.48) 0.30 0 (-0.95, 0.89) 1.00 2.3 (-1.78, 6.47) 0.29 0.38 
ORIEN 4.28 (-4.35, 12.97) 0.36 -0.01 (-1.42, 1.38) 0.97 4.29 (-4.18, 12.92) 0.36 0.13 
PDI -1.83 (-5.9, 2.26) 0.37 0 (-0.66, 0.64) 0.98 -1.82 (-5.83, 2.26) 0.37 0.07 
KDM6B 
EMOCI 0.81 (-9.13, 10.85) 0.85 0.58 (-3.21, 4.73) 0.74 0.22 (-10.5, 10.79) 0.94 1.86 
MDI 2.3 (-1.81, 6.5) 0.30 -0.62 (-2.5, 0.82) 0.43 2.92 (-1.62, 7.38) 0.22 -13.59 
ORIEN 4.27 (-4.18, 12.88) 0.36 -1.41 (-5.4, 1.61) 0.39 5.68 (-3.62, 14.84) 0.23 -15.32 
PDI -1.84 (-5.82, 2.25) 0.37 -0.73 (-2.62, 0.65) 0.31 -1.1 (-5.49, 3.21) 0.62 19.89 
GCNT1 
EMOCI 0.81 (-9.14, 10.86) 0.85 0.24 (-1.88, 2.73) 0.82 0.56 (-9.44, 10.62) 0.91 0.78 
MDI 2.32 (-1.99, 6.5) 0.29 0.43 (-0.48, 1.83) 0.40 1.89 (-2.3, 6.08) 0.39 9.90 
ORIEN 4.29 (-4.44, 13.02) 0.36 0.31 (-1.49, 2.58) 0.75 3.98 (-4.74, 12.76) 0.38 2.23 
PDI -1.81 (-6, 2.24) 0.38 0.42 (-0.46, 1.79) 0.40 -2.24 (-6.3, 1.83) 0.27 -7.34 
RPS29 EMOCI 0.82 (-9.28, 10.71) 0.85 -0.43 (-3.21, 1.47) 0.69 1.26 (-8.38, 11.09) 0.80 0.23 
 166 
MDI 2.3 (-1.86, 6.51) 0.30 0.09 (-0.63, 0.94) 0.82 2.22 (-1.9, 6.43) 0.32 1.26 
ORIEN 4.3 (-4.41, 13.07) 0.36 -0.25 (-2.36, 1.21) 0.76 4.54 (-3.93, 13.19) 0.32 -0.74 
PDI -1.82 (-5.87, 2.29) 0.38 -0.02 (-0.82, 0.68) 0.97 -1.8 (-5.81, 2.3) 0.38 0.13 
CHTF18 
EMOCI 0.79 (-9.02, 10.69) 0.85 0.8 (-2.33, 4.65) 0.61 -0.01 (-9.92, 10.19) 0.99 2.97 
MDI 2.31 (-1.93, 6.61) 0.30 -0.29 (-1.93, 1.13) 0.66 2.61 (-1.62, 6.94) 0.25 -5.48 
ORIEN 4.29 (-4.44, 13.08) 0.36 -0.64 (-4.01, 2.26) 0.64 4.93 (-3.73, 13.84) 0.30 -5.70 
PDI -1.81 (-6, 2.23) 0.38 -0.82 (-2.68, 0.36) 0.22 -1 (-5.04, 3.15) 0.64 23.29 
PRDM16 
EMOCI 0.78 (-8.89, 10.58) 0.85 1.45 (-1.08, 5.4) 0.30 -0.67 (-10.37, 9.29) 0.93 6.13 
MDI 2.32 (-1.92, 6.55) 0.29 -0.45 (-2.07, 0.71) 0.44 2.76 (-1.38, 7.02) 0.22 -8.90 
ORIEN 4.28 (-4.36, 12.99) 0.36 0.04 (-2.68, 2.8) 0.97 4.24 (-4.33, 13.05) 0.37 0.55 
PDI -1.83 (-5.88, 2.24) 0.37 0.23 (-0.94, 1.63) 0.69 -2.06 (-6.1, 2.09) 0.33 -3.83 
TAPBP 
EMOCI 0.78 (-8.89, 10.71) 0.86 0.83 (-1.45, 4.22) 0.50 -0.05 (-9.94, 9.89) 0.99 3.07 
MDI 2.3 (-1.87, 6.51) 0.30 0.21 (-0.85, 1.53) 0.68 2.1 (-2.1, 6.36) 0.36 4.25 
ORIEN 4.27 (-4.25, 12.91) 0.36 0.57 (-1.47, 3.45) 0.59 3.7 (-4.95, 12.41) 0.42 5.34 
PDI -1.83 (-5.88, 2.25) 0.37 0.2 (-0.83, 1.49) 0.68 -2.03 (-6.11, 2.11) 0.34 -2.98 
TRAPPC12 
EMOCI 0.78 (-9.09, 10.79) 0.86 -0.24 (-2.59, 1.54) 0.81 1.02 (-8.97, 11.16) 0.82 0.08 
MDI 2.31 (-1.89, 6.56) 0.30 0.25 (-0.57, 1.44) 0.57 2.06 (-2.16, 6.32) 0.35 4.81 
ORIEN 4.28 (-4.26, 13.06) 0.36 0.08 (-1.67, 1.95) 0.91 4.2 (-4.54, 13.06) 0.36 0.68 









Measure β Total (CI) 
β Total 
P-value β Indirect (CI) 
β Indirect 







EMOCI -5.76 (-14.7, 3.54) 0.21 -2.94 (-8.45, 1.15) 0.19 -2.82 (-12.56, 6.9) 0.59 39.07 
MDI -0.94 (-5.76, 4.05) 0.72 -2.67 (-5.86, -0.37) 0.02 1.73 (-3.25, 6.69) 0.52 64.63 
ORIEN -3.45 (-14.06, 7.62) 0.54 -3.58 (-10.1, 1.29) 0.17 0.13 (-11.42, 11.65) 0.98 34.83 
PDI 0.74 (-3.23, 4.85) 0.72 -2.27 (-4.92, -0.37) 0.02 3.02 (-1.07, 7.09) 0.16 -55.06 
ICAM5 
EMOCI -5.77 (-14.74, 3.57) 0.20 2.11 (-1.49, 6.86) 0.27 -7.88 (-17.58, 2.23) 0.10 -24.71 
MDI -0.95 (-5.71, 3.96) 0.72 1.03 (-0.9, 3.5) 0.30 -1.98 (-7.15, 3.4) 0.46 -12.80 
ORIEN -3.46 (-14.13, 7.4) 0.54 1.53 (-2.9, 6.79) 0.49 -4.99 (-16.61, 7.1) 0.41 -12.11 
PDI 0.73 (-3.21, 4.75) 0.72 0.22 (-1.5, 2.05) 0.79 0.51 (-3.8, 4.99) 0.80 3.75 
GORASP2 
EMOCI -5.8 (-15.03, 3.44) 0.22 -0.2 (-2.3, 1.48) 0.83 -5.6 (-14.62, 3.42) 0.22 1.47 
MDI -0.97 (-5.85, 3.92) 0.72 -0.07 (-1.05, 0.71) 0.85 -0.9 (-5.71, 3.92) 0.74 0.82 
ORIEN -3.5 (-14.46, 7.45) 0.52 -0.28 (-2.96, 1.85) 0.80 -3.22 (-13.89, 7.45) 0.57 2.24 
PDI 0.71 (-3.34, 4.67) 0.73 -0.17 (-1.54, 0.92) 0.76 0.88 (-2.96, 4.73) 0.66 1.08 
TRAPPC6A 
EMOCI -5.77 (-14.76, 3.4) 0.21 0.76 (-1.51, 3.99) 0.51 -6.54 (-15.81, 2.96) 0.17 -6.38 
MDI -0.94 (-5.74, 4.05) 0.72 1.07 (-0.32, 3.26) 0.15 -2.01 (-6.77, 2.86) 0.42 -10.49 
ORIEN -3.45 (-14.07, 7.62) 0.55 1.64 (-1.06, 6) 0.28 -5.08 (-15.96, 6.04) 0.36 -9.73 
PDI 0.72 (-3.33, 4.75) 0.72 -0.52 (-2.05, 0.41) 0.34 1.23 (-2.79, 5.36) 0.55 -5.03 
VPS11 
EMOCI -5.81 (-15.1, 3.26) 0.21 0.82 (-1.81, 4.04) 0.53 -6.63 (-15.42, 2.16) 0.14 -6.42 
MDI -0.98 (-5.91, 3.86) 0.72 0.41 (-0.92, 2.06) 0.53 -1.39 (-6.07, 3.3) 0.58 -0.46 
ORIEN -3.5 (-14.45, 7.37) 0.52 0.74 (-1.85, 4.05) 0.57 -4.24 (-14.83, 6.36) 0.44 -1.83 
PDI 0.72 (-3.29, 4.75) 0.72 0.11 (-0.62, 1.06) 0.77 0.61 (-3.37, 4.58) 0.76 1.11 
MTA1 
EMOCI -5.79 (-14.98, 3.46) 0.22 0.01 (-1.51, 1.52) 0.99 -5.8 (-14.94, 3.27) 0.21 0.08 
MDI -0.97 (-5.86, 3.92) 0.73 0.02 (-0.84, 0.87) 0.97 -0.99 (-5.83, 3.83) 0.71 0.39 
ORIEN -3.5 (-14.49, 7.46) 0.53 0.07 (-2.00, 2.3) 0.95 -3.57 (-14.34, 7.13) 0.52 0.46 
PDI 0.71 (-3.33, 4.74) 0.73 0.05 (-1.05, 1.17) 0.94 0.66 (-3.24, 4.53) 0.74 2.79 
CCSER1 
EMOCI -5.76 (-14.73, 3.73) 0.21 2.05 (-0.63, 6.34) 0.16 -7.81 (-17.18, 1.75) 0.09 -23.66 
MDI -0.95 (-5.71, 4) 0.72 0.95 (-0.45, 3.15) 0.22 -1.9 (-6.91, 3.2) 0.46 -10.07 
ORIEN -3.45 (-14.07, 7.76) 0.54 2.29 (-0.83, 7.28) 0.19 -5.74 (-16.9, 5.63) 0.30 -17.58 
PDI 0.73 (-3.22, 4.76) 0.72 0.26 (-1.02, 1.79) 0.68 0.47 (-3.73, 4.74) 0.81 3.83 
EXT1 
EMOCI -5.77 (-14.79, 3.36) 0.21 -1.27 (-5.81, 2.47) 0.48 -4.51 (-14.14, 5.1) 0.37 14.98 
MDI -0.96 (-5.72, 3.94) 0.72 -0.8 (-3.23, 1.17) 0.40 -0.16 (-5.27, 4.93) 0.96 10.18 
ORIEN -3.47 (-14.19, 7.41) 0.53 -0.77 (-5.85, 3.91) 0.72 -2.7 (-14.18, 8.74) 0.67 5.55 
PDI 0.73 (-3.21, 4.77) 0.72 -0.69 (-2.7, 0.92) 0.38 1.42 (-2.79, 5.61) 0.53 -12.01 
KDM6B 
EMOCI -5.77 (-14.82, 3.46) 0.21 1.34 (-2.88, 6.18) 0.50 -7.12 (-17.09, 3.21) 0.16 -15.70 
MDI -0.97 (-5.83, 3.89) 0.72 -0.42 (-2.86, 1.79) 0.70 -0.55 (-5.86, 4.96) 0.85 4.21 
ORIEN -3.47 (-14.14, 7.38) 0.53 0.97 (-4.16, 6.49) 0.70 -4.43 (-16.31, 7.86) 0.46 -7.64 
PDI 0.72 (-3.32, 4.76) 0.72 -0.94 (-3.13, 0.75) 0.30 1.66 (-2.67, 6.15) 0.45 -16.79 
GCNT1 
EMOCI -5.82 (-15.07, 3.06) 0.21 -4.94 (-10.6, -0.77) 0.01 -0.88 (-10.1, 8.67) 0.86 68.66 
MDI -0.97 (-5.83, 3.93) 0.72 -0.67 (-3.05, 1.37) 0.53 -0.3 (-5.54, 5.13) 0.92 8.33 
ORIEN -3.5 (-14.43, 7.3) 0.53 -3.38 (-9.54, 0.93) 0.13 -0.12 (-11.63, 11.78) 0.99 36.50 
 168 
PDI 0.73 (-3.22, 4.73) 0.71 0.31 (-1.48, 2.23) 0.72 0.42 (-3.92, 4.9) 0.84 5.49 
RPS29 
EMOCI -5.77 (-14.75, 3.48) 0.21 -1.64 (-6.29, 2.01) 0.36 -4.13 (-13.75, 5.45) 0.41 20.20 
MDI -0.96 (-5.76, 3.92) 0.72 -0.59 (-2.97, 1.44) 0.53 -0.37 (-5.5, 4.74) 0.91 7.36 
ORIEN -3.44 (-14.17, 7.86) 0.53 -3.37 (-9.43, 0.7) 0.13 -0.07 (-11.29, 11.1) 1.00 34.57 
PDI 0.73 (-3.22, 4.78) 0.71 -0.37 (-2.27, 1.34) 0.65 1.09 (-3.14, 5.31) 0.62 -6.07 
CHTF18 
EMOCI -5.8 (-15, 3.43) 0.22 0.81 (-1.45, 4.05) 0.51 -6.61 (-15.89, 2.81) 0.16 -6.88 
MDI -0.97 (-5.8, 3.86) 0.72 0.16 (-1.22, 1.7) 0.80 -1.13 (-6.08, 3.9) 0.68 -0.07 
ORIEN -3.48 (-14.25, 7.4) 0.54 0.13 (-3.12, 3.38) 0.92 -3.6 (-14.68, 7.64) 0.53 -0.21 
PDI 0.73 (-3.19, 4.85) 0.72 -0.58 (-2.2, 0.41) 0.30 1.31 (-2.7, 5.39) 0.54 -6.32 
PRDM16 
EMOCI -5.78 (-14.79, 3.47) 0.21 -0.96 (-5.48, 3.06) 0.61 -4.81 (-14.58, 4.82) 0.34 11.11 
MDI -0.95 (-5.73, 3.96) 0.72 -0.93 (-3.49, 1.11) 0.35 -0.02 (-5.18, 5.06) 0.99 12.29 
ORIEN -3.46 (-14.17, 7.47) 0.53 -1.21 (-6.6, 3.54) 0.59 -2.25 (-13.84, 9.17) 0.72 10.47 
PDI 0.73 (-3.18, 4.81) 0.72 -1.12 (-3.34, 0.45) 0.19 1.85 (-2.36, 6) 0.41 -20.51 
TAPBP 
EMOCI -5.8 (-15.04, 3.42) 0.22 1.27 (-1.51, 5.11) 0.40 -7.07 (-16.44, 2.31) 0.14 -12.63 
MDI -0.97 (-5.85, 3.93) 0.72 0.54 (-0.96, 2.5) 0.49 -1.51 (-6.5, 3.49) 0.56 -3.71 
ORIEN -3.5 (-14.48, 7.47) 0.53 1.78 (-1.41, 6.42) 0.31 -5.27 (-16.36, 5.82) 0.36 -12.69 
PDI 0.73 (-3.2, 4.78) 0.72 -0.55 (-2.27, 0.7) 0.38 1.28 (-2.82, 5.39) 0.56 -7.40 
TRAPPC12 
EMOCI -5.8 (-14.89, 3.43) 0.22 -1.06 (-5.48, 2.68) 0.55 -4.74 (-14.45, 4.87) 0.34 11.46 
MDI -0.96 (-5.74, 3.94) 0.72 0.5 (-1.45, 2.74) 0.61 -1.46 (-6.63, 3.65) 0.60 -5.91 
ORIEN -3.49 (-14.29, 7.41) 0.54 -0.01 (-4.83, 4.68) 0.98 -3.47 (-15.04, 7.98) 0.57 0.15 
PDI 0.72 (-3.3, 4.74) 0.72 -0.37 (-2.27, 1.29) 0.65 1.09 (-3.17, 5.3) 0.61 -4.58 
T2 
RAB5A 
EMOCI -6.06 (-14.03, 1.98) 0.13 -1.95 (-5.81, 0.6) 0.17 -4.11 (-12.25, 4.08) 0.32 26.31 
MDI -1.2 (-5.6, 3.33) 0.61 -1.42 (-3.69, 0.05) 0.06 0.22 (-4.24, 4.71) 0.91 35.68 
ORIEN -5.23 (-15, 4.62) 0.29 -2.17 (-6.83, 1.11) 0.21 -3.06 (-13.14, 7.07) 0.56 26.86 
PDI -0.29 (-3.79, 3.23) 0.89 -0.72 (-2.38, 0.48) 0.25 0.43 (-3.19, 4.08) 0.81 7.11 
ICAM5 
EMOCI -6.06 (-14.01, 1.94) 0.13 2.68 (-1.12, 7.46) 0.19 -8.74 (-17.65, 0.05) 0.05 -35.68 
MDI -1.21 (-5.59, 3.2) 0.60 1.18 (-1.02, 3.77) 0.30 -2.38 (-7.37, 2.54) 0.34 -24.04 
ORIEN -5.24 (-14.86, 4.5) 0.29 2.22 (-2.68, 7.87) 0.36 -7.46 (-18.54, 3.49) 0.17 -25.43 
PDI -0.29 (-3.8, 3.22) 0.89 0.48 (-1.29, 2.42) 0.59 -0.78 (-4.78, 3.17) 0.70 -2.12 
GORASP2 
EMOCI -6.11 (-13.97, 1.71) 0.13 -0.01 (-1.73, 1.72) 0.99 -6.1 (-13.92, 1.52) 0.12 0.23 
MDI -1.22 (-5.61, 3.15) 0.59 0 (-0.76, 0.75) 0.98 -1.22 (-5.61, 3.05) 0.60 0.43 
ORIEN -5.29 (-15, 4.36) 0.29 -0.01 (-2.24, 2.19) 0.97 -5.28 (-14.9, 4.1) 0.28 0.59 
PDI -0.31 (-3.84, 3.2) 0.88 0 (-1.07, 0.98) 1.00 -0.31 (-3.7, 3) 0.87 4.75 
TRAPPC6A 
EMOCI -6.07 (-13.86, 1.83) 0.12 1.22 (-1.45, 4.78) 0.37 -7.29 (-15.66, 1.05) 0.08 -14.69 
MDI -1.2 (-5.6, 3.34) 0.61 1.54 (0, 3.87) 0.05 -2.73 (-7.23, 1.76) 0.21 -31.19 
ORIEN -5.23 (-15.02, 4.61) 0.29 2.16 (-1.06, 6.9) 0.22 -7.39 (-17.62, 2.82) 0.15 -23.89 
PDI -0.3 (-3.78, 3.18) 0.89 -0.31 (-1.76, 0.93) 0.61 0.01 (-3.72, 3.72) 0.97 0.93 
VPS11 
EMOCI -6.12 (-14.16, 1.87) 0.13 0.41 (-1.93, 2.96) 0.72 -6.53 (-14.17, 0.95) 0.09 -3.20 
MDI -1.23 (-5.63, 3.12) 0.60 0.2 (-0.97, 1.55) 0.73 -1.44 (-5.72, 2.75) 0.52 0.42 
ORIEN -5.29 (-15.04, 4.52) 0.28 0.39 (-1.98, 3.19) 0.74 -5.68 (-15.24, 3.67) 0.23 -1.38 
PDI -0.3 (-3.8, 3.17) 0.89 0.05 (-0.57, 0.78) 0.89 -0.36 (-3.85, 3.06) 0.86 0.42 
MTA1 
EMOCI -6.1 (-13.99, 1.8) 0.12 0.33 (-1.2, 2.49) 0.67 -6.43 (-14.27, 1.39) 0.11 -2.12 
MDI -1.23 (-5.6, 3.17) 0.59 0.32 (-0.5, 1.63) 0.50 -1.55 (-5.88, 2.77) 0.50 -1.93 
ORIEN -5.29 (-15.03, 4.45) 0.29 0.98 (-1.17, 4.25) 0.39 -6.28 (-15.79, 3.21) 0.19 -7.39 
PDI -0.31 (-3.84, 3.21) 0.89 0.47 (-0.44, 1.76) 0.32 -0.78 (-4.15, 2.58) 0.68 0.27 
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CCSER1 
EMOCI -6.05 (-13.97, 2.11) 0.13 3.62 (-0.05, 8.69) 0.05 -9.68 (-18.37, -1.09) 0.03 -49.24 
MDI -1.2 (-5.64, 3.3) 0.61 1.77 (-0.25, 4.47) 0.11 -2.97 (-7.84, 1.84) 0.21 -38.18 
ORIEN -5.22 (-14.98, 4.84) 0.29 4.44 (-0.09, 10.68) 0.06 -9.66 (-20.38, 0.93) 0.07 -54.18 
PDI -0.29 (-3.77, 3.21) 0.89 0.88 (-0.81, 2.86) 0.31 -1.17 (-5.11, 2.73) 0.55 -8.93 
EXT1 
EMOCI -6.07 (-13.88, 1.82) 0.12 -0.71 (-3.32, 1.03) 0.43 -5.36 (-13.2, 2.53) 0.17 7.30 
MDI -1.21 (-5.58, 3.16) 0.59 -0.29 (-1.62, 0.69) 0.56 -0.93 (-5.31, 3.48) 0.71 4.07 
ORIEN -5.25 (-15.03, 4.47) 0.29 -0.36 (-3.17, 1.91) 0.74 -4.9 (-14.64, 4.9) 0.33 2.51 
PDI -0.29 (-3.82, 3.2) 0.89 -0.12 (-1.12, 0.7) 0.76 -0.18 (-3.68, 3.34) 0.95 0.59 
KDM6B 
EMOCI -6.07 (-13.91, 1.82) 0.12 1.4 (-1.66, 5.25) 0.37 -7.47 (-15.93, 0.98) 0.08 -17.38 
MDI -1.22 (-5.59, 3.12) 0.59 0.07 (-1.85, 1.96) 0.94 -1.29 (-6.02, 3.45) 0.59 0.13 
ORIEN -5.25 (-15.01, 4.52) 0.29 0.84 (-3.16, 5.26) 0.67 -6.09 (-16.57, 4.4) 0.25 -8.21 
PDI -0.3 (-3.79, 3.16) 0.89 -0.29 (-1.88, 1.11) 0.67 -0.01 (-3.78, 3.76) 0.97 0.66 
GCNT1 
EMOCI -6.13 (-14.13, 1.73) 0.13 -3.52 (-8.09, -0.36) 0.02 -2.61 (-10.56, 5.4) 0.53 50.98 
MDI -1.23 (-5.59, 3.17) 0.59 -0.63 (-2.62, 0.93) 0.45 -0.59 (-5.26, 4.11) 0.81 12.22 
ORIEN -5.28 (-15.02, 4.37) 0.29 -2.01 (-6.67, 1.39) 0.28 -3.28 (-13.56, 7.08) 0.54 24.48 
PDI -0.3 (-3.82, 3.19) 0.89 0.18 (-1.2, 1.64) 0.77 -0.48 (-4.22, 3.29) 0.81 0.00 
RPS29 
EMOCI -6.07 (-13.87, 1.8) 0.12 -0.76 (-3.5, 1.16) 0.45 -5.31 (-13.29, 2.69) 0.18 8.15 
MDI -1.21 (-5.63, 3.19) 0.59 -0.24 (-1.65, 0.93) 0.68 -0.98 (-5.43, 3.5) 0.69 3.34 
ORIEN -5.23 (-14.98, 4.58) 0.29 -1.32 (-5.02, 1.01) 0.31 -3.91 (-13.68, 5.89) 0.44 13.88 
PDI -0.3 (-3.79, 3.14) 0.89 0 (-1, 1.02) 0.98 -0.3 (-3.86, 3.27) 0.89 0.14 
CHTF18 
EMOCI -6.1 (-13.96, 1.79) 0.12 1.34 (-1.5, 5.06) 0.39 -7.44 (-15.69, 0.91) 0.08 -16.22 
MDI -1.22 (-5.61, 3.15) 0.59 0.49 (-1.14, 2.46) 0.56 -1.71 (-6.32, 2.95) 0.48 -6.66 
ORIEN -5.26 (-14.95, 4.35) 0.29 0.36 (-3.54, 4.56) 0.84 -5.63 (-15.88, 4.75) 0.29 -3.74 
PDI -0.29 (-3.76, 3.19) 0.89 -0.48 (-2.07, 0.84) 0.45 0.19 (-3.47, 3.9) 0.90 3.23 
PRDM16 
EMOCI -6.08 (-13.97, 1.84) 0.12 -0.9 (-4.73, 2.46) 0.58 -5.18 (-13.57, 3.29) 0.23 11.93 
MDI -1.21 (-5.55, 3.17) 0.59 -0.82 (-3.01, 0.99) 0.36 -0.39 (-5.03, 4.3) 0.89 15.82 
ORIEN -5.25 (-15.04, 4.49) 0.29 -0.91 (-5.56, 3.24) 0.65 -4.34 (-14.69, 6.12) 0.42 9.74 
PDI -0.29 (-3.78, 3.21) 0.89 -0.79 (-2.6, 0.64) 0.28 0.5 (-3.19, 4.22) 0.79 8.15 
TAPBP 
EMOCI -6.11 (-13.98, 1.71) 0.12 1.63 (-1.33, 5.56) 0.30 -7.74 (-16, 0.66) 0.07 -20.48 
MDI -1.23 (-5.6, 3.16) 0.60 0.64 (-1.05, 2.71) 0.47 -1.86 (-6.48, 2.83) 0.44 -9.71 
ORIEN -5.28 (-14.98, 4.38) 0.29 1.95 (-1.72, 6.77) 0.32 -7.23 (-17.42, 3.13) 0.16 -20.35 
PDI -0.3 (-3.84, 3.16) 0.89 -0.16 (-1.73, 1.35) 0.81 -0.13 (-3.83, 3.62) 0.97 -0.67 
TRAPPC12 
EMOCI -6.11 (-13.97, 1.79) 0.13 -0.73 (-3.63, 1.41) 0.48 -5.37 (-13.48, 2.54) 0.18 8.05 
MDI -1.21 (-5.6, 3.15) 0.60 0.46 (-0.71, 2.11) 0.44 -1.68 (-6.18, 2.72) 0.47 -5.82 
ORIEN -5.26 (-15.03, 4.54) 0.29 0.39 (-2.44, 3.69) 0.76 -5.65 (-15.69, 4.15) 0.27 -2.86 
PDI -0.3 (-3.78, 3.19) 0.89 0.25 (-0.73, 1.5) 0.60 -0.55 (-4.15, 2.96) 0.79 -0.35 
T3 
RAB5A 
EMOCI -1.39 (-9.94, 7.02) 0.77 -1.63 (-5.18, 0.68) 0.17 0.24 (-7.81, 8.67) 0.94 16.10 
MDI 1.61 (-2.89, 6.07) 0.49 -1.13 (-3.27, 0.41) 0.14 2.74 (-1.39, 7.07) 0.22 -22.37 
ORIEN -0.71 (-11.1, 9.48) 0.91 -1.56 (-5.52, 0.82) 0.23 0.85 (-9, 11.16) 0.85 5.81 
PDI 0.11 (-3.55, 3.73) 0.95 -0.73 (-2.29, 0.29) 0.17 0.84 (-2.62, 4.46) 0.65 1.04 
ICAM5 
EMOCI -1.42 (-9.74, 7.05) 0.76 1.1 (-2.86, 5.45) 0.57 -2.52 (-11.83, 6.79) 0.59 -7.15 
MDI 1.59 (-2.79, 6.09) 0.50 0.4 (-1.71, 2.64) 0.69 1.19 (-3.73, 6.11) 0.63 8.34 
ORIEN -0.74 (-10.79, 9.6) 0.90 0.68 (-4.15, 5.75) 0.77 -1.42 (-12.67, 9.84) 0.81 0.13 
PDI 0.09 (-3.47, 3.76) 0.93 0.39 (-1.34, 2.24) 0.65 -0.29 (-4.31, 3.73) 0.91 4.22 
GORASP2 EMOCI -1.45 (-9.77, 6.94) 0.76 0.28 (-1.37, 2.28) 0.73 -1.73 (-9.84, 6.48) 0.70 0.15 
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MDI 1.58 (-2.82, 6.05) 0.51 0.09 (-0.69, 1) 0.83 1.49 (-2.82, 5.86) 0.53 0.97 
ORIEN -0.77 (-10.79, 9.3) 0.90 0.35 (-1.67, 2.79) 0.73 -1.12 (-10.9, 8.77) 0.83 0.78 
PDI 0.08 (-3.52, 3.66) 0.95 0.23 (-0.87, 1.43) 0.66 -0.15 (-3.56, 3.29) 0.96 5.43 
TRAPPC6A 
EMOCI -1.42 (-9.72, 7.05) 0.76 1.34 (-3.62, 6.65) 0.59 -2.76 (-12.7, 7.09) 0.58 -8.58 
MDI 1.6 (-2.94, 6.02) 0.50 2.08 (-0.36, 5.06) 0.12 -0.48 (-5.62, 4.61) 0.87 57.95 
ORIEN -0.72 (-10.87, 9.38) 0.92 3 (-2.76, 9.58) 0.31 -3.73 (-15.64, 8.07) 0.53 -9.51 
PDI 0.08 (-3.52, 3.73) 0.94 -0.73 (-3.06, 1.37) 0.51 0.82 (-3.47, 5.06) 0.70 -5.46 
VPS11 
EMOCI -1.46 (-9.73, 6.88) 0.75 2.43 (-0.16, 6.38) 0.08 -3.89 (-12.22, 4.6) 0.37 -18.98 
MDI 1.57 (-2.79, 5.96) 0.51 1.04 (-0.27, 3.04) 0.13 0.53 (-3.92, 5.07) 0.81 25.43 
ORIEN -0.78 (-10.73, 9.26) 0.90 2.26 (-0.68, 6.8) 0.16 -3.03 (-13.22, 7.36) 0.58 -5.38 
PDI 0.09 (-3.51, 3.72) 0.94 0.37 (-0.75, 1.83) 0.52 -0.29 (-3.99, 3.49) 0.90 2.06 
MTA1 
EMOCI -1.43 (-9.65, 7.06) 0.76 0.07 (-1.89, 2.18) 0.92 -1.51 (-9.66, 7.04) 0.74 0.17 
MDI 1.58 (-2.84, 5.99) 0.51 0.27 (-0.61, 1.58) 0.55 1.31 (-2.97, 5.8) 0.58 3.61 
ORIEN -0.77 (-10.87, 9.3) 0.91 0.74 (-1.22, 3.85) 0.49 -1.51 (-11.27, 8.72) 0.79 0.10 
PDI 0.07 (-3.5, 3.64) 0.95 0.56 (-0.4, 1.94) 0.26 -0.49 (-3.88, 3.07) 0.81 5.60 
CCSER1 
EMOCI -1.41 (-9.76, 6.99) 0.76 1.2 (-2.04, 5.03) 0.45 -2.62 (-11.61, 6.51) 0.57 -7.53 
MDI 1.59 (-2.85, 6.03) 0.50 0.73 (-0.97, 2.78) 0.38 0.86 (-3.88, 5.67) 0.71 16.53 
ORIEN -0.73 (-10.91, 9.36) 0.92 1.74 (-2.15, 6.48) 0.36 -2.47 (-13.29, 8.51) 0.65 -3.49 
PDI 0.1 (-3.51, 3.72) 0.93 0.51 (-0.89, 2.16) 0.45 -0.41 (-4.29, 3.52) 0.85 3.39 
EXT1 
EMOCI -1.4 (-9.97, 7.1) 0.75 0.68 (-1.16, 3.35) 0.50 -2.08 (-10.33, 6.37) 0.64 -0.16 
MDI 1.59 (-2.85, 6.01) 0.50 0.24 (-0.61, 1.44) 0.60 1.36 (-3.05, 5.87) 0.56 3.92 
ORIEN -0.73 (-10.81, 9.43) 0.92 0.41 (-1.41, 2.97) 0.67 -1.14 (-11.23, 9.2) 0.84 0.22 
PDI 0.1 (-3.51, 3.72) 0.93 0.15 (-0.51, 1.08) 0.66 -0.06 (-3.67, 3.64) 1.00 0.93 
KDM6B 
EMOCI -1.43 (-9.77, 7.1) 0.76 -0.11 (-3.83, 3.46) 0.94 -1.32 (-10.51, 7.81) 0.78 1.29 
MDI 1.58 (-2.83, 6.04) 0.51 -0.54 (-2.62, 1.23) 0.55 2.12 (-2.72, 6.93) 0.37 -10.70 
ORIEN -0.75 (-10.78, 9.53) 0.91 -0.85 (-5.47, 3.26) 0.67 0.09 (-10.98, 11.08) 0.95 0.61 
PDI 0.09 (-3.53, 3.75) 0.93 -0.41 (-2.09, 1.05) 0.59 0.49 (-3.46, 4.42) 0.79 -2.63 
GCNT1 
EMOCI -1.47 (-9.76, 6.87) 0.74 -1.88 (-5.89, 1.1) 0.23 0.41 (-7.42, 8.47) 0.89 26.02 
MDI 1.58 (-2.82, 6) 0.51 -0.41 (-1.83, 0.44) 0.43 1.98 (-2.42, 6.51) 0.40 -4.43 
ORIEN -0.77 (-10.72, 9.29) 0.90 -1.18 (-4.64, 1.01) 0.33 0.4 (-9.58, 10.67) 0.91 4.15 
PDI 0.09 (-3.51, 3.78) 0.93 0.08 (-0.72, 1) 0.84 0.01 (-3.62, 3.75) 0.97 0.77 
RPS29 
EMOCI -1.4 (-9.99, 7.1) 0.75 -0.93 (-3.88, 0.86) 0.35 -0.47 (-8.62, 7.96) 0.93 7.12 
MDI 1.59 (-2.87, 6.01) 0.50 -0.32 (-1.7, 0.57) 0.50 1.92 (-2.43, 6.41) 0.41 -3.36 
ORIEN -0.71 (-11.09, 9.47) 0.91 -1.34 (-5.12, 1.02) 0.29 0.63 (-9.13, 10.73) 0.88 4.91 
PDI 0.09 (-3.47, 3.78) 0.93 -0.07 (-1, 0.74) 0.87 0.16 (-3.41, 3.86) 0.91 -0.08 
CHTF18 
EMOCI -1.43 (-9.72, 7.06) 0.76 0.04 (-2.32, 2.46) 0.96 -1.47 (-9.89, 7.28) 0.75 0.14 
MDI 1.59 (-2.79, 6.09) 0.51 -0.03 (-1.29, 1.22) 0.96 1.61 (-2.83, 6.23) 0.50 -0.14 
ORIEN -0.74 (-10.75, 9.54) 0.90 -0.48 (-3.65, 2.23) 0.71 -0.26 (-10.4, 10.28) 0.99 0.83 
PDI 0.1 (-3.54, 3.7) 0.94 -0.45 (-1.79, 0.42) 0.34 0.55 (-3.04, 4.28) 0.76 -0.54 
PRDM16 
EMOCI -1.4 (-9.99, 7.06) 0.75 -1.03 (-4.07, 0.76) 0.32 -0.38 (-8.56, 8.14) 0.95 7.66 
MDI 1.6 (-2.94, 6.08) 0.50 -0.55 (-2.16, 0.4) 0.32 2.15 (-2.18, 6.64) 0.36 -8.15 
ORIEN -0.72 (-10.9, 9.33) 0.92 -1.05 (-4.52, 1.12) 0.39 0.33 (-9.59, 10.66) 0.93 2.51 
PDI 0.1 (-3.54, 3.69) 0.94 -0.37 (-1.61, 0.4) 0.39 0.47 (-3.08, 4.17) 0.79 0.08 
TAPBP 
EMOCI -1.43 (-9.75, 7.06) 0.76 0.17 (-2.34, 2.9) 0.88 -1.6 (-10.1, 7.16) 0.73 -0.54 
MDI 1.58 (-2.78, 6.07) 0.51 0.01 (-1.35, 1.41) 0.97 1.57 (-2.92, 6.2) 0.51 0.37 
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ORIEN -0.75 (-10.8, 9.52) 0.90 0.42 (-2.53, 3.8) 0.77 -1.17 (-11.42, 9.39) 0.85 0.12 
PDI 0.1 (-3.5, 3.74) 0.93 -0.3 (-1.61, 0.72) 0.54 0.4 (-3.25, 4.17) 0.82 -1.09 
TRAPPC12 
EMOCI -1.45 (-9.82, 6.87) 0.75 -0.36 (-2.53, 1.1) 0.66 -1.09 (-9.6, 7.45) 0.81 1.43 
MDI 1.59 (-2.8, 6.07) 0.50 0.16 (-0.65, 1.26) 0.71 1.43 (-3.07, 5.94) 0.53 2.31 
ORIEN -0.75 (-10.71, 9.47) 0.90 0.18 (-1.66, 2.45) 0.83 -0.93 (-11.24, 9.41) 0.87 0.38 





Chapter 5 Discussion 
Dissertation Objectives 
Lead (Pb) exposure is a persistent problem in the United States and around the 
world. Pregnant women and their developing fetuses are particularly vulnerable to Pb 
because both past and present exposures can affect gestational growth and 
development. The health impacts of prenatal Pb exposure can be framed with the 
Developmental Origins of Health and Disease (DOHaD) hypothesis 1. Accumulating 
evidence for DOHaD includes potential mechanisms such as epigenetic reprogramming 
via DNA methylation (5mC) and, less studied, hydroxymethylation (5hmC), linking 
developmental exposures to adverse childhood and adulthood outcomes. In an effort to 
address these questions, in this dissertation I aimed to determine if perinatal Pb 
exposure alters DNA 5mC and 5hmC levels, assessed through both whole-genome and 
candidate gene methods, and determine if DNA methylation mediates the relationship 
between prenatal Pb exposure and adverse neurodevelopment (Figure 1.2).  
For the entire dissertation, I utilized a longitudinal human birth cohort with known 
perinatal exposures to Pb, biological samples at birth and into adolescence, and 
measures of infant neurodevelopment: Early Life Exposure in Mexico to Environmental 
Toxicants (ELEMENT) 2. In Aim 1, I tested whether early-life exposure to Pb alters the 
epigenome at birth in umbilical cord blood (UCB), as has been suggested in previous 
human, animal model, and in vitro studies 3-7, but expanded to include the independent 
effects of trimester-specific exposures and cumulative exposure over the gestational 
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period. In the Aim 2, I evaluated gene-specific DNA 5mC and 5hmC in adolescent 
whole blood from the same cohort to determine whether the association of gestational 
Pb exposure and epigenetics persists into adolescence. I expanded from previous 
literature to determine if 5hmC is associated with the exposure. In Aim 3, applying the 
UCB DNA methylation from the first aim, I analyzed whether DNA methylation at birth 
would mediate the association between trimester-specific Pb exposure and 
neurodevelopmental outcomes, in line with the DOHaD paradigm. 
Summary of research findings  
 The findings of this research (Figure 5.1) provide insights into epigenetic 
responses following developmental Pb exposure, indicating surprising complexities that 
should be taken into account in interpreting human and animal studies. In Aim 1 
(Chapter 2), I found that prenatal Pb exposure was associated with altered epigenetic 
patterns at birth and the alterations were trimester-specific. Epigenome-wide analyses 
identified three differentially methylation positions (DMP (i.e., CpG site)) that mapped to 
RAB5A, EXT1, and a non-genic region and one differentially methylated region (DMR) 
within PDGFRL associated with first trimester (T1) BLLs, one DMP and one DMR with 
third trimester (T3) BLLs that were both within an intergenic region, and two DMPs and 
one DMR with tibia bone Pb, a measure of cumulative exposure across the entire 
gestational period, which mapped to LRFN1, a non-genic site, and TRHR, respectively. 
The number of associated DMPs were quite small, indicating that at least with the 
sample size present and the range of BLLs, there wasn’t any observed extensive DNA 
methylation response. Further studies are needed to determine if Pb differentially 
modifies the expression of genes regulated by these DMPs and DMRs as RNA was not 
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available in ELEMENT infant cord blood. Additionally, performing an additional 
experiment encompassing a larger sample size and large variability in Pb exposure 
could enable detection of more extensive changes. Pathway analysis identified multiple 
gene pathways enriched for differential methylation with several pathways overlapping 
between T1 and T2 including nodal signaling, neurological system processes, and 
neurotransmitter activity-related genes. This suggests that trimester-specific prenatal Pb 
exposure may modify DNA methylation profiles at birth, and this should be considered 
as one potential mechanism underlying Pb’s neurotoxic effects during development. 
 In Aim 2 (Chapter 3), I identified associations of sex-specific and trimester-
specific prenatal Pb exposure with DNA 5mC and 5hmC levels, independently, at 
multiple cytosine-phosphate-guanine (CpG) sites within gene regions previously 
associated with prenatal Pb exposure in human whole blood within the same cohort as 
Aim 1 but at the adolescent-age timepoint (11-17 years old). I build upon Aim 1 by 
investigating genes with identified alterations associated with T1 BLLs within that aim, 
RAB5A, NINJ2, HCN2, and TPPP, but included a later timepoint and distinguished 
between 5mC and 5hmC. I provided evidence for variable 5hmC in human whole blood 
with 12.5% of the study participants displaying 5hmC levels measuring above 15% in at 
least one CpG site measured. I also show that prenatal Pb exposure’s alterations of 
gene-specific 5mC and 5hmC levels in blood are stable from birth into adolescence, 
which is discussed in more detail in the next section. To strengthen these findings, I 
quantified gene expression in a subset of individuals and showed that increased 5mC 
was negatively correlated with NINJ2 expression, whereas increased 5hmC was 
positively correlated, which follows previous research 8, 9. Overall, this provides 
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evidence to consider 5hmC as a regulatory response mechanism to environmental 
exposure and should be explored further. Finally, I detected significant sex-specific 
associations. I detected more statistically significant Pb-induced 5mC and 5hmC 
changes among females as compared to males. 
 In Aim 3 (Chapter 4), I elucidated a potential mechanism linking developmental 
Pb exposure to early-life adverse neurodevelopmental outcomes. I performed a 
pairwise mediation analysis to identify DNA methylation’s mediating effects on the 
association between exposure and outcome. I provided evidence that epigenetics may 
contribute as a potential biological mechanism underlying Pb’s adverse health effects 
on neurodevelopment, specifically at 24-months of age in both a mediating and 
suppressive manner. Little evidence was shown for significant reductions in 
neurodevelopmental scores by Pb exposure at the 12-month timepoint. Our pilot study 
builds upon previous research by considering DNA methylation at functionally-relevant 
genes as a potential mechanism underlying Pb’s adverse effects on neurodevelopment.  
 This dissertation research corroborates previous human, animal, and in vivo 
literature demonstrating associations between prenatal Pb exposure and epigenetics 3-7, 
and builds on it by incorporating multiple biomarkers of exposure, utilizing a longitudinal 
study design, two epigenetic marks (5mC and 5hmC), as well as investigating the 
mediating effect of the epigenome on neurodevelopmental outcomes at two infancy 
timepoints. Additional studies, either animal or in vitro, are needed to characterize the 
underlying biology to explain these observations. 
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Synthesis of evidence for proposed mechanism 
In the epigenome-wide analysis performed in Aim 1, statistically significant DMPs 
identified were mostly hypomethylated with a couple being hypermethylated, which 
follows the proposed model that Pb inhibits DNMTs from binding and reduces methyl 
marks (Figure 1.1). However, the statistically significant DMRs were hypermethylated, 
which may indicate that cells are responding to the exposure by silencing gene 
promotors or enhancers of certain genes. Studies have provided evidence for both 
increases and decreases in methylation at specific DNA sequences serving as 
biomarkers for a variety of diseases, including neurodevelopmental 10-16. Globally, the 
effect estimates between Pb and DNA methylation were mostly hypermethylated for the 
blood Pb measures (T1: 67.7% sites positively associated with Pb; T2: 66.3%; T3: 
61.4%), but mostly hypomethylated for the patella and tibia Pb measures, 54.7% and 
63.7%, respectively. These findings were similar to a study performed in the US within 
the Early Autism Risk Longitudinal Investigation (EARLI) cohort (n=97), which found 
global pregnancy DNA hypermethylation (~55.8% of CpG sites tested) and as well as 
site-specific hypermethylation associated with T1 and T2 BLLs (mean: 0.4 μg/dL, lower 
than our current study) 17. The significant site-specific CpG’s were related to nervous 
system development and calcium ion binding, similar to our study which also had 
statistically significant genes annotate back to pathways involved in various neurological 
and neurodevelopmental functions. In contrast, a study utilizing newborn dried blood 
spots from the Michigan-based Healthy Families Project (n=96) identified mostly 
hypomethylation with increase Pb exposures (mean: 0.78 µg/dL) 18. Overall, there 
seems to be evidence for some hypomethylation and hypermethylation with Pb, 
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depending on the genes and/or gene regions assessed, showing that there isn’t clear 
evidence yet for Pb’s impact on DNA methylation (Table 1.1). Further studies are 
needed to strengthen previous findings. In this dissertation, these genes were 
investigated further in Aims 2 and 3. RAB5A plays a role in localizing early endosomes 
and intercellular membrane trafficking and fusion, and perturbations around the 
endosomal dynamics may underlie neuronal dysfunction and degeneration in various 
neurodegenerative diseases 19. The primary role of EXT1 is heparan sulfate 
biosynthesis, which regulates multiple biological processes including cell proliferation, 
growth factor signaling, and mammalian neuronal development 20-23. LRFN1 promotes 
neurite outgrowth and synapse formation in hippocampal neurons and has a role in the 
developing nervous system with involvement in regulating and conserving excitatory 
synapses 24-26. TRHR activates the phosphatidylinositol-calcium-protein kinase C 
transduction pathway, which signals synthesis, secretion, and bioactivity of the thyroid 
stimulating hormone in the pituitary gland 27, 28. PDGFRL does not have a known 
function in development but it does encode a tumor suppressor that inhibits the growth 
of colorectal cancer cells 29. These gene-specific findings suggest that epigenetic 
mechanisms are being modified by prenatal Pb during critical developmental periods 
and DNA methylation should continue to be explored as a potential mechanism 
underlying Pb’s neurodevelopmental effects. In Aims 2 and 3, I also investigated genes 
that were not significantly associated with prenatal Pb in Aim 1 but had log fold changes 
in methylation per unit increase in prenatal Pb at or above 5% or were involved in 
various neurological functions; Aim 2: TPPP, NINJ2, and HCN2; Aim 3: KDM6B, 
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GCNT1, RPS29, CHTF18, PRDM16, TAPBP, TRAPPC12, ICAM5, GORASP2, 
TRAPPC6A, VPS11, MTA1, and CCSER1. They will be discussed below. 
 In the targeted gene sequencing analysis within Aim 2, all three trimester BLLs 
were associated with hypermethylation within HCN2, a gene known to regulate 
dopamine neuronal activity 30. All three trimester BLLs, as well as patella bone Pb, were 
associated with hyper-hydroxymethylation within NINJ2, a transmembrane protein that 
mediates cell-to-cell and cell-to-extracellular matrix interactions during development, 
differentiation, and regeneration of the nervous system by promoting neurite growth 31. 
In contrast, T3 BLLs were associated with hypomethylation, but this opposing direction 
is expected because studies have shown that as 5mC levels decrease, 5hmC would 
subsequently increase 32. Of the significant findings among males, prenatal exposure 
was associated with hypermethylation in TPPP in adolescence, which plays a role in the 
integrity of the microtubule network as a potential hallmark of synucleinopathies 
(neurodegenerative diseases characterized by abnormal accumulation of TPPP/p25 
and alpha-synuclein) 33. Further, there is evidence that sex can influence the severity of 
Pb neurotoxicity 6, 34, 35. Although, based on magnitude, direction and CI overlap of the 
associations between Pb and 5mC or 5hmC in sex-stratified analyses in Aim 2, we 
cannot state with certainty that these effects are truly sex-specific. For example, T2 
BLLs were positively associated with NINJ2 5hmC in females (β=0.48 (95% CI: 0.10, 
0.86)), while the association was close to null for males (β=0.07 (95% CI: –0.20, 0.34)), 
and the associations between 5mC with T1 BLLs and patella Pb were negative for 
females and remained close to null for males, but confidence intervals overlapped. 
These data are inconsistent with previous studies which showed Pb-associated DNA 
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methylation changes identified sex-specific effects, mostly in females 6, 36. Yet, 
collectively this dissertation and other studies suggest that sex, as well as exposure 
timing and exposure dose, may influence an individual’s susceptibility to the effects of 
Pb.  
 After completing Aim 2, a question arose on whether the associations between 
Pb and DNA methylation that I identified at birth (Aim 1) were consistent in direction and 
magnitude in adolescence (Aim 2). Since Aim 1 and Aim 2 were conducted with 
different methylation quantification platforms, I decided to utilize previously quantified 
adolescent-age DNA methylation genome-wide profiles from the same platform as Aim 
1, MethylationEPIC array, to determine if the changes at birth persisted into 
adolescence. Of the samples available with data at both time points, we were able to 
compare 72 matched UCB and adolescent whole blood samples. First, I pulled all the 
previously normalized and batch corrected beta values (for Methods, see Chapter 2: 
Methods – Epigenetic Analysis) for each sample from the CpGs identified in Aim 1 and 
Aim 2 as statistically association with first trimester BLLs or effect estimates greater 
than |5%| when analyzing first trimester BLLs and are linked to neurodevelopment of 
this dissertation (cg17138393, cg00984923, cg25353752, cg26371957, cg19692784, 
cg14911689, cg05578102, cg26654770, cg01201512, cg06657917, cg03390844, 
cg01328348, cg00002033, cg03463208). Beta values represent proportion methylated. 
We then plotted the beta values between the two timepoints for the CpG sites listed 
above that mapped back to genes (Figure 5.2 and 5.3). Not to my surprise, some 
genes contain consistent levels of methylation between birth and adolescence while 
others do not 37, 38. DNA methylation regulates expression and not all genes need to be 
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expressed at all points in development. For example, LRFN1 has low methylation at 
birth, meaning the gene is likely expressed, but high methylation later in life (Figure 5.2, 
top left). This is likely due to LRFN1’s role in neurite growth while the nervous system is 
developing. This function isn’t necessarily needed later in life. These predictable 
changes in DNA methylation are termed ‘age-related methylation,’ and these changes 
have important implications that may underlie later-life disease development through 
transcriptional control and expression 39-41. 
 Next, I pulled all effect estimates from the linear regression models previously 
performed (for Methods, see Chapter 2: Methods – Statistical analyses) from the 
matched UCB and adolescent-aged samples. I ran Pearson’s product-moment 
correlation to quantify the correlation of the relationship between matched effect 
estimates of the association between prenatal Pb and DNA methylation at birth and in 
adolescence. Globally (at all >700,000 CpG sites), the effect estimates were slightly 
correlated (T1: R=0.29; T2: R=0.15; T3: R=0.12; Patella: R=0.13; Tibia: R=0.12). 
Although, when I looked at the fourteen CpG sites of most interest related to Aim 1 and 
Aim 2, I showed that prenatal Pb’s effect on DNA methylation is highly correlated from 
birth into adolescence for each biomarker of exposure except tibia (Figure 5.4). 
Interestingly, T1 BLLs effect estimates had the strongest correlation (R=0.96) from birth 
to adolescence and the association among all CpG’s from birth to adolescence was 
stable, potentially suggesting that perturbations occurring during the first trimester are 
reprogramming the epigenome and these changes are remaining through adolescence, 
at least at these 15 CpG sites. Thus, I provide evidence that Pb’s toxicoepigenomic 
effects are stable at some but not all CpG sites. 
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Finally, the mediation analysis provided evidence that gene-specific DNA 
methylation at birth within several genes mediated or suppressed the association 
between T2 measures of prenatal Pb and neurodevelopmental measures at 24-months 
of age; the strongest evidence was with CCSER1 methylation suppressing the 
association and GCNT1 methylation mediating with both showing percent 
suppressed/mediated around 50% within the model. Although CCSER1 is frequently 
identified in human cancers, it has recently been associated with attention deficit 
hyperactivity disorder after expression was discovered in the cerebellum 42, 43. GCNT1 
acts like a cell surface marker indicating whether a T-cell has received Notch signaling, 
which stimulates proliferation during neurogenesis and plays a key role in regulation in 
embryonic development 44-46. Mediating effects were also identified with VPS11, which 
alterations have been hypothesized in contributing to progressive developmental delays 
by attenuating the degradation of plasma membrane receptors 47. This pilot study 
provides preliminary evidence into how epigenetic reprogramming events relate to 
specific biological pathways influencing fetal neurodevelopment and builds upon 
previous research on prenatal Pb and its association with decreased childhood IQ and 
neurobehavioral problems. 
Although epigenomic changes in early gestation would be expected to propagate 
across all tissues, it is still important to consider tissue-specificity when conducting 
differential methylation studies. To fully synthesize the proposed mechanisms, I decided 
to utilize a renowned blood-brain epigenetic database to compare our blood results with 
brain epigenomic profiles 48. From among the 15 CpG sites I studied extensively in this 
dissertation, 8 were include in the database. Of these 8 CpG sites, 5 were moderately to 
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highly correlated between blood and the prefrontal cortex (cg14911689: r=0.88, 
p=8.81e-25; cg26654770: r=0.88, p=1.93e-24; cg01201512: r=0.86, p=4.7e-23; 
cg06657917: r=0.72, p=5.84e-13; cg26371957: r=0.44, p=9.96e-5), entorhinal cortex 
(cg14911689: r=0.84, p=1.39e-19; cg26654770: r=0.85, p=1.23e-20; cg01201512: 
r=0.82, p=1.74e-18; cg06657917: r=0.79, p=5.29e-16; cg26371957: r=0.48, p=2.22e-5), 
superior temporal gyrus (cg14911689: r=0.89, p=6.54e-27; cg26654770: r=0.90, 
p=1.46e-27; cg01201512: 0.87, p=2.0e-24; cg06657917: r=0.80, p=5.93e-18; 
cg26371957: r=0.38, p=0.66e-3), and cerebellum (cg14911689: r=0.78, p=6.78e-16; 
cg26654770: r=0.70, p=1.62e-11; cg01201512: r=0.52, p=4.21e-6; cg26371957 (r=0.15, 
p=0.21) and cg06657917 (r=0.038, p=0.75)  were not correlated with the cerebellum) 
brain regions. DNA methylation in umbilical cord blood of 3 CpG-sites were not 
correlated with any brain regions (cg25353752, cg00002033, cg03463208). This 
database is a great first resource to see which sites correlate between brain and blood, 
but this tool does not account for exposures and the samples are from individuals over 
50 years of age. Since 5 of the 8 CpG sites were correlated, this suggests that some 
biomarkers in blood are possible for certain genes. Brain samples should be the primary 
tissue of interest to better understand the underlying pathological processes behind 
prenatal Pb exposure and neurodevelopmental molecular processes. 
Significance of findings 
 Despite multiple public health initiatives aimed at reducing Pb exposure, such as 
the removal of Pb from gasoline, paint and other products, it remains a major concern in 
the United States (US) and around the world. In fact, it has been estimated that one-
third of all US homes have Pb-based paint with a high percentage of these homes being 
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rental properties 49. Further, there is growing fear about exposure risk due to the aging 
infrastructure, especially after a highly publicized contamination from failed Pb pipes in 
Flint, MI, which spiked testing that revealed other US cities with similar problems 50, 51. 
In middle- and low-income countries, additional contamination sources include Pb-
glazed ceramics and Pb-acid battery production and recycling 52.  These are just some 
sources of unwanted environmental Pb exposure, which are especially dangerous for 
pregnant women, children, and other susceptible populations. While research continues 
to suggest that there is no safe level of Pb, studies are still conducted to understand the 
impacts of low-level Pb exposure, which is considered to be <5 μg/dL in blood, mainly 
focusing on early stages of development. It has been known for centuries that Pb has 
adverse neurological effects, but current research does not fully answer the question 
around the epigenetic mechanisms that underlie Pb-induced damaging impacts on 
cognitive development. There is a growing body of evidence that environmental 
exposures play a role in cognition. As such, biomarkers of the developmental 
environment, including the epigenome, have potential to provide valuable information 
about cognitive delays. 
 The evidence for DOHaD, which states that environmental insults ranging from 
nutrient starvation to active exposure to toxicants cause damages to the developing 
body which can manifest once the organism is older, is quite strong for some exposures 
1. Thus, it is plausible that DNA methylation or other epigenetic changes is a 
mechanism by which early life Pb exposure leaves a stable mark that modifies 
biological function manifesting in adverse outcomes, including neurological outcomes, 
later in life. In an effort to better understand the mechanisms of action for developmental 
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Pb exposure, recent studies have investigated the epigenetic effects, showing that 
developmental Pb can alter genome-wide, imprinted genes, and gene promotor-specific 
methylation in human models 4, 6, 53. However, these studies failed to include biomarkers 
of both trimester-specific and cumulative exposure (i.e., maternal bone Pb). Bone Pb is 
an excellent proxy for long-term cumulative exposure over the gestational period 54, 55. 
Although I did not identify similar associations between the two bone Pb measures with 
DNA methylation and hydroxymethylation, this is anticipated. Patella stored Pb has a 
half-life ranging from months to years 55, whereas Pb in tibia has a residence time of 25-
30 years 54. While both serve as proxies for gestational Pb exposure, the relationship 
between maternal bone Pb and fetal exposure dose throughout pregnancy is influenced 
by the differences in half-life and bioavailability (i.e., following bone turnover). Here, I 
followed-up on previous studies, providing preliminary evidence that gene-specific DNA 
methylation changes occur, with specific effects taking place during particular 
timepoints. Further, DNA methylation changes at birth persisted at some but not all 
genes into adolescence. Given the precise biological processes that occur during fetal 
development, modified regulations of neurological-related genes have the potential to 
adversely impact cognitive health. As such, our results show Pb-related differential 
methylation may represent an epigenetic mechanism by which Pb impacts cognition. 
 While previous human and animal exposure studies have provided insight into 
epigenome-environment interactions, they have primarily used the standard bisulfite 
sequencing methods, which collectively measures both 5mC and 5hmC. These two 
epigenetic marks typically have opposing associations with gene transcription and 
expression 56. Failing to distinguish between the two independent marks might result in 
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inaccurate conclusions. Previous work has demonstrated that 5hmC is tissue-specific 
with highest levels present in the brain and low levels in whole blood 57. Here, I 
extended our study to include 5mC, 5hmC, and total methylation (5mC+5hmC) to better 
estimate which exact epigenetic mark(s) Pb may modify. Not only was I able to detect 
5hmC in human whole blood, but I also provided evidence for Pb-induced gene-specific 
and sex-specific changes with each epigenetic mark. However, I do not provide 
evidence for biological mechanisms that might explain the epigenetic changes that are 
occurring. Additional studies are needed to expand beyond our findings to include more 
diverse study populations, different tissue types for epigenetic analysis, use of animal 
studies to control confounders, and larger sample sizes with adequate statistical power 
in order to make accurate conclusions around the conclusions present.  
Impact and innovation 
 This is the first study to investigate the mediating effects of DNA methylation on 
the association between prenatal Pb exposure and neurodevelopment outcomes in 
infancy. Historically, studies have either looked at Pb’s effects on DNA methylation or 
Pb’s effects on neurodevelopmental outcomes. Here, I combined the two in order to 
paint a better picture of the biological mechanisms. Our findings suggest that the impact 
of developmental exposures to Pb on neurodevelopmental measures, especially 
emotional scores, may be both mediated and suppressed by DNA methylation, 
depending on the gene. This may provide evidence for dynamic biological processes, 
meaning that epigenetic regulation of many genes could be impacted by Pb’s toxic 
effects, but depending on the function of the gene and the direction and magnitude of 
the effect, these changes could contribute to Pb toxicity, protect against some of Pb’s 
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effects, or have no meaningful biological effect. Therefore, this work suggests that more 
research investigating the health impacts of developmental Pb is needed to better 
understand the role of epigenomics in Pb’s long-term effects.  
The analysis of multiple biomarkers of prenatal Pb exposure allowed us to 
narrow-down exposure timing from the broad ‘prenatal’ period to ‘trimester-specific,’ for 
which future research could illuminate on prevention and intervention methods in a 
more time-specific manner. I expected to see more significant results associated with 
first trimester exposures because neurogenesis occurs at an astonishing rate followed 
by neuronal proliferation and migration during that time 58, 59. Although other important 
processes, such as dendrite formation, synapses formation and circuit organization, 
neuronal differentiation, axonal elongation, and myelination, occurring during the later 
gestational period 60-65. The longitudinal aspect of our study allowed us to characterize 
the epigenome’s ability to maintain stability from birth into adolescence and further 
estimate more accurate exposure-outcome relationships by developmental timepoint. 
The quantification of two epigenetic marks, 5mC and 5hmC, allowed us to identify 
whether environmental exposures alter 5mC, 5hmC, or both. Most current methods 
collectively measure both without distinguishing between the two; but recent studies 
suggest that the functional role of 5hmC is distinct from 5mC 66. I provide evidence for 
this widely-debated mark, 5hmC, having its own distinct role into the mechanisms 
behind Pb-induced epigenetic alternations. Additional studies are needed to differentiate 
the two marks and determine if previous findings combining the two epigenetic marks 
are making accurate conclusions based on their combined method (5mC+5hmC) 
outcomes.   
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 This study is also the first to examine the independent associations of 5mC and 
5hmC with prenatal Pb exposure. Previous work has shown that gene transcription and 
expression differs between these two epigenetic marks 56. For example, increases in 
5mC results in decreases in expression, whereas increases in 5hmC results in 
increases in expression. Our results showed this opposing trend within NINJ2. When 
assessing prenatal Pb exposure, as 5mC increased, 5hmC subsequently decreased. 
Further, this is one of a few studies to isolate 5hmC in human whole blood and the only 
study to compare levels of 5hmC to prenatal Pb exposure in humans. This work helps to 
interpret results reported in past epidemiological studies and informs the planning of 
future studies because it shows that the standard bisulfite sequencing methods 
(combines 5mC+5hmC) may not provide accurate conclusions regarding the distinct 
epigenetic marks. It is also informative to future studies, providing insight into more 
rigorous data collection when measuring DNA methylation and offering a novel method 
for quantitative 5hmC measures in human whole blood. 
Limitations 
 Despite the innovative and novel aspects of this study, there are also aspects of 
this dissertation that limit the ability to conclusively prove underlying biological 
mechanisms. The results of this study were associative in nature as opposed to causal 
but helped us identify genes of interest for further exploration. In terms of other 
limitations, I was unable to utilize positive hydroxymethylation controls for Aim 2 
pyrosequencing. There are currently no commercially available hydroxymethylation 
controls for the oxBS pyrosequencing method. Although, I did run eight oxBS samples 
in triplicate within two gene regions to measure the coefficient of variation (<10%) for 
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the 5mC measures and utilized human methylated (0%) and unmethylated (100%) 
controls (I.e., 5mC+5hmC) in order to account for this limitation. Given how recently 
5hmC has emerged as a topic of research interest, precise differences in how 
gestational Pb exposure alters 5hmC epigenome-wide in both mice and humans 
remains unclear. Our research team has previously thought of this and is currently 
studying this in mice. 
Additionally, the low number of human samples in all aims limited statistical 
power. Specifically, the small sample sizes within Aim 1 and Aim 3 prevented us from 
performing sex-specific analyses. The small number of families that had UCB collected 
originally and loss to follow-up played a major role in reducing the sample size. Also, the 
environment of the recruited human cohort was not controlled which is an inherent 
limitation in any epidemiology study, meaning that background exposure to various 
environmental factors may be confounding the reported results. Further, the tissue 
collected, blood, is a limitation given our primary tissue of interest, brain. Although, 
given our first trimester results, blood could potentially be a surrogate tissue for target 
tissues following early-life epigenetic perturbations. However, more research is needed 
to confirm this. Human brain samples are inherently rare and can only be obtained post-
mortem making longitudinal studies impossible. Therefore, I recommend future studies 
to incorporate larger sample sizes in order to increase statistical power and account for 
environmental variability and population heterogeneity, as well as animal models with 
controlled environments, so we may more robustly identify key genes and molecular 
pathways linking Pb exposure to outcomes.  
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Recommendations for future research 
 This research attempte to integrate data from multiple timepoints within a 
longitudinal birth cohort to investigate the contribution of toxicant-mediated DNA 
methylation perturbations to adverse neurodevelopmental outcomes in early-life. Even 
though I found a number of significant results, interpretation of these data is limited by 
the aforementioned limitations, but these data are suggestive of the role of DNA 
methylation and hydroxymethylation in Pb toxicity and may help inform the design of 
additional studies. Replication of these findings in diverse human cohorts is needed to 
fully understand the risks of development Pb exposures.  
The targeted epigenomic analysis in Aim 2 provided valuable information 
regarding the distinct roles of 5mC and 5hmC, even though it only covered four gene-
regions out of the entire genome. Bisulfite conversion, used in Aim 1 and 3 which is the 
most widely used method to measure DNA methylation, does not distinguish between 
5mC and 5hmC. In future studies, DNA hydroxymethylation analyses, using 
technologies such as antibody pull-down methods (hydroxymethylation DNA 
immunoprecipitation sequencing (hMeDIP-seq)), oxidative bisulfite sample conversion 
(paired with MethylationEPIC beadarray) or other methods to distinguish the two 
epigenomic marks, would provide insight into global, epigenome-wide 
hydroxymethylation, and targeted changes. Given the novelty of the findings in Aim 2, 
this epigenetic mark needs to be quantified in future environmental epigenetic studies in 
order to provide the most accurate insights. 
Since it is difficult to control for all potential confounding effects within human 
longitudinal cohorts, animal model studies of Pb exposure are needed. Murine studies 
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have careful control measures, where exposures represent the only difference between 
two groups of mice (exposed versus unexposed). In addition, murine studies allow 
research to define the exposure period, meaning when the exposure starts and stops. 
This way researchers can ensure that gestational exposure is occurring during fetal 
development and no other exposures are confounding the effects. Moreover, it is still 
important to consider tissue-specificity when conducting differential methylation studies. 
Murine studies allow access to tissues that are not necessarily available in humans, like 
brain which is the primary tissue of interest in terms of Pb toxicity. Additional cross-
species and cross-tissue studies are needed. 
In fact, in collaboration with the Toxicant Exposures and Responses by Genomic 
and Epigenomic Regulators of Transcription (TaRGET II) consortium 67, we are 
assessing how epigenomic marks correlated between surrogate tissues and target 
tissues using murine models in order to address this cross-tissue and interindividual 
variation in epigenomic profiles in disease susceptibility 67. Dams, which are genetically 
invariant mice 93% identical to C57BL/6J strain, were assigned to control or Pb-acetate 
(32ppm) water two weeks prior to mating. Exposure continued throughout gestation and 
lactation until weaning at post-natal day 21 (PND21), upon which all offspring consumed 
control water. In utero exposure, thus, occurred in offspring throughout fetal 
development. We collected whole blood and brain of 5-month-old male and female mice 
and we will perform whole-genome bisulfite sequencing (WGBS) and 
hydroxymethylation DNA immunoprecipitation sequencing (hMeDIP-seq) in hopes to 
provide valuable insight into the effects of developmental exposure on epigenomic 
reprogramming in a tissue-, sex-, and cell-type-specific manner.  
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Overall conclusions 
In this dissertation project, I utilized a longitudinal human birth cohort, ELEMENT, 
of perinatal exposures to Pb to provide evidence supporting the hypothesis that 
developmental exposures to Pb have negative impacts on cognition in early life, and to 
investigate a novel molecular mechanism underlying this relationship - epigenetics. I 
aimed to fill this critical gap in the literature by assessing prenatal Pb exposure effects 
on DNA 5mC and 5hmC patterns, and its association with neurodevelopmental 
outcomes. This is the first longitudinal human study to investigate the mediating role of 
epigenetics at birth on the relationship between developmental Pb and early-life 
neurodevelopmental measures, and I revealed both mediating and partial reversal (I.e., 
suppressive) effects. I further reported trimester-specific associations between Pb 
exposure and DNA methylation, as well as sex-specific effects. Incorporating the 
independent measures of 5mC and 5hmC was another unique aspect of this research. I 
found that prenatal Pb exposure altered the 5mC and 5hmC, individually, and 
emphasizes the importance of distinguishing the two in toxicoepigenetic studies. The 
contrast in these two epigenomic marks I observed might be one explanation for the 
discrepancies in previous research regarding DNA methylation’s relationship with gene 
expression, which is normally inverse.  
In terms of public health, I show that there is still more research needed to 
determine the various exposure doses and timing that may impact DNA methylation. 
Nonetheless, this dissertation may provide evidence for specific genes or gene 
pathways to investigate that might explain prenatal Pb-induced later life health 
outcomes. DNA methylation differences that I show should be followed up within this 
 192 
cohort to determine if these changes continue to persist into adulthood; and if they 
changes persist, determine whether they are associated with adverse neuro-related 
outcomes, such as Alzheimer’s. This work contributes to the growing body of evidence 
calling for the prevention of all Pb exposure. But if intervention is the case, we also 
provide potential genes worth pursuing. These results suggest that environmental 
factors play a key role in the developmental origins of health and disease and that DNA 
methylation may play a mediating and/or suppressive role when assessing exposure-
outcome models. This idea has important implications for public health policies related 
to gestational exposure prevention and intervention through lowering blood Pb levels 
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Figure 5.1: Conceptual model summarizing the dissertation aims and results. Each aim 
is indicated by colored dashed lines (Aim 1 = blue, Aim 2 = purple, Aim 3 = green). 
Biomarkers and variables considered within statistical modeling are indicated within 




Figure 5.2: CpG-site-specific beta values (representing proportion methylated) from 
matched umbilical cord and venous blood at birth and adolescence. Each color and line 
represent an individually matched sample. 
 



























































































Figure 5.3: NINJ2 CpG-site-specific beta values (proportion methylated) from birth to 
adolescence. Each line represents an individual matched sample grouped by the SNP 
(C/G) rs34038797 (red=CC, green=GC, blue=GG, purple=not genotyped), a discovered 




















































































































Figure 5.4: Correlation of beta effect estimates of change in DNA methylation (DNAm) per one-unit increase in prenatal 
Pb exposure for each biomarker at birth versus adolescence. Each dot represents the effect estimate for the association 
between the Pb biomarker and DNAm at each CpG-site at birth (x-axis) compared to the adolescent timepoint (y-axis). 
Black line is the correlation, where the grey shadow is the 95% confidence interval. 
 
Note: CpG sites compared are cg17138393, cg00984923, cg25353752, cg26371957, cg19692784, cg14911689, cg05578102, cg26654770, 
cg01201512, cg06657917, cg03390844, cg01328348, cg00002033, cg034632088 
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